Lysine acetyltransferase inhibitors

Abstract

Provided herein are methods of treating a disease or condition associated with p300 activity, an inflammatory disorder, an allergic disorder, an autoimmune disease, or a cancer. These methods utilise a CREB -binding protein (CBP) and p300 lysine acetyltransferase inhibitor (KATi), which are used alone or in combination with a further active agent such as a glucocorticoid or an immunomodulatory imide drag (e.g. pomalidomide).

Description

KRBIO.024WO PATENT LYSINE ACETYLTRANSFERASE INHIBITORS CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This patent application claims the benefit of priority to U.S. Provisional Patent Application No.63 / 618,252, filed January 5, 2023; U.S. Provisional Patent Application No. 63 / 561,712, filed March 5, 2023; U.S. Provisional Patent Application No. 63 / 661,423, filed June 18, 2024; U.S. Provisional Patent Application No. 63 / 664,086, filed June 25, 2024; U.S. Provisional Patent Application No. 63 / 561,710, filed March 5, 2024; U.S. Provisional Patent Application No. 63 / 561,715, filed March 5, 2024; U.S. Provisional Patent Application No. 63 / 703,835, filed October 5, 2024; U.S. Provisional Patent Application No. 63 / 720,128, filed November 13, 2024; Patent Cooperation Treaty Patent Application No. PCT / US2024 / 051649, filed October 16, 2024; Patent Cooperation Treaty Patent Application No. PCT / US2024 / 051649, filed October 16, 2024; and Patent Cooperation Treaty Patent Application No. PCT / US2024 / 051640, filed October 16, 2024, each of which is incorporated herein by reference in its entirety. BACKGROUND Field

[0002] The present disclosure relates to compounds and their use in the treatment of various diseases, including cancer and inflammatory conditions. This disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions comprising such compounds. The present disclosure relates to a compound and its use in the treatment of various diseases, including autoimmune and inflammatory conditions. Background

[0003] Lysine acetylation is a reversible post-translational modification. Lysine acetyltransferases (KATs) catalyze the transfer of an acetyl group from acetyl CoA (AcCoA) to the ε-amino group on lysine residues of substrate proteins (Lee, K., Workman, J. Nat Rev Mol Cell Biol 8, 284–295 (2007)). Lysine deacetylases (KDACs) catalyze the removal of theacetyl group. Specific protein domains, including bromodomains, can bind proteins in an acetylation-dependent manner (R. Marmorstein and M.-M. Zhou. Cold Spring Harb Perspect Biol 2014;6:a018762). The presence or absence of the acetyl group can impact protein function, including protein-protein interactions. This is because the acetyl group on the target lysine residue neutralizes the charge of the lysine ε-amino group which is known to impact chromatin compaction in the nucleus.

[0004] Emerging evidence highlights a diverse set of cofactors and substrate macromolecules that can be regulated by KATs. In addition to transferring acetyl groups, these proteins can also transfer longer chain acyl groups, including crotonyl (from crotonyl CoA), to lysine resides of substrate proteins (Kaczmarska et al. Nat Chem Biol. 2017 Jan; 13(1): 21– 29). The function of longer chain acyl group modification is not well understood and this application will focus on acetyl transferase activity of proteins. Similarly, the KAT ELP3 is known to acetylate non-protein substrates, including transfer RNAs (Lin, TY., Abbassi, N.E.H., Zakrzewski, K. et al. Nat Commun 10, 625 (2019)), further expanding the biological impact of acetyltransferase function. The protein activity and its enzymatic inhibition with CoA-competitive KAT inhibitors (KATi) likely encompasses different acyl chain groups and diverse substrates.

[0005] The human genome encodes at least 12 KATs, consisting of three subfamilies based on amino acid sequence similarity: MYST family, GNAT family and Orphan family. The human KAT proteins p300 and CREB-binding protein (CBP) are paralogs in the Orphan family of human KATs with well-established roles in gene regulation.

[0006] The p300 protein is encoded by the E1A Binding Protein (EP300) gene (Uniprot ID: Q09472) that is located on human chromosome 22p13.2. The CBP protein is encoded by the CREBBP gene (Uniprot ID: Q92793) that is located on human chromosome 16p13.

[0007] p300 and CBP are multidomain proteins that consist of an enzymatic KAT domain and multiple protein-protein interaction domains, including a bromodomain and KIX domain. The KAT domain catalyzes acetylation of histones and non-histone proteins where acetylated histones are associated with actively transcribed regions of the genome. The protein-protein interaction domains aid in localizing p300 or CBP to distinct locations in the genome.

[0008] There is a continued need to provide compounds that are effective KAT inhibitors having desirable pharmacokinetic properties for use as therapeutics. There is a continued need to provide compounds that are effective KAT inhibitors having desirable pharmacokinetic properties for use as therapeutics, particularly for autoimmune and inflammatory conditions. SUMMARY

[0009] In some embodiments, compounds useful KAT inhibitors are provided herein. In some embodiments, compounds provided herein bind to p300 protein on a competition TR-FRET assay of Example B. (I), or S, SO, or-CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, -CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R1band R1care each independently hydrogen, halo, -OH, C1-C6 alkyl, -O-(C1-C6 alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), - CONH2, -CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R2ais hydrogen, -CN, -C1-C6 alkyl, - CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, -CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R2band R2care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), - CONH2, -CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6alkyl, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1- C6alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-memberedheterocycloalkyl, -CONH2, -CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); R6is optionally substituted , optionally substituted C3-C10 cycloalkyl, or optionallysubstituted 3- to 10-membered heterocycloalkyl; R7is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; J is NH, N(C1-C6 alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10alkylene, optionally substituted C2-C10alkenylene, or optionally substituted C2-C10alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6alkyl, -C1-C6haloalkyl, -CN, -CO2H, -CO2(C1-C6alkyl), -CONH2, -CONH(C1-C6alkyl), -CON(C1- C6 alkyl)2, -SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), - SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10- membered , wherein said alkyl, aryl, cycloalkyl,substituted with 1, 2, or 3 substituents Q; each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6 alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10 cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6 alkyl), optionally substituted C7-C16 arylalkyl, -C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl), optionally substituted C6-C10 aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1.

[0011] In some embodiments, A1is NR1aor O. In some embodiments, A1is NR1a.

[0012] In some embodiments, A2is NR2a, O, or S. In some embodiments, A2is NR2a. In some embodiments, A2is O. In some embodiments, A2is S.

[0013] In some embodiments, R3aand R3bare each hydrogen. In some embodiments, R3aand R3btaken together are =O. In some embodiments, R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring.

[0014] In some embodiments, W is N.

[0015] In some embodiments, X is CR9.

[0016] In some embodiments, Y is CR10.

[0017] In some embodiments, Z is CR11.

[0018] Some embodiments relate to a compound, having the structure of Formula (IIa-1) (IIa-1), or a pharmaceutically acceptable salt thereof.relate to a compound, having the structure of Formula (IIa-2)

[0020] Some embodiments relate to a compound, having the structure of Formula (IIb-1) (IIb-1), or a pharmaceutically acceptable salt thereof. relate to a compound, having the structure of Formula(IIb-2) (IIb-2), or a pharmaceutically acceptable salt thereof.relate to a compound, having the structure of Formula (IIc-1) (IIc-1), or a pharmaceutically acceptable salt thereof.relate to a compound, having the structure of Formula (IIc-2) a pharmaceutically acceptable salt thereof.to a compound, having the structure of Formula (IId-1)

[0025] Some embodiments relate to a compound, having the structure of Formula (IIe-1) a pharmaceutically acceptable salt thereof. to a compound, having the structure of Formula(IIe-2) a pharmaceutically acceptable salt thereof. to a compound, having the structure of Formula(IIIa-1) (IIIa-1), or a pharmaceutically acceptable salt thereof.relate to a compound, having the structure of Formula (IIIa-2) (IIIa-2), or a pharmaceutically acceptable salt thereof.relate to a compound, having the structure of Formula (IIIb-1)

[0030] Some embodiments relate to a compound, having the structure of Formula (IIIb-2) (IIIb-2), or a pharmaceutically acceptable salt thereof. relate to a compound, having the structure of Formula(IIIc-1) a pharmaceutically acceptable salt thereof. to a compound, having the structure of Formula(IIIc-2) (IIIc-2), or a pharmaceutically acceptable salt thereof.relate to a compound, having the structure of Formula (IIId-1) a pharmaceutically acceptable salt thereof.to a compound, having the structure of Formula (IIIe-1)

[0035] Some embodiments relate to a compound, having the structure of Formula (IIIe-2) a pharmaceutically acceptable salt thereof. is hydrogen. In some embodiments, R1ais -C1-C6some - (C1-C6alkyl).

[0037] In some embodiments, R4aand R4bare each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl.

[0038] In some embodiments, R4ais substituted phenyl. In some embodiments, R4ais phenyl. In some embodiments, R4ais optionally substituted C3-C10cycloalkyl. In some embodiments, R4ais optionally substituted 3- to 10-membered heteroaryl. In some embodiments, R4ais optionally substituted 3- to 10-membered heterocycloalkyl. In some embodiments, R4ais optionally substituted C1-C6alkyl.

[0039] In some embodiments, J is O, NH, or CH2. In some embodiments, J is NH.

[0040] In some embodiments, R5is L-R6.

[0041] In some embodiments, L is optionally substituted C1-C10alkylene. In some embodiments, L is -CH2CH2- or -CH2CH(CH3)-.

[0042] In some embodiments, R6is optionally substituted phenyl. In some embodiments, R6is optionally substituted C3-C10cycloalkyl.

[0043] In some embodiments, R6is optionally substituted 3- to 10-membered heteroaryl. In some embodiments, R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl. In some embodiments, R6is optionally substituted 3- to 10- memebered heterocycloalkyl.

[0044] In some embodiments, each of R8, R9, R10, and R11is independently hydrogen, -C1-C6alkyl, -C1-C6haloalkyl, -CONH2, -CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, C6-C10aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q.

[0045] In some embodiments, each of R8, R9, R10, and R11is independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, -C1-C6 haloalkyl, -CN, -CO2H, - CO2(C1-C6alkyl), -CONH2, -CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, -SO2NH2, - SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q.

[0046] In some embodiments, each of R9, R10, and R11is hydrogen.

[0047] In some embodiments, R10is -CONH2, -CONH(C1-C6 alkyl), or -CON(C1- C6 alkyl)2. In some embodiments, R10is phenyl optionally substituted with 1, 2, or 3 substituents Q. In some embodiments, R10is 5- to 10-membered heteroaryl optionally substituted with 1, 2, or 3 substituents Q. In some embodiments, R10is pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, or indolyl, benzimidazolyl, each optionally substituted with 1, 2, or 3 substituents Q.

[0048] In some embodiments, each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, - (CH2)mNH2, -(CH2)mSO2(optionally substituted C1-C6alkyl), -C(=O)NH2, - (CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, -(CH2)mC(=O)NH(optionally substituted C6-C10 aryl), - (CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7-C16arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), and optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl).

[0049] Also disclosed herein is a compound, or a pharmaceutically acceptable salt thereof, having the structure of any one of any one of the compounds described herein.

[0050] Also disclosed herein is a pharmaceutical composition comprising a compound as described herein and a pharmaceutically acceptable excipient.

[0051] Also disclosed herein is a method of treating a disease or disorder associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound or composition described herein. In some embodiments, the method described herein comprises administering to the subject one or more additional active agents.

[0052] In some embodiments, compounds of Formula (IIIe-1) are provided herein , or aR1ais hydrogen; R2band R2care each independently hydrogen; R3aand R3bare each independently hydrogen; R4ais phenyl; R4bis hydrogen; J is NH; R5is -L-R6; L is -CH2CH2- or -CH2CH(CH3)-; R6is aryl substituted with 1 to 3 substituents selected from -CH2C(O)H, alkyl, substituted alkyl, cyano, halogen, and R60, wherein the aryl is phenyl and the C1-C6substituted alkyl is C1-C6 alkylene substituted with 1 to 3 R60, spiro-connected cycloalkyl or spiro- connected heterocycloalkyl; R60is alkyl, cyano, -COOH, halogen, haloalkyl and alkoxy; and R10is hydrogen, halogen, methyl, methyl-substituted pyrazole, or –(C1-C4alkyl)COOH or a pharmaceutically acceptable salt thereof.

[0053] In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R10is hydrogen. In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R10is halogen. In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R10is fluoro. In some embodiments, the compound of Formula (IIIe- 1) is a compound wherein R10is methyl. In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R10is methyl-substituted pyrazole. In some embodiments, the compound of Formula (IIIe-1) is a compound . In some embodiments, the compound of Formula (IIIe-1) is is –(C1-C4alkyl)COOH. In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R10is –(CH2)COOH. In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R10is –(CH2)2COOH. In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R10is –(CH2)3COOH.

[0054] In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R6is phenyl substituted with –(CH2)COOH, or phenyl substituted with C1-C6alkylene substituted with -COOH or cyano and optionally substituted with a spiro-connected C3 to C6 cycloalkyl or a spiro-connected 3 to 6 member heterocycloalkyl. In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R6is phenyl further substituted with one or two methyl. In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R6is phenyl substituted with cyano or alkyl substituted with cyano. In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R6is ,. In some embodiments, the compound of Formula (IIIe-1) is a compound wherein . In some embodiments, the R6isor. In some embodiments, the compound of Formula (IIIe-1) is acompound wherein . In some embodiments, thefrom:.

[0055] In some embodiments, the compound of Formula (IIIe-1) is a compound wherein R6is phenyl substituted with C1-C6 alkylene substituted with -COOH and substituted with a spiro-connected C3to C6cycloalkyl or a spiro-connected 3 to 6 memberheterocycloalkyl. In some embodiments, the compound of Formula (IIIe-1) is a compound .- cyano, or - some the compound of Formula (IIIe-1) is a compound wherein R60is independently methyl, fluoro or methoxy.

[0057] In some embodiments, the compound of Formula (IIIe-1) is a compound wherein the compound is a compound of Formula (VI-A), or a pharmaceutically acceptable salt thereof:

[0058] In some embodiments, the compound of Formula (IIIe-1) is a compound wherein the compound is a compound of Formula (VI-A-1), or a pharmaceutically acceptable salt thereof:

[0059] In some embodiments, the compound of Formula (IIIe-1) is a compound wherein the compound is a compound of Formula (VI-A-2), or a pharmaceutically acceptable salt thereof:

[0060] In some embodiments, the compound of Formula (IIIe-1) is a compound H N , a

[0061] In some embodiments, the compound of Formula (IIIe-1) is a compound wherein the compound is the ,or , or a pharmaceutically acceptable salt thereof.compound of Formula (IIIe-1) is a compound wherein the a pharmaceutically acceptable salt thereof.

[0063] In some embodiments, the compound of Formula (IIIe-1) is a compound wherein the a pharmaceutically acceptable salt thereof.

[0064] In some embodiments, a pharmaceutical composition comprising the compound of any one of the compounds disclosed herein and a pharmaceutically acceptable excipient.

[0065] In some embodiments, methods of treating a disease or disorder associated with p300 activity in a subject are provided, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of the compounds disclosed herein or the pharmaceutical composition comprising a compound disclosed herein.

[0066] In a first aspect of the disclosure, provided herein is a method of treating a disease or disorder associated with p300 activity in a subject, said method comprisingadministering to the subject a therapeutically effective amount of Compound 762: a pharmaceutically acceptable salt thereof. provided herein is a method for treatinga or group consisting of an inflammatory disorder and an autoimmune disease, in a subject in need thereof, comprising administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof.

[0068] In some embodiments, the autoimmune disease is selected from the group consisting of: Crohn’s disease, ulcerative colitis, Graves’ disease, Hashimoto’s thyroiditis, multiple sclerosis, Guillain-Barre syndrome, rheumatoid arthritis, systemic lupus erythematosus, Behçet’s disease, Reynaud’s syndrome, acute disseminated encephalomyelitis Sjögren’s syndrome, type I diabetes mellitus, and vitiligo. In some embodiments, the autoimmune disease is Sjögren’s syndrome.

[0069] In some embodiments, the inflammatory disorder is selected from the group consisting of ulcerative colitis, Crohn’s disease, irritable bowel disease, chronic obstructive pulmonary disease (COPD). gout, scleroderma, acute disseminated encephalomyelitis, psoriasis, asthma, ulcerative colitis, Alzheimer’s disease, and Parkinson’s disease

[0070] In some embodiments, the disease or disorder is characterized by overexpression of IL-17 cytokines.

[0071] In some embodiments, the disease or disorder is characterized by overexpression of IgG.

[0072] In some embodiments, the subject may be a mammal. In some specific embodiments, the subject is a human. BRIEF DESCRIPTION OF THE DRAWINGS

[0073] FIG. 1 depicts the effects of Compound 762 in a KLH-induced T-cell dependent antibody response assay.

[0074] FIG. 2 depicts the effects of Compound 762 on cytokine production in human Th17 cells.

[0075] FIG.3 depicts the progress of tumor volume in the days after the start of the indicated treatment.

[0076] FIG. 4 depicts the percent body weight change in the days after the start of the indicated treatment.

[0077] FIG.5A depicts the results of an in vitro cell viability assay for MM.1S cells viability upon treatment with pomalidomide and Compound 120.

[0078] FIG. 5B depicts the Bliss synergy plot for combination testing of pomalidomide with Compound 120 on MM1.S cells.

[0079] FIG.6A depicts the results of an in vitro cell viability assay for RPMI-8226 cells viability upon treatment with pomalidomide and Compound 120.

[0080] FIG. 6B depicts the Bliss synergy plot for combination testing of pomalidomide with Compound 120 on RPMI-8226 cells.

[0081] FIG.7A depicts the results of an in vitro cell viability assay for MM.1S cells viability upon treatment with dexamethasone (dex) and Compound 120.

[0082] FIG. 7B shows the Bliss synergy plot for combination testing of dexamethasone with Compound 120 on MM.1S cells.

[0083] FIG.8A depicts the results of an in vitro cell viability assay for RPMI-8226 cells viability upon treatment with dexamethasone (dex) and Compound 120.

[0084] FIG. 8B shows the Bliss synergy plot for combination testing of dexamethasone with Compound 120 on RPMI-8226 cells.

[0085] FIG. 9A is a graph showing IgG production levels as a function of concentration of Compound 762 or deucravacitinib.

[0086] FIG. 9B is a graph showing IgA production levels as a function of concentration of Compound 762 or deucravacitinib.

[0087] FIG. 9C is a graph showing IgM production levels as a function of concentration of Compound 762 or deucravacitinib.

[0088] FIG. 10 is a graph showing KLH0IgG concentration as a function of time with treatment with compound 762 or cyclosporin A or vehicle.

[0089] FIG. 11 is a graph showing the IL-17A concentration as a function of concentration of Compoun 762, deucravacitinib or JNJ-61803534.

[0090] FIG. 12 is a graph showing the expression of TFs in cells treated with Compound 762.

[0091] FIG. 13 are graphs showing expression of IL-23 / TGF-beta polarized Th17 cells treated with compound 762.

[0092] FIG.14A is a graph showing the clinical score in the in vivo rat CIA model with treatment of different concentrations of Compound 762, vehicle or dexamethasone.

[0093] FIG. 14B are graphs showing anti-collagen II antibody levels by class of antibody after treatment with Compound 762.

[0094] FIG. 15A is a graph of pathological paw scores after different concentrations of compound 762.

[0095] FIG.15B are images of H&E staining for dexamethasone, vehicle and after compound 762 treatment.

[0096] FIG.16 is a schematic showing biological mechanisms related to activity of compound 762. DETAILED DESCRIPTION

[0097] Provided herein are CBP and p300 KATi with demonstrated anti- proliferative properties in selected cancers, as well as on hematological models. Also provided are methods of treating a subject by administering a therapeutically effective dose of a pharmaceutical composition including the KATi.

[0098] Provided herein are methods of treating a subject by administering a therapeutically effective dose of a pharmaceutical composition including Compound 762 or a pharmaceutically acceptable salt thereof. In some embodiments, the methods provided herein are directed to treating autoimmune diseases and / or inflammatory disorders in a subject.

[0099] For a given compound as described herein, if the IUPAC name includes the phrase “S or R” or “R or S,” the compound has a single configuration at that stereocenter, but the configuration is arbitrarily assigned. If the IUPAC name includes the phrase “S and R” or “R and S,” the compound is a mixture of compounds with both R and S configurations at that position. Thus, a single IUPAC name may refer to 1, 2, 4, or more individual compounds.

[0100] Unless otherwise specified herein, the stereochemistry in the chemical structures assigned at a benzylic stereocenter to R4a(when R4ais phenyl) is shown relative tothe stereochemistry in the chemical structures at the carbon between the R7and A2positions of Formula I, but is otherwise arbitrarily assigned. In addition, unless otherwise specified herein, the stereochemistry in the chemical structures of the L group methyl substituents was also arbitrarily assigned when L is -(CH2)(CH)(CH3)-. Stereochemistry of substituents in the chemical structures on -(CH2)COOH in R6are also arbitrarily assigned, unless otherwise indicated.

[0101] Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

[0102] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

[0103] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, some potential and exemplary methods and materials may now be described. Any and all publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.

[0104] It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a droplet” includes a plurality of such droplets and reference to “the discrete entity” includes reference to one or more discrete entities, and so forth.

[0105] It is further noted that the claims may be drafted to exclude any element, e.g., any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely”, “only” and the like in connection with the recitation of claim elements, or the use of a “negative” limitation.

[0106] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed. To the extent the definition or usage of any term herein conflicts with a definition or usage of a term in an application or reference incorporated by reference herein, the instant application shall control.

[0107] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order which is logically possible. (I), or S, SO, or-CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, -CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, or -SO2(alkyl); R1band R1care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), - CONH2, -CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R2ais hydrogen, -CN, -C1-C6 alkyl, - CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, -CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, or-SO2(alkyl); R2band R2care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), - CONH2, -CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6alkyl, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1- C6 alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); R6is optionally substituted , optionally substituted C3-C10 cycloalkyl,or optionally substituted 3- to 10-membered heterocycloalkyl; R7is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; J is NH, N(C1-C6 alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10alkylene, optionally substituted C2-C10alkenylene, or optionally substituted C2-C10alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, -C1-C6haloalkyl, -CN, -CO2H, -CO2(C1-C6alkyl), -CONH2, -CONH(C1-C6alkyl), -CON(C1- C6 alkyl)2, -SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), - SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, , wherein said alkyl, aryl, cycloalkyl, y substituted with 1, 2, or 3 substituents Q; each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10 aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6 alkyl), optionally substituted C7-C16 arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted C3-C10cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl), optionally substituted C6-C10aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1.

[0109] In some embodiments, A1is NR1aor O. In some embodiments, A1is NR1a.

[0110] In some embodiments, A2is NR2a, O, or S. In some embodiments, A2is NR2a. In some embodiments, A2is O. In some embodiments, A2is S.

[0111] In some embodiments, R3aand R3bare each hydrogen. In some embodiments, R3aand R3btaken together are =O. In some embodiments, R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring.

[0112] In some embodiments, W is N.

[0113] In some embodiments, X is CR9.

[0114] In some embodiments, Y is CR10.

[0115] In some embodiments, Z is CR11.

[0116] Some embodiments relate to a compound, having the structure of Formula (IIe-1) R11R1a3aR10N R R3b 9 J R N R5 R4a R4b (IIe-1), or a pharmaceutically acceptable salt thereof.

[0117] Some embodiments relate to a compound, having the structure of Formula (IIe-2) R11R1a10R3aR N R3b a pharmaceutically acceptable salt thereof. to a compound, having the structure of Formula(IIIe-1) R1a R3a a pharmaceutically acceptable salt thereof.to a compound, having the structure of Formula (IIIe-2) R1aR3aa pharmaceutically acceptable salt thereof.to a compound, having the structure of Formula (IV-A) or Formula (IV-B): ,B), or a pharm R4ais phenyl; R6is optionally substituted aryl, optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10- membered heterocycloalkyl; and R10is hydrogen, halogen, alkyl optionally substituted with -COOH, or pyrazolyl substituted with alkyl.

[0121] In some embodiments, R1ais hydrogen. In some embodiments, R1ais -C1- C6alkyl. In some embodiments, R1ais -CO(C1-C6alkyl).

[0122] In some embodiments, R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl.

[0123] In some embodiments, R4ais substituted phenyl. In some embodiments, R4ais phenyl. In some embodiments, R4ais optionally substituted C3-C10cycloalkyl. In some embodiments, R4ais optionally substituted 3- to 10-membered heteroaryl. In some embodiments, R4ais optionally substituted 3- to 10-membered heterocycloalkyl. In some embodiments, R4ais optionally substituted C1-C6alkyl.

[0124] In some embodiments, J is O, NH, or CH2. In some embodiments, J is NH.

[0125] In some embodiments, R5is L-R6.

[0126] In some embodiments, L is optionally substituted C1-C10alkylene. In some embodiments, L is -CH2CH2- or -CH2CH(CH3)-.

[0127] In some embodiments, R6is optionally substituted phenyl. In some embodiments, R6is phenyl substituted with cyano. In some embodiments, R6is phenyl substituted with one 1-3 R60, where each R60is independently selected from alkyl, alkylsubstituted with -COOH, alkyl substituted with cycloalkyl and -COOH, alkyl substituted with cyano, or alkyl substituted with alkoxy. In some embodiments, at least one R60is – (CH2)COOH. In some embodiments, at least one R60is cyano or –(CH2)CN.

[0128] In some embodiments, R6is phenyl or pyridinyl substituted with carboxy and optionally further substituted with alkyl, halogen, haloakyl or alkoxy. In some embodiments, R6is phenyl substituted with –(C1-C4 alkyl)-COOH and optionally further substituted with one or more of fluoro, methyl or methoxy. In some embodiments, R6is phenyl substituted with –(spirocyclic cycloaklyl)-COOH or –(spirocyclic heterocycloalkyl)-COOH and optionally further substituted with methyl. In some embodiments, R6is phenyl substituted with -COOH, –(CH2)-COOH or –(CH2)2-COOH and optionally further substituted with methyl. , is

[0130] In some embodiments, R6, wherein R60is –(alkyl)COOH. In some embodiments, R6is . In someembodiments, R6is . In some embodiments, R6isIn some . In some embodiments, R6is. In some embodiments, orIn some . In somesome embodiments, R6.

[0131] In some embodiments, R6is wherein R60is -CN, -(CH2)CN or –(alkyl)COOH. In some embodiments, R6is . In someembodiments, . In some embodiments, R6is.

[0132] In some embodiments , wherein each R60is independently alkyl, haloalkyl, or halog least one R60is methyl optionally substituted with one or more fluoro, or fluoro. In some embodiments, at least one R60is -CF3. In some embodiments, at least one R60is methyl. In some embodiments, at least one R60is methyl. In some embodiments, R6. In some embodiments,.with one or more methyl, fluoro, -CF3 methoxy, -O-(C1-C4 alkyl)-COOH, or -(C1-C4 alkyl)-COOH. In some embodiments, R6. In some embodiments, R6.

[0134] InR6is phenyl orC4alkyl, C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; wherein the alkyl is optionally substituted with C3-C10cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl. In some embodiments, R6is methyl substituted with a 5- to 6- member heteroaryl. In some embodiments, R6is . In some embodiments, R6is methyl substituted with a 5- to 6- memberheterocycloalkyl. In some In some embodiments, R6is phenyl substituted with a C3-C6or a 5- to 6-member heteroaryl, each optionally substituted with one or more R60. In some embodiments, . some embodiments, R6is optionally substituted C3-C10cycloalkyl. Insome .

[0136] is optionally substituted 3- to 10-memberedheteroaryl. In some embodiments, R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl. In some embodiments, R6is optionally substituted 3- to 10- memebered heterocycloalkyl.

[0137] In some embodiments, R6is a fused bicyclic ring system comprising a phenyl or pyridinyl ring fused to a 3 to 6 member heterocycloalkyl or to a C3-C6cycloalkyl. In some embodiments, R6is a dihydroindinene, a dihydroisobenzofuran, or a dihydro cyclopental[b]pyridine. In some embodiments, R6, oreach optionally substituted with alkyl, carboxyl, halogen orR6is a dihydroindinene, a dihydroisobenzofuran, or a dihydro cyclopental[b]pyridine each optionally substituted with -COOH or –(C1-C4 alkyl)COOH. In some embodiments, R6is ,

[0138] In some embodiments, R6is phenyl or pyridinyl substituted with an amide, wherein the amide is optionally substituted with phenyl or a 5- to 6- member heteroaryl. In some .

[0139] substituted with carboxy.In some .

[0140] In pyridinyl substituted with -O-(C1-C4alkyl)-COOH. In some embodiments, R6is phenyl or pyridinyl substituted with -O-(CH2)- COOH, -COOH or -(CH2)-COOH.

[0141] In some embodiments, each of R8, R9, R10, and R11is independently hydrogen, -C1-C6 alkyl, -C1-C6 haloalkyl, -CONH2, -CONH(C1-C6 alkyl), -CON(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q.

[0142] In some embodiments, each of R8, R9, R10, and R11is independently selected from the group consisting of hydrogen, halo, -C1-C6alkyl, -C1-C6haloalkyl, -CN, -CO2H, - CO2(C1-C6 alkyl), -CONH2, -CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, -SO2NH2, - SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q.

[0143] In some embodiments, each of R9, R10, and R11is hydrogen.

[0144] In some embodiments, R10is -CONH2, -CONH(C1-C6alkyl), or -CON(C1- C6alkyl)2. In some embodiments, R10is phenyl optionally substituted with 1, 2, or 3 substituents Q. In some embodiments, R10is 5- to 10-membered heteroaryl optionally substituted with 1, 2, or 3 substituents Q. In some embodiments, R10is pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, or indolyl, benzimidazolyl, each optionally substituted with 1, 2, or 3 substituents Q.

[0145] In some embodiments, each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, - (CH2)mNH2, -(CH2)mSO2(optionally substituted C1-C6alkyl), -C(=O)NH2, - (CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, -(CH2)mC(=O)NH(optionally substituted C6-C10 aryl), - (CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7-C16arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6alkyl), and optionally substituted C3-C10cycloalkyl-(C1-C6alkyl).

[0146] Some embodiments relate to a compound, having the structure of Formula (V-A):wherein R10is hydrogen, alkyl optionally substituted with -COOH, or pyrazolyl substituted with alkyl; J is NH; R5is -L-R6; L is -CH2CH2- or -CH2CH(CH3)-; R6is substituted phenyl or R6is substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl.

[0147] In some embodiments, a compound is a compound of the structure of Formula (V-A), wherein R10is hydrogen, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is as defined above. Some embodiments relate to a compound, having the structure of Formula (V-A), wherein R10is hydrogen, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is phenyl substituted with -CN, -(CH2)CN, or –(alkyl)COOH and up to two R60, as defined above. In some embodiments, a compound is a compound of Formula (V-A), wherein R10is hydrogen, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is phenyl optionally substituted with –(CH2)COOH and 0-2 R60, as defined above.

[0148] In some embodiments, a compound is a compound of Formula (V-A), wherein R10is hydrogen, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is pyridinyl optionally substituted with 1-3 R60, as defined above. In some embodiments, a compound is a compound of Formula (V-A), wherein R10is hydrogen, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is pyridinyl optionally substituted with –(alkyl)COOH and 0-2 R60, as defined above. In some embodiments, a compound is a compound of Formula (V-A), wherein R10is hydrogen, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is pyridinyl optionally substituted with –(CH2)COOH and 0-2 R60, as defined above.

[0149] In some embodiments, a compound is a compound of the structure of Formula (V-A), wherein R10is a R10is 5- to 10-membered heteroaryl optionally substituted with 1, 2, or 3 substituents Q. In some embodiments, a compound is a compound of the structure of Formula (V-A), wherein R10is a methyl pyrazolyle. In some embodiments, acompound is a compound of the structure of Formula (IV-A), .

[0150] In some embodiments, a compound is aof Formula (V-A), wherein R10is a methyl pyrazolyl, J is NH, R5is -L-R6, L is -CH2CH2- or - CH2CH(CH3)-, and R6is as defined above. Some embodiments relate to a compound, having the structure of Formula (V-A), wherein R10is methyl pyrazolyl, J is NH, R5is -L-R6, L is - CH2CH2- or -CH2CH(CH3)-, and R6is phenyl substituted with -CN, -(CH2)CN, or – (alkyl)COOH and up to two R60, as defined above. In some embodiments, a compound is a compound of Formula (V-A), wherein R10is methyl pyrazolyl, J is NH, R5is -L-R6, L is - CH2CH2- or -CH2CH(CH3)-, and R6is phenyl optionally substituted with –(CH2)COOH and 0-2 R60, as defined above.

[0151] In some embodiments, a compound is a compound of Formula (V-A), wherein R10is methyl pyrazolyl, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is pyridinyl optionally substituted with 1-3 R60, as defined above. In some embodiments, a compound is a compound of Formula (V-A), wherein R10is methyl pyrazolyl, J is NH, R5is - L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is pyridinyl optionally substituted with – (alkyl)COOH and 0-2 R60, as defined above. In some embodiments, a compound is a compound of Formula (V-A), wherein R10is methyl pyrazolyl, J is NH, R5is -L-R6, L is - CH2CH2- or -CH2CH(CH3)-, and R6is pyridinyl optionally substituted with –(CH2)COOH and 0-2 R60, as defined above.

[0152] In some embodiments, a compound is a compound of the structure of Formula (V-A), wherein R10is a methyl, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)- , and R6is as defined above. Some embodiments relate to a compound, having the structure of Formula (V-A), wherein R10is methyl, J is NH, R5is -L-R6, L is -CH2CH2- or - CH2CH(CH3)-, and R6is phenyl substituted with -CN, -(CH2)CN, or –(alkyl)COOH and up to two R60, as defined above. In some embodiments, a compound is a compound of Formula (V- A), wherein R10is methyl, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is phenyl optionally substituted with –(CH2)COOH and 0-2 R60, as defined above.

[0153] In some embodiments, a compound is a compound of Formula (V-A), wherein R10is methyl, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is pyridinyl optionally substituted with 1-3 R60, as defined above. In some embodiments, a compound is a compound of Formula (V-A), wherein R10is methyl, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is pyridinyl optionally substituted with –(alkyl)COOH and 0-2 R60, as defined above. In some embodiments, a compound is a compound of Formula (V-A), wherein R10is methyl, J is NH, R5is -L-R6, L is -CH2CH2- or -CH2CH(CH3)-, and R6is pyridinyl optionally substituted with –(CH2)COOH and 0-2 R60, as defined above.

[0154] Some embodiments relate to a compound, having the structure of Formula (VI-A-1) or Formula (VI-A-2):wherein R10and R6are as defined above with respect to Formula (VI-A), with the specified absolute or relative stereochemistry.

[0155] In some embodiments, a compound is a compound of Formula (VI-A-1) or Formula (V-A-2), wherein R10is hydrogen and R6is substituted phenyl as defined above. In some embodiments, a compound is a compound of Formula (VI-A-1) or Formula (VI-A-2), wherein R10is hydrogen and R6is phenyl substituted with –(alkyl)COOH, -CN or –(alkyl)CN. In some embodiments, a compound is a compound of Formula (VI-A-1) or Formula (VI-A-2), wherein R10is hydrogen and R6is phenyl substituted with –(CH2)COOH, -CN or –(CH2)CN. In some embodiments, a compound is a compound of Formula (VI-A-1) or Formula (VI-A-2), wherein R10is hydrogen and R6is phenyl substituted with –(CH2)COOH, -CN or –(CH2)CN. In some embodiments, a compound is a compound of Formula (VI-A-1) or Formula (VI-A-2), ,

[0156] In some embodiments, a compound is a compound of Formula (VI-A-1) or Formula (VI-A-2), wherein R10is methyl and R6is substituted phenyl as defined above. In some embodiments, a compound is a compound of Formula (VI-A-1) or Formula (VI-A-2), wherein R10is methyl and R6is phenyl substituted with –(alkyl)COOH, -CN or –(alkyl)CN. In some embodiments, a compound is a compound of Formula (VI-A-1) or Formula (VI-A-2), wherein R10is methyl and R6is phenyl substituted with –(CH2)COOH, -CN or –(CH2)CN. In some embodiments, a compound is a compound of Formula (VI-A-1) or Formula (VI-A-2), wherein R10is methyl and R6is phenyl substituted with –(CH2)COOH, -CN or –(CH2)CN. In some embodiments, a compound is a compound of Formula (VI-A-1) or Formula (VI-A-2), ,,or Formula (VI-A-2), is substituted phenyl as defined above. In someof Formula (VI-A-1) or Formula (VI-A-2), is phenyl substituted with –(alkyl)COOH, - CN or –(alkyl)is a compound of Formula (VI-A-1)or Formula (VI-A-2), wherein is phenyl substituted with – (CH2)COOH, -CN or –(CH2) compound is a compound of Formula (VI-A-1) or Formula (VI-A-2), is phenyl substituted with –(CH2)COOH, -CN or –(CH2) is acompound of Formula (VI-A-1) or Formula (VI-A-2), R6,substituted with 1 substituent Q and Q is methyl. In some embodiments, R10is hydrogen. In some embodiments, R10is halo. In some embodiments, R10is fluoro. In some embodiments, . In some embodiments, R10is -C1-C6 alkyl. In some

[0159] In some embodiments, R6is pyridinyl substituted with -CN or phenyl substituted with one or more R60, wherein one R60is C1-C4alkyl substituted with one or more COOH, cycloalkyl, or heterocycloalkyl, or phenyl substituted with -CH2C(O)OR70wherein each R70is hydrogen.

[0160] In some embodiments, R6is phenyl substituted with -CN or phenyl substituted with one or more R60, wherein one R60is C1-C4 alkyl substituted with one or more COOH, cycloalkyl, or heterocycloalkyl, or phenyl substituted with -CH2C(O)OR70wherein each R70is hydrogen. In some embodiments, R6is phenyl substituted with -CH2C(O)OR70, wherein R70is hydrogen. In some embodiments, R6is phenyl substituted with two or more R60, wherein one R60is C1-C4 alkyl optionally substituted with spirocyclic cycloalkyl. In some embodiments, R6is phenyl substituted with two or more R60, wherein one R60is C1-C4alkyl optionally substituted with spirocyclic heterocycloalkyl. In some embodiments, R6is is , , , ,or nd H a pharmaceutically acceptable salt thereof. In some HN embodiments, the compound , or a pharmaceutically acceptableis the ,or a pharmaceutically acceptable saltthereof.compound is the compound Insome embodiments, the compound is the compou , or a pharmaceutically acceptable salt thereof. the compound a pharmaceutically acceptable salt thereof. is the compounda pharmaceutically acceptable salt thereof. Inis the compound a pharmaceutically acceptable salt thereof. Inis the compound a pharmaceutically acceptable salt thereof.or a pharmaceutically acceptable salt thereof, having the structure of any one of any one of the compounds described herein.

[0163] Also disclosed herein is a pharmaceutical composition comprising a compound as described herein and a pharmaceutically acceptable excipient.Additional Embodiments In addition, one or more of the following embodiments are also provided: 1. A compound of Formula (I): , or aA1is NR1a, O, C(=O), S, SO, or SO2; C6alkyl), -CO2(C1-C6alkyl), -CONH2, -CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, or -SO2(alkyl); R1band R1care each independently hydrogen, halo, -OH, C1-C6 alkyl, -O-(C1-C6 alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; R2ais hydrogen, -CN, -C1-C6 alkyl, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R2band R2care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6alkyl, -NH2, - NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1- C6 alkyl), or -CON(C1-C6 alkyl)2; or R4aand R4btogether with the carbon atom to which theyare attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, or-O-(C1-C6 alkyl); R6is optionally substituted , optionally substituted C3-C10 cycloalkyl, heteroaryl, oroptionally substituted 3- to 10-membered heterocycloalkyl; R7is hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; J is NH, N(C1-C6 alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10 alkylene, optionally substituted C2-C10 alkenylene, or optionally substituted C2-C10alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, -C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, -SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10- , areeach Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10 aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6 alkyl), optionally substituted C7-C16 arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted C3-C10cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl), optionally substituted C6-C10aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1; or 2. The compound of Embodiment 1, wherein A1is NR1aor O; or 3. The compound of Embodiment 1 or Embodiment 2, wherein A1is NR1a; or 4. The compound of any one of Embodiments 1 to 3, wherein A2is NR2a, O, or S; or 5. The compound of Embodiment 4, wherein A2is NR2a; or 6. The compound of Embodiment 4, wherein A2is O; or 7. The compound of Embodiment 4, wherein A2is S; or 8. The compound of any one of Embodiments 1 to 7, wherein R3aand R3bare each hydrogen; or 9. The compound of any one of Embodiments 1 to 7, wherein R3aand R3btaken together are =O; or 10. The compound of any one of Embodiments 1 to 7, wherein R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; or 11. The compound of any one of Embodiments 1 to 10, wherein W is N; orThe compound of any one of Embodiments 1 to 11, wherein X is CR9; or The compound of any one of Embodiments 1 to 12, wherein Y is CR10; or The compound of any one of Embodiments 1 to 13, wherein Z is CR11; or The compound of Embodiment 1, having the structure of Formula (IIa-1) (IIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIa-2) (IIa-2), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIb-1) (IIb-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIb-2) (IIb-2), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIc-1) (IIc-1), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIc-2)or -1) or -1) 2)1) (IIIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIIa-2) (IIIa-2), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIIb-1)or 2) or 1) 2) 1)1) R1aa pharmaceutically acceptable salt thereof; or1, having the structure of Formula (IIIe-2)R1a10R3aR N R3ba pharmaceutically acceptable salt thereof; or of Embodiments 1 to 32, wherein R1ais hydrogen;or 34. The compound of any one of Embodiments 1 to 32, wherein R1ais -C1-C6 alkyl; or 35. The compound of any one of Embodiments 1 to 32, wherein R1ais -CO(C1-C6 alkyl); or 36. The compound of any one of Embodiments 1 to 35, wherein R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; or 37. The compound of any one of Embodiments 1 to 35, wherein R4ais substituted phenyl; or 38. The compound of any one of Embodiments 1 to 35, wherein R4ais phenyl; or 39. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted C3-C10 cycloalkyl; or 40. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted 3- to 10-membered heteroaryl; or 41. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted 3- to 10-membered heterocycloalkyl; or 42. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted C1-C6 alkyl; or 43. The compound of any one of Embodiments 1 to 42, wherein J is O, NH, or CH2; or 44. The compound of any one of Embodiments 1 to 43, wherein J is NH; or 45. The compound of any one of Embodiments 1 to 44, wherein R5is L-R6; or46. The compound of any one of Embodiments 1 to 45, wherein L is optionally substituted C1-C10 alkylene; or 47. The compound of Embodiment 46, wherein L is -CH2CH2- or -CH2CH(CH3)-; or 48. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted phenyl; or 49. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted C3-C10 cycloalkyl; or 50. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted 3- to 10-membered heteroaryl; or 51. The compound of Embodiment 50, wherein R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; or 52. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted 3- to 10-memebered heterocycloalkyl; or 53. The compound of any one of Embodiments 1 to 52, wherein each of R8, R9, R10, and R11is independently hydrogen, -C1-C6 alkyl, -C1-C6 haloalkyl, -CONH2, -CONH(C1-C6 alkyl), -CON(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 54. The compound of any one of embodiments 1 to 52, wherein each of R8, R9, R10, and R11is independently selected from the group consisting of hydrogen, halo, -C1-C6alkyl, - C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, -CONH(C1-C6 alkyl), -CON(C1- C6 alkyl)2, -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 55. The compound of any one of Embodiments 1 to 52, wherein each of R9, R10, and R11is hydrogen; or 56. The compound of any one of Embodiments 1 to 52, wherein R10is -CONH2, - CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; or57. The compound of any one of Embodiments 1 to 52, wherein R10is phenyl optionally substituted with 1, 2, or 3 substituents Q; or 58. The compound of any one of Embodiments 1 to 52, wherein R10is 5- to 10- membered heteroaryl optionally substituted with 1, 2, or 3 substituents Q; or 59. The compound of Embodiment 52, wherein R10is pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, or indolyl, benzimidazolyl, each optionally substituted with 1, 2, or 3 substituents Q; or 60. The compound of any one of Embodiments 1-59, wherein each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, -(CH2)mNH2, -(CH2)mSO2(optionally substituted C1- C6 alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), - (CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, -(CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7- C16 arylalkyl, -C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), and optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl); or 61. A compound, having the structure of any one of Compounds 101-692 or 694- 764, or a pharmaceutically acceptable salt thereof; or 62. A pharmaceutical composition comprising the compound of any one of Embodiments 1 to 61 and a pharmaceutically acceptable excipient; or 63. A method of treating a disease or disorder associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1-61 or the pharmaceutical composition of embodiment 62; or 64. A method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of the compound of any one of embodiments 1-61 or the pharmaceutical composition of embodiment 62 to the subject; or65. The method of embodiment 63 or 64, wherein the disease or condition is a cancer selected from the group consisting of a hematologic malignancy and a solid tumor; or 66. The method of embodiment 65, wherein the disease or condition is a hematologic malignancy selected from the group consisting of lymphoma, multiple myeloma, or leukemia; or 67. The method of embodiment 66, wherein the disease or condition is selected from the group consisting of small lymphocytic lymphoma, non-Hodgkin’s lymphoma, indolent non-Hodgkin’s lymphoma, refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+ / - villous lymphocytes), Nodal marginal zone lymphoma (+ / - monocytoid B-cells), Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides, B-cell lymphoma, diffuse large B-cell lymphoma, Mediastinal large B-cell lymphoma, Intravascular large B-cell lymphoma, Primary effusion lymphoma, small non-cleaved cell lymphoma, Burkitt’s lymphoma, multiple myeloma, plasmacytoma, acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, minimal residual disease, hairy cell leukemia, primary myelofibrosis, secondary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disease, and Waldestrom’s macroglobulinemia; or 68. The method of embodiment 65, wherein the disease or condition is a solid tumor, wherein the solid tumor is from a cancer selected from the group consisting of pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, thyroid cancer, gall bladder cancer, lung cancer (e; org; or non-small cell lung cancer, small-cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (e; org; or, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignantpleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi’s sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, and ACTH-producing tumors; or 69. The method of embodiment 63 or 64, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, Goodpasture’s syndrome, glomerulonephritis, hemorrhage, pulmonary hemorrhage, atherosclerosis, rheumatoid arthritis, psoriatic arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis, Behçet disease, autoimmune thyroiditis, Reynaud’s syndrome, acute disseminated encephalomyelitis, chronic idiopathic thrombocytopenic purpura, multiple sclerosis, Sjögren’s syndrome, autoimmune hemolytic anemia, tissue graft rejection, hyperacute rejection of transplanted organs, allograft rejection, graft-versus-host disease, diseases involving leukocyte diapedesis, disease states due to leukocyte dyscrasia and metastasis, granulocyte transfusion-associated syndromes, cytokine-induced toxicity, scleroderma, vasculitis, asthma, psoriasis, chronic inflammatory bowel disease, ulcerative colitis, Crohn’s disease, necrotizing enterocolitis, irritable bowel syndrome, dermatomyositis, Addison’s disease, Parkinson’s disease, Alzheimer’s disease, diabetes, type I diabetes mellitus, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome, multiple organ injury syndrome secondary to septicemia, trauma, hypovolemic shock, allergic conjunctivitis, vernal conjunctivitis, and thyroid-associated ophthalmopathy, eosinophilic granuloma, eczema, chronic bronchitis, acute respiratory distress syndrome, allergic rhinitis, coryza, hay fever, bronchial asthma, silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, emphysema, pneumonia, bacterial pneumonia, bronchiectasis, and pulmonary oxygen toxicity, reperfusion injury of the myocardium, brain, or extremities, thermal injury, cystic fibrosis, keloid formation or scar tissue formation, fever and myalgias due to infection, and brain or spinal cord injury due to minor trauma, diseases involving leukocyte diapedesis, acute hypersensitivity, delayed hypersensitivity, urticaria, food allergies, skin sunburn, inflammatory pelvic disease, urethritis, uveitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, alcoholic hepatitis, gastritis, enteritis, contact dermatitis, atopic dermatitis, gingivitis, appendicitis,pancreatitis, cholocystitis, polycythemia vera, essential thrombocythemia, and polycystic kidney disease; or 70. The method of embodiment 63 or 64, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or 71. The method of embodiment 63 or 64, wherein the disease or condition is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, and systemic lupus erythematosus. 72. The method of any one of embodiments 63-71, wherein the compound is Compound 120, , or a pharmaceutically acceptable salt73. The method of any one of embodiments 63-71, wherein the compound is Compound 670, a pharmaceutically acceptable salt

[0164] In addition, one or more of the following embodiments are also provided: 1. A compound of Formula (I): , or a 11A is NRa, O, , or A2is NR2a, O, CR2bR2c, C(=O), S, SO, or SO2; R1ais hydrogen, -CN, -C1-C6 alkyl, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, or -SO2(alkyl); R1band R1care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; R2ais hydrogen, -CN, -C1-C6alkyl, -CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R2band R2care each independently hydrogen, halo, -OH, C1-C6 alkyl, -O-(C1-C6 alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6 alkyl, -NH2, - NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1- C6 alkyl), or -CON(C1-C6 alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring;R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); R6is optionally substituted , optionally substituted C3-C10cycloalkyl, heteroaryl, oroptionally substituted 3- to 10- R7is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; J is NH, N(C1-C6 alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10alkylene, optionally substituted C2-C10alkenylene, or optionally substituted C2-C10 alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6alkyl, -C1-C6haloalkyl, -CN, -CO2H, -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, -SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10- membered heteroaryl, 4- to 10-membered,areeach Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionallysubstituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6 alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10 cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6 alkyl), optionally substituted C7-C16 arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6alkyl), optionally substituted C3-C10cycloalkyl-(C1-C6alkyl), optionally substituted C6-C10 aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1; or 2. The compound of Embodiment 1, wherein A1is NR1aor O; or 3. The compound of Embodiment 1 or Embodiment 2, wherein A1is NR1a; or 4. The compound of any one of Embodiments 1 to 3, wherein A2is NR2a, O, or S; or 5. The compound of Embodiment 4, wherein A2is NR2a; or 6. The compound of Embodiment 4, wherein A2is O; or 7. The compound of Embodiment 4, wherein A2is S; or 8. The compound of any one of Embodiments 1 to 7, wherein R3aand R3bare each hydrogen; or 9. The compound of any one of Embodiments 1 to 7, wherein R3aand R3btaken together are =O; or 10. The compound of any one of Embodiments 1 to 7, wherein R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; or 11. The compound of any one of Embodiments 1 to 10, wherein W is N; or 12. The compound of any one of Embodiments 1 to 11, wherein X is CR9; or 13. The compound of any one of Embodiments 1 to 12, wherein Y is CR10; orThe compound of any one of Embodiments 1 to 13, wherein Z is CR11; or The compound of Embodiment 1, having the structure of Formula (IIa-1) (IIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIa-2) (IIa-2), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIb-1) (IIb-1), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIb-2) oror -1) or -1) 2)1) (IIIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIIa-2) (IIIa-2), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIIb-1)or 2) or 1) 2) 1)1) R1aa pharmaceutically acceptable salt thereof; or1, having the structure of Formula (IIIe-2)R1a10R3aR N R3ba pharmaceutically acceptable salt thereof; or of Embodiments 1 to 32, wherein R1ais hydrogen;or 34. The compound of any one of Embodiments 1 to 32, wherein R1ais -C1-C6 alkyl; or 35. The compound of any one of Embodiments 1 to 32, wherein R1ais -CO(C1-C6 alkyl); or 36. The compound of any one of Embodiments 1 to 35, wherein R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; or 37. The compound of any one of Embodiments 1 to 35, wherein R4ais substituted phenyl; or 38. The compound of any one of Embodiments 1 to 35, wherein R4ais phenyl; or 39. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted C3-C10 cycloalkyl; or 40. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted 3- to 10-membered heteroaryl; or 41. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted 3- to 10-membered heterocycloalkyl; or 42. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted C1-C6 alkyl; or 43. The compound of any one of Embodiments 1 to 42, wherein J is O, NH, or CH2; or 44. The compound of any one of Embodiments 1 to 43, wherein J is NH; or 45. The compound of any one of Embodiments 1 to 44, wherein R5is L-R6; or46. The compound of any one of Embodiments 1 to 45, wherein L is optionally substituted C1-C10 alkylene; or 47. The compound of Embodiment 46, wherein L is -CH2CH2- or -CH2CH(CH3)-; or 48. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted phenyl; or 49. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted C3-C10 cycloalkyl; or 50. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted 3- to 10-membered heteroaryl; or 51. The compound of Embodiment 50, wherein R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; or 52. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted 3- to 10-memebered heterocycloalkyl; or 53. The compound of any one of Embodiments 1 to 52, wherein each of R8, R9, R10, and R11is independently hydrogen, -C1-C6 alkyl, -C1-C6 haloalkyl, -CONH2, -CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 54. The compound of any one of embodiments 1 to 52, wherein each of R8, R9, R10, and R11is independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, - C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, -CONH(C1-C6 alkyl), -CON(C1- C6alkyl)2, -SO2NH2, -SO2NH(C1-C6alkyl), -SO2N(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 55. The compound of any one of Embodiments 1 to 52, wherein each of R9, R10, and R11is hydrogen; or 56. The compound of any one of Embodiments 1 to 52, wherein R10is -CONH2, - CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; or57. The compound of any one of Embodiments 1 to 52, wherein R10is phenyl optionally substituted with 1, 2, or 3 substituents Q; or 58. The compound of any one of Embodiments 1 to 52, wherein R10is 5- to 10- membered heteroaryl optionally substituted with 1, 2, or 3 substituents Q; or 59. The compound of Embodiment 52, wherein R10is pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, or indolyl, benzimidazolyl, each optionally substituted with 1, 2, or 3 substituents Q; or 60. The compound of any one of Embodiments 1-59, wherein each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, -(CH2)mNH2, -(CH2)mSO2(optionally substituted C1- C6 alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), - (CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, -(CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7- C16 arylalkyl, -C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), and optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl); or 61. A compound, having the structure of any one of Compounds 101-692 or 694- 764, or a pharmaceutically acceptable salt thereof; or 62. A compound having a structure selected from the group consisting of: ,r a 63. A compound having the , or a pharmaceutically acceptable salt thereof;64. A compound having the structure of a pharmaceutically acceptable salt thereof; or65. A compound having the or a pharmaceutically acceptable salt thereof; or66. A compound having the , or a pharmaceutically acceptable salt thereof;67. A pharmaceutical composition comprising the compound of any one of Embodiments 1 to 66 and a pharmaceutically acceptable excipient; or 68. A method of treating a disease or disorder associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1-66 or the pharmaceutical composition of Embodiment 67; or 69. A method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of the compound of any one of Embodiments 1-66 or the pharmaceutical composition of Embodiment 67 to the subject; or 70. The method of embodiment 68 or 69, wherein the disease or condition is a cancer selected from the group consisting of a hematologic malignancy and a solid tumor; or 71. The method of Embodiment 70, wherein the disease or condition is a hematologic malignancy selected from the group consisting of lymphoma, multiple myeloma, or leukemia; or 72. The method of Embodiment 71, wherein the disease or condition is selected from the group consisting of small lymphocytic lymphoma, non-Hodgkin’s lymphoma, indolent non-Hodgkin’s lymphoma, refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+ / - villous lymphocytes), Nodal marginal zone lymphoma (+ / - monocytoid B-cells), Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides, B-cell lymphoma, diffuse large B-cell lymphoma, Mediastinal large B-cell lymphoma, Intravascular large B-cell lymphoma, Primary effusion lymphoma, small non-cleaved cell lymphoma, Burkitt’s lymphoma, multiple myeloma, plasmacytoma, acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, minimal residual disease, hairy cell leukemia, primary myelofibrosis, secondary myelofibrosis, chronic myeloid leukemia,myelodysplastic syndrome, myeloproliferative disease, and Waldestrom’s macroglobulinemia; or 73. The method of Embodiment 70, wherein the disease or condition is a solid tumor, wherein the solid tumor is from a cancer selected from the group consisting of pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, thyroid cancer, gall bladder cancer, lung cancer (e; org; or non-small cell lung cancer, small-cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (e; org; or, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi’s sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, and ACTH-producing tumors; or 74. The method of Embodiment 68 or 69, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, Goodpasture’s syndrome, glomerulonephritis, hemorrhage, pulmonary hemorrhage, atherosclerosis, rheumatoid arthritis, psoriatic arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis, Behçet disease, autoimmune thyroiditis, Reynaud’s syndrome, acute disseminated encephalomyelitis, chronic idiopathic thrombocytopenic purpura, multiple sclerosis, Sjögren’s syndrome, autoimmune hemolytic anemia, tissue graft rejection, hyperacute rejection of transplanted organs, allograft rejection, graft-versus-host disease, diseases involving leukocyte diapedesis, disease states due to leukocyte dyscrasia and metastasis, granulocyte transfusion-associated syndromes, cytokine-induced toxicity, scleroderma, vasculitis, asthma, psoriasis, chronic inflammatory bowel disease, ulcerative colitis, Crohn’s disease, necrotizing enterocolitis, irritable bowel syndrome, dermatomyositis, Addison’s disease, Parkinson’s disease, Alzheimer’s disease, diabetes, type I diabetes mellitus, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome, multiple organ injury syndrome secondary to septicemia, trauma, hypovolemic shock, allergic conjunctivitis, vernal conjunctivitis, and thyroid-associatedophthalmopathy, eosinophilic granuloma, eczema, chronic bronchitis, acute respiratory distress syndrome, allergic rhinitis, coryza, hay fever, bronchial asthma, silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, emphysema, pneumonia, bacterial pneumonia, bronchiectasis, and pulmonary oxygen toxicity, reperfusion injury of the myocardium, brain, or extremities, thermal injury, cystic fibrosis, keloid formation or scar tissue formation, fever and myalgias due to infection, and brain or spinal cord injury due to minor trauma, diseases involving leukocyte diapedesis, acute hypersensitivity, delayed hypersensitivity, urticaria, food allergies, skin sunburn, inflammatory pelvic disease, urethritis, uveitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, alcoholic hepatitis, gastritis, enteritis, contact dermatitis, atopic dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitis, polycythemia vera, essential thrombocythemia, and polycystic kidney disease; or 75. The method of Embodiment 68 or 69, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or 76. The method of Embodiment 68 or 69, wherein the disease or condition is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, and systemic lupus erythematosus; or 77. The method of any one of Embodiments 68 to 76, further comprising administering to the subject one or more additional active agents; or 78. The method of Embodiment 77, wherein the one or more additional active agents are selected from the group consisting of: Pomalidomide, Lenalidomide, Mezigdomide, and Thalidomide; or 79. The method of any one of Embodiments 68 to 76, wherein the one or more additional active agents is Pomalidomide.80. The method of any one of embodiments 69-79, wherein the compound is Compound 120, , or a pharmaceutically acceptable salt81. The method of any one of embodiments 69-79, wherein the compound is Compound 670, a pharmaceutically acceptable salt

[0165] In addition, one or more of the following embodiments are also provided: 1. A method of treating a disease or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject, said method comprising administering to the subject a therapeutically effective amount a glucocorticoid and a compound of Formula (I): , or aA1is NR1a, O, CR1bR1c, C(=O), S, SO, or SO2; A2is NR2a, O, CR2bR2c, C(=O), S, SO, or SO2; R1ais hydrogen, -CN, -C1-C6 alkyl, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl);R1band R1care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R2ais hydrogen, -CN, -C1-C6alkyl, -CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R2band R2care each independently hydrogen, halo, -OH, C1-C6 alkyl, -O-(C1-C6 alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6 alkyl, -NH2, - NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1- C6 alkyl), or -CON(C1-C6 alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); R6is optionally substituted , optionally substituted C3-C10cycloalkyl,heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; R7is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl;J is NH, N(C1-C6alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10 alkylene, optionally substituted C2-C10 alkenylene, or optionally substituted C2-C10 alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, -C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, -SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6alkyl), -SO2N(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10- membered heteroaryl, 4- to 10-membered,and , wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6 alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10 cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7-C16arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl-(C1-C6alkyl), optionally substituted C6-C10aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1; or 2. The method of Embodiment 1, wherein A1is NR1aor O; or 3. The method of Embodiment 1 or Embodiment 2, wherein A1is NR1a; or 4. The method of any one of Embodiments 1 to 3, wherein A2is NR2a, O, or S; or 5. The method of Embodiment 4, wherein A2is NR2a; or 6. The method of Embodiment 4, wherein A2is O; or 7. The method of Embodiment 4, wherein A2is S; or 8. The method of any one of Embodiments 1 to 7, wherein R3aand R3bare each hydrogen; or 9. The method of any one of Embodiments 1 to 7, wherein R3aand R3btaken together are =O; or 10. The method of any one of Embodiments 1 to 7, wherein R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; or 11. The method of any one of Embodiments 1 to 10, wherein W is N; or 12. The method of any one of Embodiments 1 to 11, wherein X is CR9; or 13. The method of any one of Embodiments 1 to 12, wherein Y is CR10; or 14. The method of any one of Embodiments 1 to 13, wherein Z is CR11; or 15. The method of Embodiment 1, having the structure of Formula (IIa-1) (IIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIa-2) (IIa-2), or a pharmaceutically acceptable salt thereof; or17. The method of Embodiment 1, having the structure of Formula (IIb-1) (IIb-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIb-2) (IIb-2), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIc-1) or orR11R1aR3aR9(IId-1), or a pharmaceutically acceptable salt thereof; orEmbodiment 1, having the structure of Formula (IIe-1) orThe method of Embodiment 1, having the structure of Formula (IIe-2) a pharmaceutically acceptable salt thereof; or 1, having the structure of Formula (IIIa-1)(IIIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIIa-2) (IIIa-2), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIIb-1) (IIIb-1), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIIb-2) (IIIb-2), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIIc-1) or29. The method of Embodiment 1, having the structure of Formula (IIIc-2) or orR1a1R3aR0N or oror 34. The method of any one of Embodiments 1 to 32, wherein R1ais -C1-C6 alkyl; or 35. The method of any one of Embodiments 1 to 32, wherein R1ais -CO(C1-C6alkyl); or 36. The method of any one of Embodiments 1 to 35, wherein R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; or37. The method of any one of Embodiments 1 to 35, wherein R4ais substituted phenyl; or 38. The method of any one of Embodiments 1 to 35, wherein R4ais phenyl; or 39. The method of any one of Embodiments 1 to 35, wherein R4ais optionally substituted C3-C10 cycloalkyl; or 40. The method of any one of Embodiments 1 to 35, wherein R4ais optionally substituted 3- to 10-membered heteroaryl; or 41. The method of any one of Embodiments 1 to 35, wherein R4ais optionally substituted 3- to 10-membered heterocycloalkyl; or 42. The method of any one of Embodiments 1 to 35, wherein R4ais optionally substituted C1-C6alkyl; or 43. The method of any one of Embodiments 1 to 42, wherein J is O, NH, or CH2; or 44. The method of any one of Embodiments 1 to 43, wherein J is NH; or 45. The method of any one of Embodiments 1 to 44, wherein R5is L-R6; or 46. The method of any one of Embodiments 1 to 45, wherein L is optionally substituted C1-C10alkylene; or 47. The method of Embodiment 46, wherein L is -CH2CH2- or -CH2CH(CH3)-; or 48. The method of any one of Embodiments 1 to 47, wherein R6is optionally substituted phenyl; or 49. The method of any one of Embodiments 1 to 47, wherein R6is optionally substituted C3-C10 cycloalkyl; or 50. The method of any one of Embodiments 1 to 47, wherein R6is optionally substituted 3- to 10-membered heteroaryl; or 51. The method of Embodiment 50, wherein R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; or 52. The method of any one of Embodiments 1 to 47, wherein R6is optionally substituted 3- to 10-memebered heterocycloalkyl; or 53. The method of any one of Embodiments 1 to 52, wherein each of R8, R9, R10, and R11is independently hydrogen, -C1-C6alkyl, -C1-C6haloalkyl, -CONH2, -CONH(C1-C6alkyl),-CON(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 54. The method of any one of embodiments 1 to 52, wherein each of R8, R9, R10, and R11is independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, - C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, -CONH(C1-C6 alkyl), -CON(C1- C6alkyl)2, -SO2NH2, -SO2NH(C1-C6alkyl), -SO2N(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 55. The method of any one of Embodiments 1 to 52, wherein each of R9, R10, and R11is hydrogen; or 56. The method of any one of Embodiments 1 to 52, wherein R10is -CONH2, - CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; or 57. The method of any one of Embodiments 1 to 52, wherein R10is phenyl optionally substituted with 1, 2, or 3 substituents Q; or 58. The method of any one of Embodiments 1 to 52, wherein R10is 5- to 10- membered heteroaryl optionally substituted with 1, 2, or 3 substituents Q; or 59. The method of Embodiment 52, wherein R10is pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, or indolyl, benzimidazolyl, each optionally substituted with 1, 2, or 3 substituents Q; or 60. The method of any one of Embodiments 1-59, wherein each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, -(CH2)mSO2(optionally substituted C1-C6 alkyl), - C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6alkyl)2, -(CH2)mC(=O)NH(optionally substituted C6-C10aryl), - (CH2)mSO2NH(optionally substituted C1-C6 alkyl), optionally substituted C7-C16 arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), and optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl); or 61. A method of treating a disease or condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and any one of Compounds 101-692 or 694-764, or a pharmaceutically acceptable salt thereof; or 62. A method of treating a disease or condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and a compound having a structure selected from the group consisting of: , aa subject, said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and A compound having the structure of a pharmaceutically acceptable salt thereof; oror condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amounta glucocorticoid and a compound having the structur , or a pharmaceutically acceptable salt thereof; or 65. A method of treating a disease or condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and a compound having the structure of a pharmaceutically acceptable salt thereof; oror condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and compound having the structure of a pharmaceutically acceptable salt thereof; orEmbodiments 1-66, wherein the glucocorticoid is dexamethasone; or 68. The method of any one of Embodiments 1 to 67, wherein the disease or condition is a cancer selected from the group consisting of a hematologic malignancy and a solid tumor; or 69. The method of Embodiment 68, wherein the disease or condition is a hematologic malignancy selected from the group consisting of lymphoma, multiple myeloma, or leukemia; or 70. The method of Embodiment 69, wherein the disease or condition is selected from the group consisting of small lymphocytic lymphoma, non-Hodgkin’s lymphoma,indolent non-Hodgkin’s lymphoma, refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+ / - villous lymphocytes), Nodal marginal zone lymphoma (+ / - monocytoid B-cells), Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides, B-cell lymphoma, diffuse large B-cell lymphoma, Mediastinal large B-cell lymphoma, Intravascular large B-cell lymphoma, Primary effusion lymphoma, small non-cleaved cell lymphoma, Burkitt’s lymphoma, multiple myeloma, plasmacytoma, acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, minimal residual disease, hairy cell leukemia, primary myelofibrosis, secondary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disease, and Waldestrom’s macroglobulinemia; or 71. The method of Embodiment 68, wherein the disease or condition is a solid tumor, wherein the solid tumor is from a cancer selected from the group consisting of pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, thyroid cancer, gall bladder cancer, lung cancer (e; org; or non-small cell lung cancer, small-cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (e; org; or, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi’s sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, and ACTH-producing tumors; or 72. The method of any one of Embodiments 1 to 67, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, Goodpasture’s syndrome, glomerulonephritis, hemorrhage, pulmonary hemorrhage,atherosclerosis, rheumatoid arthritis, psoriatic arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis, Behçet disease, autoimmune thyroiditis, Reynaud’s syndrome, acute disseminated encephalomyelitis, chronic idiopathic thrombocytopenic purpura, multiple sclerosis, Sjögren’s syndrome, autoimmune hemolytic anemia, tissue graft rejection, hyperacute rejection of transplanted organs, allograft rejection, graft-versus-host disease, diseases involving leukocyte diapedesis, disease states due to leukocyte dyscrasia and metastasis, granulocyte transfusion-associated syndromes, cytokine-induced toxicity, scleroderma, vasculitis, asthma, psoriasis, chronic inflammatory bowel disease, ulcerative colitis, Crohn’s disease, necrotizing enterocolitis, irritable bowel syndrome, dermatomyositis, Addison’s disease, Parkinson’s disease, Alzheimer’s disease, diabetes, type I diabetes mellitus, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome, multiple organ injury syndrome secondary to septicemia, trauma, hypovolemic shock, allergic conjunctivitis, vernal conjunctivitis, and thyroid-associated ophthalmopathy, eosinophilic granuloma, eczema, chronic bronchitis, acute respiratory distress syndrome, allergic rhinitis, coryza, hay fever, bronchial asthma, silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, emphysema, pneumonia, bacterial pneumonia, bronchiectasis, and pulmonary oxygen toxicity, reperfusion injury of the myocardium, brain, or extremities, thermal injury, cystic fibrosis, keloid formation or scar tissue formation, fever and myalgias due to infection, and brain or spinal cord injury due to minor trauma, diseases involving leukocyte diapedesis, acute hypersensitivity, delayed hypersensitivity, urticaria, food allergies, skin sunburn, inflammatory pelvic disease, urethritis, uveitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, alcoholic hepatitis, gastritis, enteritis, contact dermatitis, atopic dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitis, polycythemia vera, essential thrombocythemia, and polycystic kidney disease; or 73. The method of any one of Embodiments 1 to 67, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or systemic lupus erythematosus, myestenia gravis,rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or 74. The method of any one of Embodiments 1 to 67, wherein the disease or condition is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, and systemic lupus erythematosus; or 75. The method of method of any one of Embodiments 1 to 61 or 67, wherein the Compound is Compound 120; or 76. A pharmaceutical composition, comprising a glucocorticoid and a compound of Formula (I): , or aA1is NR1a, O, CR1bR1c, C(=O), S, SO, or SO2;C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R1band R1care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R2ais hydrogen, -CN, -C1-C6alkyl, -CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, or -SO2(alkyl); R2band R2care each independently hydrogen, halo, -OH, C1-C6 alkyl, -O-(C1-C6 alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6 alkyl, -NH2, - NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, or-O-(C1-C6 alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionallysubstituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1- C6alkyl), or -CON(C1-C6alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); R6is optionally substituted , optionally substituted C3-C10 cycloalkyl,heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; R7is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; J is NH, N(C1-C6 alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10 alkylene, optionally substituted C2-C10 alkenylene, or optionally substituted C2-C10alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6alkyl, -C1-C6haloalkyl, -CN, -CO2H, -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, -SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-N membered heteroaryl, 4- to 10-membered,, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are with 1, 2, or 3 substituents Q;each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6 alkyl), optionally substituted C7-C16 arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6alkyl), optionally substituted C3-C10cycloalkyl-(C1-C6alkyl), optionally substituted C6-C10 aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1.

[0166] In addition, one or more of the following embodiments are also provided 1. A method of treating a disease or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject, said method comprising administering to the subject a therapeutically effective amount a glucocorticoid and a compound of Formula (I):I), or a pharmaceutically : A1is NR1a, O, CR1bR1c, C(=O), S, SO, or SO2; A2is NR2a, O, CR2bR2c, C(=O), S, SO, or SO2; R1ais hydrogen, -CN, -C1-C6alkyl, -CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R1band R1care each independently hydrogen, halo, -OH, C1-C6 alkyl, -O-(C1-C6 alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; R2ais hydrogen, -CN, -C1-C6 alkyl, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, or -SO2(alkyl); R2band R2care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6alkyl, -NH2, - NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, or-O-(C1-C6 alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1- C6alkyl), or -CON(C1-C6alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, or-O-(C1-C6 alkyl);R6is optionally substituted ary , optionally substituted C3-C10 cycloalkyl, optio heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; R7is hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; J is NH, N(C1-C6alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10 alkylene, optionally substituted C2-C10 alkenylene, or optionally substituted C2-C10 alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, -C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, -SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6alkyl), -SO2N(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10- membered heteroaryl, 4- to 10-membered ,areeach Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionallysubstituted C1-C6alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10 aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10 cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7-C16arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted C3-C10cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl), optionally substituted C6-C10aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1; or 2. The method of Embodiment 1, wherein A1is NR1aor O; or 3. The method of Embodiment 1 or Embodiment 2, wherein A1is NR1a; or 4. The method of any one of Embodiments 1 to 3, wherein A2is NR2a, O, or S; or 5. The method of Embodiment 4, wherein A2is NR2a; or 6. The method of Embodiment 4, wherein A2is O; or 7. The method of Embodiment 4, wherein A2is S; or 8. The method of any one of Embodiments 1 to 7, wherein R3aand R3bare each hydrogen; or 9. The method of any one of Embodiments 1 to 7, wherein R3aand R3btaken together are =O; or 10. The method of any one of Embodiments 1 to 7, wherein R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; or 11. The method of any one of Embodiments 1 to 10, wherein W is N; or 12. The method of any one of Embodiments 1 to 11, wherein X is CR9; or 13. The method of any one of Embodiments 1 to 12, wherein Y is CR10; or 14. The method of any one of Embodiments 1 to 13, wherein Z is CR11; or 15. The method of Embodiment 1, having the structure of Formula (IIa-1)(IIa-1), or a pharmaceutically acceptable salt thereof; or d of Embodiment 1, having the structure of Formula (IIa-2) (IIa-2), or a pharmaceutically acceptable salt thereof; or d of Embodiment 1, having the structure of Formula (IIb-1) (IIb-1), or a pharmaceutically acceptable salt thereof; or d of Embodiment 1, having the structure of Formula (IIb-2) (IIb-2), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIc-1) or or(IId-1), or a pharmaceutically acceptable salt thereof; or f Embodiment 1, having the structure of Formula (IIe-1) or or(IIIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIIa-2) (IIIa-2), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIIb-1) (IIIb-1), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIIb-2)or or oror or33. The method of any one of Embodiments 1 to 32, wherein R1ais hydrogen; or 34. The method of any one of Embodiments 1 to 32, wherein R1ais -C1-C6 alkyl; or 35. The method of any one of Embodiments 1 to 32, wherein R1ais -CO(C1-C6alkyl); or 36. The method of any one of Embodiments 1 to 35, wherein R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; or 37. The method of any one of Embodiments 1 to 35, wherein R4ais substituted phenyl; or 38. The method of any one of Embodiments 1 to 35, wherein R4ais phenyl; or 39. The method of any one of Embodiments 1 to 35, wherein R4ais optionally substituted C3-C10 cycloalkyl; or 40. The method of any one of Embodiments 1 to 35, wherein R4ais optionally substituted 3- to 10-membered heteroaryl; or 41. The method of any one of Embodiments 1 to 35, wherein R4ais optionally substituted 3- to 10-membered heterocycloalkyl; or 42. The method of any one of Embodiments 1 to 35, wherein R4ais optionally substituted C1-C6alkyl; or 43. The method of any one of Embodiments 1 to 42, wherein J is O, NH, or CH2; or 44. The method of any one of Embodiments 1 to 43, wherein J is NH; or 45. The method of any one of Embodiments 1 to 44, wherein R5is L-R6; or 46. The method of any one of Embodiments 1 to 45, wherein L is optionally substituted C1-C10alkylene; or 47. The method of Embodiment 46, wherein L is -CH2CH2- or -CH2CH(CH3)-; or 48. The method of any one of Embodiments 1 to 47, wherein R6is optionally substituted phenyl; or49. The method of any one of Embodiments 1 to 47, wherein R6is optionally substituted C3-C10 cycloalkyl; or 50. The method of any one of Embodiments 1 to 47, wherein R6is optionally substituted 3- to 10-membered heteroaryl; or 51. The method of Embodiment 50, wherein R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; or 52. The method of any one of Embodiments 1 to 47, wherein R6is optionally substituted 3- to 10-memebered heterocycloalkyl; or 53. The method of any one of Embodiments 1 to 52, wherein each of R8, R9, R10, and R11is independently hydrogen, -C1-C6alkyl, -C1-C6haloalkyl, -CONH2, -CONH(C1-C6alkyl), -CON(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 54. The method of any one of embodiments 1 to 52, wherein each of R8, R9, R10, and R11is independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, - C1-C6haloalkyl, -CN, -CO2H, -CO2(C1-C6alkyl), -CONH2, -CONH(C1-C6alkyl), -CON(C1- C6 alkyl)2, -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 55. The method of any one of Embodiments 1 to 52, wherein each of R9, R10, and R11is hydrogen; or 56. The method of any one of Embodiments 1 to 52, wherein R10is -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; or 57. The method of any one of Embodiments 1 to 52, wherein R10is phenyl optionally substituted with 1, 2, or 3 substituents Q; or 58. The method of any one of Embodiments 1 to 52, wherein R10is 5- to 10- membered heteroaryl optionally substituted with 1, 2, or 3 substituents Q; or59. The method of Embodiment 52, wherein R10is pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, or indolyl, benzimidazolyl, each optionally substituted with 1, 2, or 3 substituents Q; or 60. The method of any one of Embodiments 1-59, wherein each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6haloalkoxy, -(CH2)mNH2, -(CH2)mSO2(optionally substituted C1-C6alkyl), - C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, -(CH2)mC(=O)NH(optionally substituted C6-C10 aryl), - (CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7-C16arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6 alkyl), optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6alkyl), and optionally substituted C3-C10cycloalkyl-(C1-C6alkyl); or 61. A method of treating a disease or condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and any one of Compounds 101-692 or 694-764, or a pharmaceutically acceptable salt thereof; or 62. A method of treating a disease or condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and a compound having a structure selected from the group consisting of: ,r a 63. A method of treating a disease or condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and A compound having the structure of a pharmaceutically acceptable salt thereof; oror condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount a glucocorticoid and a compound having the , or a pharmaceutically acceptable salt thereof; or65. A method of treating a disease or condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and a compound having the structure of a pharmaceutically acceptable salt thereof; oror condition associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amountof a glucocorticoid and compound having the structure of a pharmaceutically acceptable salt thereof; or Embodiments 1-66, wherein the glucocorticoid isor 68. The method of any one of Embodiments 1 to 67, wherein the disease or condition is a cancer selected from the group consisting of a hematologic malignancy and a solid tumor; or 69. The method of Embodiment 68, wherein the disease or condition is a hematologic malignancy selected from the group consisting of lymphoma, multiple myeloma, or leukemia; or 70. The method of Embodiment 69, wherein the disease or condition is selected from the group consisting of small lymphocytic lymphoma, non-Hodgkin’s lymphoma, indolent non-Hodgkin’s lymphoma, refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+ / - villous lymphocytes), Nodal marginal zone lymphoma (+ / - monocytoid B-cells), Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides, B-cell lymphoma, diffuse large B-cell lymphoma, Mediastinal large B-cell lymphoma, Intravascular large B-cell lymphoma, Primary effusion lymphoma, small non-cleaved cell lymphoma, Burkitt’s lymphoma, multiple myeloma, plasmacytoma, acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, minimal residual disease, hairy cell leukemia, primary myelofibrosis, secondary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disease, and Waldestrom’s macroglobulinemia; or71. The method of Embodiment 68, wherein the disease or condition is a solid tumor, wherein the solid tumor is from a cancer selected from the group consisting of pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, thyroid cancer, gall bladder cancer, lung cancer (e; org; or non-small cell lung cancer, small-cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (e; org; or, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi’s sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, and ACTH-producing tumors; or 72. The method of any one of Embodiments 1 to 67, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, Goodpasture’s syndrome, glomerulonephritis, hemorrhage, pulmonary hemorrhage, atherosclerosis, rheumatoid arthritis, psoriatic arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis, Behçet disease, autoimmune thyroiditis, Reynaud’s syndrome, acute disseminated encephalomyelitis, chronic idiopathic thrombocytopenic purpura, multiple sclerosis, Sjögren’s syndrome, autoimmune hemolytic anemia, tissue graft rejection, hyperacute rejection of transplanted organs, allograft rejection, graft-versus-host disease, diseases involving leukocyte diapedesis, disease states due to leukocyte dyscrasia and metastasis, granulocyte transfusion-associated syndromes, cytokine-induced toxicity, scleroderma, vasculitis, asthma, psoriasis, chronic inflammatory bowel disease, ulcerative colitis, Crohn’s disease, necrotizing enterocolitis, irritable bowel syndrome, dermatomyositis, Addison’s disease, Parkinson’s disease, Alzheimer’s disease, diabetes, type I diabetes mellitus, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome, multiple organ injury syndrome secondary to septicemia, trauma, hypovolemic shock, allergic conjunctivitis, vernal conjunctivitis, and thyroid-associated ophthalmopathy, eosinophilic granuloma, eczema, chronic bronchitis, acute respiratory distress syndrome, allergic rhinitis, coryza, hay fever, bronchial asthma, silicosis, pulmonarysarcoidosis, pleurisy, alveolitis, emphysema, pneumonia, bacterial pneumonia, bronchiectasis, and pulmonary oxygen toxicity, reperfusion injury of the myocardium, brain, or extremities, thermal injury, cystic fibrosis, keloid formation or scar tissue formation, fever and myalgias due to infection, and brain or spinal cord injury due to minor trauma, diseases involving leukocyte diapedesis, acute hypersensitivity, delayed hypersensitivity, urticaria, food allergies, skin sunburn, inflammatory pelvic disease, urethritis, uveitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, alcoholic hepatitis, gastritis, enteritis, contact dermatitis, atopic dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitis, polycythemia vera, essential thrombocythemia, and polycystic kidney disease; or 73. The method of any one of Embodiments 1 to 67, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or 74. The method of any one of Embodiments 1 to 67, wherein the disease or condition is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, and systemic lupus erythematosus; or 75. The method of method of any one of Embodiments 1 to 61 or 67, wherein the Compound is Compound 120; or 76. A pharmaceutical composition, comprising a glucocorticoid and a compound of Formula (I): ,or a pharmaceutically acceptable salt thereof, wherein: A1is NR1a, O, CR1bR1c, C(=O), S, SO, or SO2; A2is NR2a, O, CR2bR2c, C(=O), S, SO, or SO2; R1ais hydrogen, -CN, -C1-C6alkyl, -CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R1band R1care each independently hydrogen, halo, -OH, C1-C6 alkyl, -O-(C1-C6 alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R2ais hydrogen, -CN, -C1-C6 alkyl, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, or -SO2(alkyl); R2band R2care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6alkyl, -NH2, - NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, or-O-(C1-C6 alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1- C6 alkyl), or -CON(C1-C6 alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, or-O-(C1-C6 alkyl);R6is optionally substituted ary , optionally substituted C3-C10 cycloalkyl, optio heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; R7is hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; J is NH, N(C1-C6alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10 alkylene, optionally substituted C2-C10 alkenylene, or optionally substituted C2-C10 alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, -C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, -SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6alkyl), -SO2N(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10- membered heteroaryl, 4- to 10-membered ,areeach Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionallysubstituted C1-C6alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10 aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10 cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7-C16arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted C3-C10cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl), optionally substituted C6-C10aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1.

[0167] In addition, one or more of the following embodiments are also provided 1. A compound of Formula (I): , or aA1is NR1a, O, CR1bR1c, C(=O), S, SO, or SO2;C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R1band R1care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R2ais hydrogen, -CN, -C1-C6alkyl, -CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, or -SO2(alkyl); R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6 alkyl, -NH2, - NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, or-O-(C1-C6 alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionallysubstituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1- C6alkyl), or -CON(C1-C6alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); R6is optionally substituted , optionally substituted C3-C10 cycloalkyl,heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; R7is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; J is NH, N(C1-C6 alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10 alkylene, optionally substituted C2-C10 alkenylene, or optionally substituted C2-C10alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6alkyl, -C1-C6haloalkyl, -CN, -CO2H, -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, optionally substituted C1-C6 alkoxy,-SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6alkyl), -SO2N(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10-membered N heteroaryl, 4- to 10-membered, and, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are eachwith 1, 2, or 3 substituents Q; each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C1-C6alkoxy, optionally substituted C1-C6haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6 alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10 cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7-C16arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl), optionally substituted C6-C10 aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1; or 2. The compound of Embodiment 1, wherein A1is NR1aor O; or 3. The compound of Embodiment 1 or Embodiment 2, wherein A1is NR1a; or 4. The compound of any one of Embodiments 1 to 3, wherein A2is NR2a, O, or S; or 5. The compound of Embodiment 4, wherein A2is NR2a; or 6. The compound of Embodiment 4, wherein A2is O; or 7. The compound of Embodiment 4, wherein A2is S; or8. The compound of any one of Embodiments 1 to 7, wherein R3aand R3bare each hydrogen; or 9. The compound of any one of Embodiments 1 to 7, wherein R3aand R3btaken together are =O; or 10. The compound of any one of Embodiments 1 to 7, wherein R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; or 11. The compound of any one of Embodiments 1 to 10, wherein W is N; or 12. The compound of any one of Embodiments 1 to 11, wherein X is CR9; or 13. The compound of any one of Embodiments 1 to 12, wherein Y is CR10; or 14. The compound of any one of Embodiments 1 to 13, wherein Z is CR11; or 15. The compound of Embodiment 1, having the structure of Formula (IIa-1) (IIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIa-2) (IIa-2), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIb-1) (IIb-1), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIb-2)or 1 ) 2 ) 1) R91) (IIIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIIa-2) (IIIa-2), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIIb-1)or 2) or 1) 2) 1)or 30. The compound of any one of Embodiments 1 to 28, wherein R1ais -C1-C6alkyl; or 31. The compound of any one of Embodiments 1 to 28, wherein R1ais -CO(C1-C6 alkyl); or32. The compound of any one of Embodiments 1 to 31, wherein R4aand R4bare each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; or 33. The compound of any one of Embodiments 1 to 31, wherein R4ais substituted phenyl; or 34. The compound of any one of Embodiments 1 to 31, wherein R4ais phenyl; or 35. The compound of any one of Embodiments 1 to 31, wherein R4ais optionally substituted C3-C10cycloalkyl; or 36. The compound of any one of Embodiments 1 to 31, wherein R4ais optionally substituted 3- to 10-membered heteroaryl; or 37. The compound of any one of Embodiments 1 to 31, wherein R4ais optionally substituted 3- to 10-membered heterocycloalkyl; or 38. The compound of any one of Embodiments 1 to 31, wherein R4ais optionally substituted C1-C6 alkyl; or 39. The compound of any one of Embodiments 1 to 38, wherein J is O, NH, or CH2; or 40. The compound of any one of Embodiments 1 to 39, wherein J is NH; or 41. The compound of any one of Embodiments 1 to 40, wherein R5is L-R6; or 42. The compound of any one of Embodiments 1 to 41, wherein L is optionally substituted C1-C10 alkylene; or 43. The compound of Embodiment 42, wherein L is -CH2CH2- or -CH2CH(CH3)-; or 44. The compound of any one of Embodiments 1 to 43, wherein R6is optionally substituted phenyl; or 45. The compound of any one of Embodiments 1 to 43, wherein R6is optionally substituted C3-C10 cycloalkyl; or 46. The compound of any one of Embodiments 1 to 43, wherein R6is optionally substituted 3- to 10-membered heteroaryl; or47. The compound of Embodiment 46, wherein R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; or 48. The compound of any one of Embodiments 1 to 43, wherein R6is optionally substituted 3- to 10-memebered heterocycloalkyl; or 49. The compound of any one of Embodiments 1 to 48, wherein each of R8, R9, R10, and R11is independently hydrogen, -C1-C6 alkyl, -C1-C6 haloalkyl, -CONH2, -CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 50. The compound of any one of embodiments 1 to 48, wherein each of R8, R9, R10, and R11is independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, - C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, -CONH(C1-C6 alkyl), -CON(C1- C6alkyl)2, -SO2NH2, -SO2NH(C1-C6alkyl), -SO2N(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 51. The compound of any one of Embodiments 1 to 48, wherein each of R9, R10, and R11is hydrogen; or 52. The compound of any one of Embodiments 1 to 48, wherein R10is -CONH2, - CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; or 53. The compound of any one of Embodiments 1 to 48, wherein R10is phenyl optionally substituted with 1, 2, or 3 substituents Q; or 54. The compound of any one of Embodiments 1 to 48, wherein R10is 5- to 10- membered heteroaryl optionally substituted with 1, 2, or 3 substituents Q; or 55. The compound of Embodiment 48, wherein R10is pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, or indolyl, benzimidazolyl, each optionally substituted with 1, 2, or 3 substituents Q; or 56. The compound of any one of Embodiments 1-55, wherein each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C1-C6alkoxy,optionally substituted C1-C6haloalkoxy, -(CH2)mNH2, -(CH2)mSO2(optionally substituted C1- C6 alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), - (CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, -(CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7- C16 arylalkyl, -C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), and optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl); or 57. A compound, having the structure of any one of Compounds 101-692 or 694- 1134, or a pharmaceutically acceptable salt thereof; or 58. A pharmaceutical composition comprising the compound of any one of Embodiments 1 to 57 and a pharmaceutically acceptable excipient; or 59. A method of treating a disease or disorder associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1-57 or the pharmaceutical composition of embodiment 58; or 60. A method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of the compound of any one of embodiments 1-57 or the pharmaceutical composition of embodiment 58 to the subject; or 61. The method of embodiment 59 or 60, wherein the disease or condition is a cancer selected from the group consisting of a hematologic malignancy and a solid tumor; or 62. The method of embodiment 61, wherein the disease or condition is a hematologic malignancy selected from the group consisting of lymphoma, multiple myeloma, or leukemia; or 63. The method of embodiment 62, wherein the disease or condition is selected from the group consisting of small lymphocytic lymphoma, non-Hodgkin’s lymphoma, indolent non-Hodgkin’s lymphoma, refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+ / - villouslymphocytes), Nodal marginal zone lymphoma (+ / - monocytoid B-cells), Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides, B-cell lymphoma, diffuse large B-cell lymphoma, Mediastinal large B-cell lymphoma, Intravascular large B-cell lymphoma, Primary effusion lymphoma, small non-cleaved cell lymphoma, Burkitt’s lymphoma, multiple myeloma, plasmacytoma, acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, minimal residual disease, hairy cell leukemia, primary myelofibrosis, secondary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disease, and Waldestrom’s macroglobulinemia; or 64. The method of embodiment 61, wherein the disease or condition is a solid tumor, wherein the solid tumor is from a cancer selected from the group consisting of pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, thyroid cancer, gall bladder cancer, lung cancer (e; org; or non-small cell lung cancer, small-cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (e; org; or, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi’s sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, and ACTH-producing tumors; or 65. The method of embodiment 59 or 60, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, Goodpasture’s syndrome, glomerulonephritis, hemorrhage, pulmonary hemorrhage, atherosclerosis, rheumatoid arthritis, psoriatic arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis, Behçet disease, autoimmune thyroiditis, Reynaud’s syndrome, acute disseminated encephalomyelitis, chronic idiopathic thrombocytopenic purpura, multiplesclerosis, Sjögren’s syndrome, autoimmune hemolytic anemia, tissue graft rejection, hyperacute rejection of transplanted organs, allograft rejection, graft-versus-host disease, diseases involving leukocyte diapedesis, disease states due to leukocyte dyscrasia and metastasis, granulocyte transfusion-associated syndromes, cytokine-induced toxicity, scleroderma, vasculitis, asthma, psoriasis, chronic inflammatory bowel disease, ulcerative colitis, Crohn’s disease, necrotizing enterocolitis, irritable bowel syndrome, dermatomyositis, Addison’s disease, Parkinson’s disease, Alzheimer’s disease, diabetes, type I diabetes mellitus, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome, multiple organ injury syndrome secondary to septicemia, trauma, hypovolemic shock, allergic conjunctivitis, vernal conjunctivitis, and thyroid-associated ophthalmopathy, eosinophilic granuloma, eczema, chronic bronchitis, acute respiratory distress syndrome, allergic rhinitis, coryza, hay fever, bronchial asthma, silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, emphysema, pneumonia, bacterial pneumonia, bronchiectasis, and pulmonary oxygen toxicity, reperfusion injury of the myocardium, brain, or extremities, thermal injury, cystic fibrosis, keloid formation or scar tissue formation, fever and myalgias due to infection, and brain or spinal cord injury due to minor trauma, diseases involving leukocyte diapedesis, acute hypersensitivity, delayed hypersensitivity, urticaria, food allergies, skin sunburn, inflammatory pelvic disease, urethritis, uveitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, alcoholic hepatitis, gastritis, enteritis, contact dermatitis, atopic dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitis, polycythemia vera, essential thrombocythemia, and polycystic kidney disease; or 66. The method of embodiment 59 or 60, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or67. The method of embodiment 59 or 60, wherein the disease or condition is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, and systemic lupus erythematosus. 68. The method of any one of embodiments 59-67, wherein the compound is Compound 120, , or a pharmaceutically acceptable salt69. The method of any one of embodiments 59-67, wherein the compound is Compound 670, a pharmaceutically acceptable salt

[0168] In addition, one or more of the following embodiments are also provided 1. A compound of Formula (I): , or aA1is NR1a, O, CR1bR1c, C(=O), S, SO, or SO2; A2is NR2a, O, CR2bR2c, C(=O), S, SO, or SO2; R1ais hydrogen, -CN, -C1-C6alkyl, -CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl);R1band R1care each independently hydrogen, halo, -OH, C1-C6alkyl, -O-(C1-C6alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R2ais hydrogen, -CN, -C1-C6alkyl, -CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R2band R2care each independently hydrogen, halo, -OH, C1-C6 alkyl, -O-(C1-C6 alkyl), -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2,-CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6 alkyl, -NH2, - NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1- C6 alkyl), or -CON(C1-C6 alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); R6is optionally substituted , optionally substituted C3-C10cycloalkyl,heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; R7is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl;J is NH, N(C1-C6alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10 alkylene, optionally substituted C2-C10 alkenylene, or optionally substituted C2-C10 alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, -C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, -SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6alkyl), -SO2N(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10- membered heteroaryl, 4- to 10-membered,and , wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6 alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10 cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7-C16arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl-(C1-C6alkyl), optionally substituted C6-C10aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1; or 2. The compound of Embodiment 1, wherein A1is NR1aor O; or 3. The compound of Embodiment 1 or Embodiment 2, wherein A1is NR1a; or 4. The compound of any one of Embodiments 1 to 3, wherein A2is NR2a, O, or S; or 5. The compound of Embodiment 4, wherein A2is NR2a; or 6. The compound of Embodiment 4, wherein A2is O; or 7. The compound of Embodiment 4, wherein A2is S; or 8. The compound of any one of Embodiments 1 to 7, wherein R3aand R3bare each hydrogen; or 9. The compound of any one of Embodiments 1 to 7, wherein R3aand R3btaken together are =O; or 10. The compound of any one of Embodiments 1 to 7, wherein R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; or 11. The compound of any one of Embodiments 1 to 10, wherein W is N; or 12. The compound of any one of Embodiments 1 to 11, wherein X is CR9; or 13. The compound of any one of Embodiments 1 to 12, wherein Y is CR10; or 14. The compound of any one of Embodiments 1 to 13, wherein Z is CR11; or 15. The compound of Embodiment 1, having the structure of Formula (IIa-1) (IIa-1), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIa-2)(IIa-2), or a pharmaceutically acceptable salt thereof; or und of Embodiment 1, having the structure of Formula (IIb-1) (IIb-1), or a pharmaceutically acceptable salt thereof; or und of Embodiment 1, having the structure of Formula (IIb-2) ora pharmaceutically acceptable salt thereof; or1, having the structure of Formula (IId-1) R11R1aR9orThe compound of Embodiment 1, having the structure of Formula (IIe-1) 2) 1)(IIIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIIa-2) (IIIa-2), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIIb-1) (IIIb-1), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIIb-2) or28. The compound of Embodiment 1, having the structure of Formula (IIIc-1) 2) 1)1)2) R1aR3aa pharmaceutically acceptable salt thereof; orof Embodiments 1 to 32, wherein R1ais hydrogen; or 34. The compound of any one of Embodiments 1 to 32, wherein R1ais -C1-C6alkyl; or35. The compound of any one of Embodiments 1 to 32, wherein R1ais -CO(C1-C6alkyl); or 36. The compound of any one of Embodiments 1 to 35, wherein R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; or 37. The compound of any one of Embodiments 1 to 35, wherein R4ais substituted phenyl; or 38. The compound of any one of Embodiments 1 to 35, wherein R4ais phenyl; or 39. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted C3-C10 cycloalkyl; or 40. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted 3- to 10-membered heteroaryl; or 41. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted 3- to 10-membered heterocycloalkyl; or 42. The compound of any one of Embodiments 1 to 35, wherein R4ais optionally substituted C1-C6 alkyl; or 43. The compound of any one of Embodiments 1 to 42, wherein J is O, NH, or CH2; or 44. The compound of any one of Embodiments 1 to 43, wherein J is NH; or 45. The compound of any one of Embodiments 1 to 44, wherein R5is L-R6; or 46. The compound of any one of Embodiments 1 to 45, wherein L is optionally substituted C1-C10alkylene; or 47. The compound of Embodiment 46, wherein L is -CH2CH2- or -CH2CH(CH3)-; or 48. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted phenyl; or 49. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted C3-C10cycloalkyl; or50. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted 3- to 10-membered heteroaryl; or 51. The compound of Embodiment 50, wherein R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; or 52. The compound of any one of Embodiments 1 to 47, wherein R6is optionally substituted 3- to 10-memebered heterocycloalkyl; or 53. The compound of any one of Embodiments 1 to 52, wherein each of R8, R9, R10, and R11is independently hydrogen, -C1-C6 alkyl, -C1-C6 haloalkyl, -CONH2, -CONH(C1-C6 alkyl), -CON(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 54. The compound of any one of embodiments 1 to 52, wherein each of R8, R9, R10, and R11is independently selected from the group consisting of hydrogen, halo, -C1-C6alkyl, - C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, -CONH(C1-C6 alkyl), -CON(C1- C6 alkyl)2, -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 55. The compound of any one of Embodiments 1 to 52, wherein each of R9, R10, and R11is hydrogen; or 56. The compound of any one of Embodiments 1 to 52, wherein R10is -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; or 57. The compound of any one of Embodiments 1 to 52, wherein R10is phenyl optionally substituted with 1, 2, or 3 substituents Q; or 58. The compound of any one of Embodiments 1 to 52, wherein R10is 5- to 10- membered heteroaryl optionally substituted with 1, 2, or 3 substituents Q; or 59. The compound of Embodiment 52, wherein R10is pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, or indolyl, benzimidazolyl, each optionally substituted with 1, 2, or 3 substituents Q; or60. The compound of any one of Embodiments 1-59, wherein each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6haloalkoxy, -(CH2)mNH2, -(CH2)mSO2(optionally substituted C1- C6 alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), - (CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, -(CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mSO2NH(optionally substituted C1-C6alkyl), optionally substituted C7- C16 arylalkyl, -C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6alkyl), and optionally substituted C3-C10cycloalkyl-(C1-C6alkyl); or 61. A compound, having the structure of any one of Compounds 101-692 or 694- 764, or a pharmaceutically acceptable salt thereof; or 62. A compound having a structure selected from the group consisting of: , a64. A compound having the structure of a pharmaceutically acceptable salt thereof; or65. A compound having the or a pharmaceutically acceptable salt thereof; or66. A compound having the , or a pharmaceutically acceptable salt thereof;67. A pharmaceutical composition comprising the compound of any one of Embodiments 1 to 66 and a pharmaceutically acceptable excipient; or 68. A method of treating a disease or disorder associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1-66 or the pharmaceutical composition of Embodiment 67; or 69. A method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of the compound of any one of Embodiments 1-66 or the pharmaceutical composition of Embodiment 67 to the subject; or 70. The method of embodiment 68 or 69, wherein the disease or condition is a cancer selected from the group consisting of a hematologic malignancy and a solid tumor; or71. The method of Embodiment 70, wherein the disease or condition is a hematologic malignancy selected from the group consisting of lymphoma, multiple myeloma, or leukemia; or 72. The method of Embodiment 71, wherein the disease or condition is selected from the group consisting of small lymphocytic lymphoma, non-Hodgkin’s lymphoma, indolent non-Hodgkin’s lymphoma, refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+ / - villous lymphocytes), Nodal marginal zone lymphoma (+ / - monocytoid B-cells), Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides, B-cell lymphoma, diffuse large B-cell lymphoma, Mediastinal large B-cell lymphoma, Intravascular large B-cell lymphoma, Primary effusion lymphoma, small non-cleaved cell lymphoma, Burkitt’s lymphoma, multiple myeloma, plasmacytoma, acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, minimal residual disease, hairy cell leukemia, primary myelofibrosis, secondary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disease, and Waldestrom’s macroglobulinemia; or 73. The method of Embodiment 70, wherein the disease or condition is a solid tumor, wherein the solid tumor is from a cancer selected from the group consisting of pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, thyroid cancer, gall bladder cancer, lung cancer (e; org; or non-small cell lung cancer, small-cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (e; org; or, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi’s sarcomas, myxoid carcinoma, round cell carcinoma,squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, and ACTH-producing tumors; or 74. The method of Embodiment 68 or 69, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, Goodpasture’s syndrome, glomerulonephritis, hemorrhage, pulmonary hemorrhage, atherosclerosis, rheumatoid arthritis, psoriatic arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis, Behçet disease, autoimmune thyroiditis, Reynaud’s syndrome, acute disseminated encephalomyelitis, chronic idiopathic thrombocytopenic purpura, multiple sclerosis, Sjögren’s syndrome, autoimmune hemolytic anemia, tissue graft rejection, hyperacute rejection of transplanted organs, allograft rejection, graft-versus-host disease, diseases involving leukocyte diapedesis, disease states due to leukocyte dyscrasia and metastasis, granulocyte transfusion-associated syndromes, cytokine-induced toxicity, scleroderma, vasculitis, asthma, psoriasis, chronic inflammatory bowel disease, ulcerative colitis, Crohn’s disease, necrotizing enterocolitis, irritable bowel syndrome, dermatomyositis, Addison’s disease, Parkinson’s disease, Alzheimer’s disease, diabetes, type I diabetes mellitus, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome, multiple organ injury syndrome secondary to septicemia, trauma, hypovolemic shock, allergic conjunctivitis, vernal conjunctivitis, and thyroid-associated ophthalmopathy, eosinophilic granuloma, eczema, chronic bronchitis, acute respiratory distress syndrome, allergic rhinitis, coryza, hay fever, bronchial asthma, silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, emphysema, pneumonia, bacterial pneumonia, bronchiectasis, and pulmonary oxygen toxicity, reperfusion injury of the myocardium, brain, or extremities, thermal injury, cystic fibrosis, keloid formation or scar tissue formation, fever and myalgias due to infection, and brain or spinal cord injury due to minor trauma, diseases involving leukocyte diapedesis, acute hypersensitivity, delayed hypersensitivity, urticaria, food allergies, skin sunburn, inflammatory pelvic disease, urethritis, uveitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, alcoholic hepatitis, gastritis, enteritis, contact dermatitis, atopic dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitis, polycythemia vera, essential thrombocythemia, and polycystic kidney disease; or75. The method of Embodiment 68 or 69, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or 76. The method of Embodiment 68 or 69, wherein the disease or condition is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, and systemic lupus erythematosus; or 77. The method of any one of Embodiments 68 to 76, further comprising administering to the subject one or more additional active agents; or 78. The method of Embodiment 77, wherein the one or more additional active agents are selected from the group consisting of: Pomalidomide, Lenalidomide, Mezigdomide, and Thalidomide; or 79. The method of any one of Embodiments 68 to 76, wherein the one or more additional active agents is Pomalidomide; or 80. The method of embodiment 68 or 69, wherein the disease or condition is an HPV+ cancer. 81. The method of any one of embodiments 69-80, wherein the compound is Compound 120,82. The method of any one of embodiments 69-80, wherein the compound is Compound 670, a pharmaceutically acceptable salt

[0169] one or more are also provided: 1. A compound of Formula (I): , or aA1is NR1a, O, CR1bR1c, C(=O), S, SO, or SO2; A2is NR2a, O, C(=O), S, SO, or SO2; R1ais hydrogen, -CN, -C1-C6 alkyl, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), -CON(C1-C6alkyl)2, or -SO2(alkyl); R1band R1care each independently hydrogen, halo, -OH, C1-C6 alkyl, -O-(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -CO(C1-C6 alkyl), -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; R2ais hydrogen, -CN, -C1-C6alkyl, -CO(C1-C6alkyl), -CO2(C1-C6alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, or -SO2(alkyl); R3aand R3bare each independently hydrogen, halo, -OH, -CN, C1-C6alkyl, -NH2, - NH(C1-C6alkyl), -N(C1-C6alkyl)2, or-O-(C1-C6alkyl); or R3aand R3btaken together are =O; or R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R4aand R4bare each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-memberedheteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1- C6 alkyl), or -CON(C1-C6 alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10cycloalkyl ring; R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, or-O-(C1-C6 alkyl); , optionally heteroaryl, oroptionally substituted 3- to 10-membered heterocycloalkyl; R7is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; J is NH, N(C1-C6alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2; L is optionally substituted C1-C10 alkylene, optionally substituted C2-C10 alkenylene, or optionally substituted C2-C10 alkynylene; W is N or CR8; X is N or CR9; Y is N or CR10; Z is N or CR11; R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, -C1-C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, - CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, optionally substituted C1-C6alkoxy,-SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, - SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered, and, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each ituted with 1, 2, or 3 substituents Q; each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10 aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6 alkyl), optionally substituted C7-C16 arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted C3-C10cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl), optionally substituted C6-C10aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1; or 2. The compound of Embodiment 1, wherein A1is NR1aor O; or 3. The compound of Embodiment 1 or Embodiment 2, wherein A1is NR1a; or 4. The compound of any one of Embodiments 1 to 3, wherein A2is NR2a, O, or S; or 5. The compound of Embodiment 4, wherein A2is NR2a; or 6. The compound of Embodiment 4, wherein A2is O; or 7. The compound of Embodiment 4, wherein A2is S; or 8. The compound of any one of Embodiments 1 to 7, wherein R3aand R3bare each hydrogen; or 9. The compound of any one of Embodiments 1 to 7, wherein R3aand R3btaken together are =O; or10. The compound of any one of Embodiments 1 to 7, wherein R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; or 11. The compound of any one of Embodiments 1 to 10, wherein W is N; or 12. The compound of any one of Embodiments 1 to 11, wherein X is CR9; or 13. The compound of any one of Embodiments 1 to 12, wherein Y is CR10; or 14. The compound of any one of Embodiments 1 to 13, wherein Z is CR11; or 15. The compound of Embodiment 1, having the structure of Formula (IIa-1) (IIa-1), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIa-2) (IIa-2), or a pharmaceutically acceptable salt thereof; or of Embodiment 1, having the structure of Formula (IIb-1) (IIb-1), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIb-2) (IIb-2), or a pharmaceutically acceptable salt thereof; orof Embodiment 1, having the structure of Formula (IIc-1)(IIc-1), or a pharmaceutically acceptable salt thereof; or 20. The compound of Embodiment 1, having the structure of Formula (IIc-2) (IIc-2), or a pharmaceutically acceptable salt thereof; or 21. The compound of Embodiment 1, having the structure of Formula (IId-1) R11R1a3aR10N R R3b9J R O R5CN R4aR4b (IId-1), or a pharmaceutically acceptable salt thereof; or 22. The compound of Embodiment 1, having the structure of Formula (IIIa-1) (IIIa-1), or a pharmaceutically acceptable salt thereof; or 23. The compound of Embodiment 1, having the structure of Formula (IIIa-2) (IIIa-2), or a pharmaceutically acceptable salt thereof; or 24. The compound of Embodiment 1, having the structure of Formula (IIIb-1) oror 1) 2) 1)or 30. The compound of any one of Embodiments 1 to 28, wherein R1ais -C1-C6 alkyl; or 31. The compound of any one of Embodiments 1 to 28, wherein R1ais -CO(C1-C6alkyl); or 32. The compound of any one of Embodiments 1 to 31, wherein R4aand R4bare each independently hydrogen, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; or33. The compound of any one of Embodiments 1 to 31, wherein R4ais substituted phenyl; or 34. The compound of any one of Embodiments 1 to 31, wherein R4ais phenyl; or 35. The compound of any one of Embodiments 1 to 31, wherein R4ais optionally substituted C3-C10 cycloalkyl; or 36. The compound of any one of Embodiments 1 to 31, wherein R4ais optionally substituted 3- to 10-membered heteroaryl; or 37. The compound of any one of Embodiments 1 to 31, wherein R4ais optionally substituted 3- to 10-membered heterocycloalkyl; or 38. The compound of any one of Embodiments 1 to 31, wherein R4ais optionally substituted C1-C6alkyl; or 39. The compound of any one of Embodiments 1 to 38, wherein J is O, NH, or CH2; or 40. The compound of any one of Embodiments 1 to 39, wherein J is NH; or 41. The compound of any one of Embodiments 1 to 40, wherein R5is L-R6; or 42. The compound of any one of Embodiments 1 to 41, wherein L is optionally substituted C1-C10alkylene; or 43. The compound of Embodiment 42, wherein L is -CH2CH2- or -CH2CH(CH3)-; or 44. The compound of any one of Embodiments 1 to 43, wherein R6is optionally substituted phenyl; or 45. The compound of any one of Embodiments 1 to 43, wherein R6is optionally substituted C3-C10 cycloalkyl; or 46. The compound of any one of Embodiments 1 to 43, wherein R6is optionally substituted 3- to 10-membered heteroaryl; or 47. The compound of Embodiment 46, wherein R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; or 48. The compound of any one of Embodiments 1 to 43, wherein R6is optionally substituted 3- to 10-memebered heterocycloalkyl; or 49. The compound of any one of Embodiments 1 to 48, wherein each of R8, R9, R10, and R11is independently hydrogen, -C1-C6alkyl, -C1-C6haloalkyl, -CONH2, -CONH(C1-C6alkyl), -CON(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, or 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 50. The compound of any one of embodiments 1 to 48, wherein each of R8, R9, R10, and R11is independently selected from the group consisting of hydrogen, halo, -C1-C6 alkyl, - C1-C6haloalkyl, -CN, -CO2H, -CO2(C1-C6alkyl), -CONH2, -CONH(C1-C6alkyl), -CON(C1- C6 alkyl)2, -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, C6-C10 aryl, C3-C10 cycloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocycloalkyl, wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; or 51. The compound of any one of Embodiments 1 to 48, wherein each of R9, R10, and R11is hydrogen; or 52. The compound of any one of Embodiments 1 to 48, wherein R10is -CONH2, - CONH(C1-C6 alkyl), or -CON(C1-C6 alkyl)2; or 53. The compound of any one of Embodiments 1 to 48, wherein R10is phenyl optionally substituted with 1, 2, or 3 substituents Q; or 54. The compound of any one of Embodiments 1 to 48, wherein R10is 5- to 10- membered heteroaryl optionally substituted with 1, 2, or 3 substituents Q; or 55. The compound of Embodiment 48, wherein R10is pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, or indolyl, benzimidazolyl, each optionally substituted with 1, 2, or 3 substituents Q; or 56. The compound of any one of Embodiments 1-55, wherein each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, -(CH2)mSO2(optionally substituted C1- C6alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6alkyl), - (CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, -(CH2)mC(=O)NH(optionally substituted C6-C10 aryl), -(CH2)mSO2NH(optionally substituted C1-C6 alkyl), optionally substituted C7- C16arylalkyl, -C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted5- to 10- membered heteroaryl-(C1-C6alkyl), optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6 alkyl), and optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl); or 57. A compound, having the structure of any one of Compounds 101-692 or 694- 1134, or a pharmaceutically acceptable salt thereof; or 58. A pharmaceutical composition comprising the compound of any one of Embodiments 1 to 57 and a pharmaceutically acceptable excipient; or 59. A method of treating a disease or disorder associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1-57 or the pharmaceutical composition of embodiment 58; or 60. A method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of the compound of any one of embodiments 1-57 or the pharmaceutical composition of embodiment 58 to the subject; or 61. The method of embodiment 59 or 60, wherein the disease or condition is a cancer selected from the group consisting of a hematologic malignancy and a solid tumor; or 62. The method of embodiment 61, wherein the disease or condition is a hematologic malignancy selected from the group consisting of lymphoma, multiple myeloma, or leukemia; or 63. The method of embodiment 62, wherein the disease or condition is selected from the group consisting of small lymphocytic lymphoma, non-Hodgkin’s lymphoma, indolent non-Hodgkin’s lymphoma, refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+ / - villous lymphocytes), Nodal marginal zone lymphoma (+ / - monocytoid B-cells), Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides, B-cell lymphoma, diffuse large B-cell lymphoma, Mediastinal large B-cell lymphoma, Intravascular large B-cell lymphoma, Primary effusion lymphoma, small non-cleaved cell lymphoma, Burkitt’s lymphoma, multiple myeloma,plasmacytoma, acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, minimal residual disease, hairy cell leukemia, primary myelofibrosis, secondary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disease, and Waldestrom’s macroglobulinemia; or 64. The method of embodiment 61, wherein the disease or condition is a solid tumor, wherein the solid tumor is from a cancer selected from the group consisting of pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, thyroid cancer, gall bladder cancer, lung cancer (e; org; or non-small cell lung cancer, small-cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (e; org; or, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi’s sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, and ACTH-producing tumors; or 65. The method of embodiment 59 or 60, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, Goodpasture’s syndrome, glomerulonephritis, hemorrhage, pulmonary hemorrhage, atherosclerosis, rheumatoid arthritis, psoriatic arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis, Behçet disease, autoimmune thyroiditis, Reynaud’s syndrome, acute disseminated encephalomyelitis, chronic idiopathic thrombocytopenic purpura, multiple sclerosis, Sjögren’s syndrome, autoimmune hemolytic anemia, tissue graft rejection, hyperacute rejection of transplanted organs, allograft rejection, graft-versus-host disease, diseases involving leukocyte diapedesis, disease states due to leukocyte dyscrasia and metastasis, granulocyte transfusion-associated syndromes, cytokine-induced toxicity, scleroderma, vasculitis, asthma, psoriasis, chronic inflammatory bowel disease, ulcerative colitis, Crohn’s disease, necrotizing enterocolitis, irritable bowel syndrome, dermatomyositis,Addison’s disease, Parkinson’s disease, Alzheimer’s disease, diabetes, type I diabetes mellitus, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome, multiple organ injury syndrome secondary to septicemia, trauma, hypovolemic shock, allergic conjunctivitis, vernal conjunctivitis, and thyroid-associated ophthalmopathy, eosinophilic granuloma, eczema, chronic bronchitis, acute respiratory distress syndrome, allergic rhinitis, coryza, hay fever, bronchial asthma, silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, emphysema, pneumonia, bacterial pneumonia, bronchiectasis, and pulmonary oxygen toxicity, reperfusion injury of the myocardium, brain, or extremities, thermal injury, cystic fibrosis, keloid formation or scar tissue formation, fever and myalgias due to infection, and brain or spinal cord injury due to minor trauma, diseases involving leukocyte diapedesis, acute hypersensitivity, delayed hypersensitivity, urticaria, food allergies, skin sunburn, inflammatory pelvic disease, urethritis, uveitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, alcoholic hepatitis, gastritis, enteritis, contact dermatitis, atopic dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitis, polycythemia vera, essential thrombocythemia, and polycystic kidney disease; or 66. The method of embodiment 59 or 60, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease; or 67. The method of embodiment 59 or 60, wherein the disease or condition is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, and systemic lupus erythematosus. 68. The method of any one of embodiments 60-67, wherein the compound is Compound 120,), or a pharmaceutically acceptable salt 69. The method of any one of embodiments 60-67, wherein the compound is Compound 670, a pharmaceutically acceptable salt

[0170] In addition, one or more of the following embodiments are also provided: 1. A compound of Formula (I): , or aA1is NR1a; A2is CR2bR2c; R1ais hydrogen; R2band R2care each independently hydrogen; R3aand R3bare each independently hydrogen; R4ais optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -CONH2, -CONH(C1- C6 alkyl), or -CON(C1-C6 alkyl)2; or R4aand R4btogether with the carbon atom to which theyare attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring; R4bis hydrogen; R5is -L-R6; R6is optionally substituted aryl, optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl; J is NH; L is -CH2CH2- or -CH2CH(CH3)-; W is N; X is CH; Y is CR10; Z is CH; R10is selected from the group consisting of hydrogen, halo, -C1-C6alkyl, -C1-C6haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, -CONH(C1-C6 alkyl), -CON(C1-C6 alkyl)2, -SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1- C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, , , wherein said alkyl, aryl, cycloalkyl,with 1, 2, or 3 substituents Q; each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6alkyl, optionally substituted C1-C6haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6 alkyl), -C(=O)NH2, -(CH2)mC(=O)NH(optionally substituted C1-C6alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6alkyl)2, - (CH2)mC(=O)NH(optionally substituted C6-C10aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10 cycloalkyl), -(CH2)mSO2NH(optionally substituted C1-C6 alkyl), optionally substituted C7-C16 arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), -(CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6alkyl), optionally substituted C3-C10cycloalkyl-(C1-C6alkyl), optionally substituted C6-C10 aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1; or 2. The compound of embodiment 1, wherein R4ais phenyl; or 3. The compound of embodiment 2, wherein R10is hydrogen; or 4. The compound of embodiment 2, wherein R10is methyl; or 5. The compound of embodiment 2, wherein R10is pyrazole and Q is methyl; or 6. The compound of any one of embodiments 1-4, wherein R6is substituted phenyl; or 7. The compound of embodiment 6, wherein R6is phenyl substituted with 1-3 R60; or 8. The compound of embodiment 7, wherein at least one R60is -CH2C(O)OH; or 9. The compound of embodiment 7, wherein at least one R60is cyano; or 10. The compound of embodiment 7, wherein at least one R60is alkyl optionally substituted with -COOH; or 11. The compound of embodiment 7, wherein at least one R60is alkyl optionally substituted with cyano; or 12. The compound of any one of embodiments 1-11, wherein L is -CH2CH2; or13. The compound of any one of embodiments 1-11, wherein L is -CH2CH(CH3)-; or 14. A pharmaceutical composition comprising the compound of any one of embodiments 1-13, and a pharmaceutically acceptable excipient; or 15. The use of a compound of any one of embodiments 1-13, for inhibiting p300 lysine acetyltransferase (KATi).

[0171] Provided herein are compounds of Formula (IIIe-1): , or aR1ais hydrogen; R2band R2care each independently hydrogen; R3aand R3bare each independently hydrogen; R4ais phenyl; R4bis hydrogen; J is NH; R5is -L-R6; L is -CH2CH2- or -CH2CH(CH3)-; R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; R10is selected from the group consisting of hydrogen, halo, -C1-C6alkyl, -C1- C6 haloalkyl, -CN, -CO2H, -CO2(C1-C6 alkyl), -CONH2, -CONH(C1-C6 alkyl), - CON(C1-C6 alkyl)2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -OH, optionally substituted C1-C6alkoxy,-SO2(alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, - SO2NH(C1-C6alkyl), -SO2N(C1-C6alkyl)2, C6-C10aryl, C3-C10cycloalkyl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocycloalkyl, , , wherein said alkyl, aryl, cycloalkyl, heteroaryl substituted with 1, 2, or 3 substituents Q;from the group consisting of: halo, -CN, -OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted C1-C6alkyl), -C(=O)NH2, - (CH2)mC(=O)NH(optionally substituted C1-C6 alkyl), -(CH2)mC(=O)N(optionally substituted C1-C6 alkyl)2, -(CH2)mC(=O)NH(optionally substituted C6-C10 aryl), - (CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), - (CH2)mC(=O)NH(optionally substituted C3-C10 cycloalkyl), - (CH2)mSO2NH(optionally substituted C1-C6 alkyl), optionally substituted C7-C16 arylalkyl, -C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), - (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(C1-C6 alkyl), optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- membered heterocycloalkyl-(C1-C6alkyl), optionally substituted C3-C10 cycloalkyl-(C1-C6 alkyl), optionally substituted C6-C10 aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1; provided that R10is -CONH2, -CONH(C1-C6alkyl), or -CON(C1-C6alkyl)2; or R10is phenyl optionally substituted with 1, 2, or 3 substituents Q; or R10is pyrazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, or indolyl, benzimidazolyl, each optionally substituted with 1, 2, or 3 substituents Q; or or a pharmaceutically acceptable salt thereof.

[0172] In addition, one or more of the following embodiments are also provided: 1. A compound of Formula (IIIe-1):1), or a pharmaceut R1ais hydrogen; R2band R2care each independently hydrogen; R3aand R3bare each independently hydrogen; R4ais phenyl; R4bis hydrogen; J is NH; R5is -L-R6; L is -CH2CH2- or -CH2CH(CH3)-; R6is aryl substituted with 1 to 3 substituents selected from -CH2C(O)H, alkyl, substituted alkyl, cyano, halogen, and R60, wherein the aryl is phenyl and the C1-C6 substituted alkyl is C1-C6 alkylene substituted with 1 to 3 R60, spiro-connected cycloalkyl or spiro- connected heterocycloalkyl; R60is alkyl, cyano, -COOH, halogen, haloalkyl and alkoxy; and R10is hydrogen, or a pharmaceutically acceptable salt thereof. 2. The compound of embodiment 1, wherein R60is -COOH, cyano, fluoro, methyl, methoxy or -CF3. 3. The compound of embodiment 2, wherein R6is phenyl substituted with – (CH2)COOH, or phenyl substituted with C1-C6alkylene substituted with -COOH or cyano and optionally substituted with a spiro-connected C3 to C6 cycloalkyl or a spiro-connected 3 to 6 member heterocycloalkyl. 4. The compound of embodiment 3, wherein R6is phenyl further substituted with one or two methyl.5. The compound of embodiment 2, wherein R6is phenyl substituted with cyano or alkyl substituted with cyano. 6. The compound of embodiment 2, ,, or8. The compound of embodiment 6, ,.methyl, fluoro or methoxy.10. The compound of embodiment 6, wherei or . 6of embodiment 2, wherein R is selected from:. 12. The compound of embodiment 2, wherein R6is phenyl substituted with C1-C6alkylene substituted with -COOH and substituted with a spiro-connected C3 to C6 cycloalkyl or a spiro-connected 3 to 6 member heterocycloalkyl. 13. The compound of embodiment 12, wherein R6,.14. A compound of Formula (IIIe-1): R1a R3a ,and are each independently hydrogen; R3aand R3bare each independently hydrogen; R4ais phenyl; R4bis hydrogen; J is NH; R5is -L-R6; L is -CH2CH2- or -CH2CH(CH3)-; R6is aryl substituted with 1 to 3 substituents selected from -CH2C(O)H, alkyl, substituted alkyl, cyano, halogen, and R60, wherein the aryl is phenyl and the C1-C6 substituted alkyl is C1-C6alkylene substituted with 1 to 3 R60, spiro-connected cycloalkyl or spiro- connected heterocycloalkyl; R10is pyrazolyl substituted with alkyl, or a pharmaceutically acceptable salt thereof. 15. The compound of embodiment 14, wherein R10is methyl, fluoro orcompound of embodiment 15, wherein R6is phenyl substituted with –(C1- C6alkyl)COOH, -CN or -CH2CN; and R60is cyano, fluoro, methyl, methoxy or -CF3.17. The compound of embodiment 16, wherei , , .18. The compound of embodiment 17, or.of any one of embodiments 1-18, wherein the compound is a compound of Formula (VI-A), or a pharmaceutically acceptable salt thereof:20. The compound of embodiment 19, wherein the compound is a compound of Formula (VI-A-1), or a pharmaceutically acceptable salt thereof:21. The compound of embodiment 19, wherein the compound is a compound of Formula (VI-A-2), or a pharmaceutically acceptable salt thereof:22. The compound of embodiment 1, wherein the compound is the compound H N a pharmaceutically acceptable salt thereof.1, wherein the compound is the compound H N24. The compound of embodiment 1, wherein the compound is the compound a pharmaceutically acceptable salt thereof. :R1a , or aR1ais hydrogen; R2band R2care each independently hydrogen; R3aand R3bare each independently hydrogen; R4ais phenyl; R4bis hydrogen; J is NH; R5is -L-R6; L is -CH2CH2- or -CH2CH(CH3)-; R6is aryl substituted with 1 to 3 substituents selected from -CH2C(O)H, alkyl, substituted alkyl, cyano, halogen, and R60, wherein the aryl is phenyl and the C1-C6 substituted alkyl is C1-C6 alkylene substituted with 1 to 3 R60, spiro-connected cycloalkyl or spiro- connected heterocycloalkyl; R10is fluoro, or a pharmaceutically acceptable salt thereof.26. The compound of embodiment 25, wherein the compound is the compound a pharmaceutically acceptable salt thereof. 25, wherein the compound is the compounda pharmaceutically acceptable salt thereof. 25, wherein the compound is the compounda pharmaceutically acceptable salt thereof.25, wherein the compound is the compound a pharmaceutically acceptable salt thereof.R1a , or aR1ais hydrogen; R2band R2care each independently hydrogen; R3aand R3bare each independently hydrogen; R4ais phenyl; R4bis hydrogen; J is NH; R5is -L-R6; L is -CH2CH2- or -CH2CH(CH3)-; R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; R10is pyrazolyl substituted with methyl, or a pharmaceutically acceptable salt thereof. 31. The compound of embodiment 30, . 32. The compound of embodiment 31,a pharmaceutically acceptable salt thereof.: R1a , or aR1ais hydrogen; R2band R2care each independently hydrogen;R3aand R3bare each independently hydrogen; R4ais phenyl; R4bis hydrogen; J is NH; R5is -L-R6; L is -CH2CH2- or -CH2CH(CH3)-; R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; R10is C1-C6 alkyl substituted with -COOH, or a pharmaceutically acceptable salt thereof. 34. A compound of Formula (IIIe-1): , or aR1ais hydrogen; R2band R2care each independently hydrogen; R3aand R3bare each independently hydrogen; R4ais phenyl; R4bis hydrogen; J is NH; R5is -L-R6; L is -CH2CH2- or -CH2CH(CH3)-; R6is optionally substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; R10is methyl, or a pharmaceutically acceptable salt thereof.35. The compound of embodiment 34, wherein the compound is the compound a pharmaceutically acceptable salt thereof. acceptable salt thereof, selected from thegroup -((R)-8-cyano-1,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-((S)-1-(((R)-((R)-8-cyano-1,2,3,4- tetrahydroquinoxalin-2-yl)(3-fluorophenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2- (3-(2-(((R)-((R)-8-cyano-3,4-dihydro-2H-benzo[b][1,4]oxazin-2- yl)(phenyl)methyl)amino)ethyl)-4-methoxyphenyl)acetic acid; 2-(4-((S or R)-1-(((S)-((R)-5- cyano-1,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-(2-(((S)-((R)-5-cyano-1,2,3,4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-((R or S)-1-(((S)-((S or R)-5-cyano- 1,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3- (2-(((S)-((R)-5-cyano-1,2,3,4-tetrahydroquinolin-3-yl)(pyridin-3-yl)methyl)amino)ethyl)-4- methylphenyl)acetic acid; 2-(3-((S)-1-(((R)-((R)-8-cyano-3,4-dihydro-2H- benzo[b][1,4]oxazin-2-yl)(phenyl)methyl)amino)propan-2-yl)-4-methoxyphenyl)acetic acid; 2-(3-(2-(((S)-((S)-5-cyano-1,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-4- fluorophenyl)acetic acid; (R or S)-2-(4-(2-(((S)-((R)-5-cyano-1,2,3,4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-(2-(((S)-((R)-5-cyano-1,2,3,4- tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-5-fluorophenyl)acetic acid; 2-(5-(2- (((S)-((R)-5-cyano-1,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-2- fluorophenyl)acetic acid; (R or S)-2-(4-((R or S)-1-(((R)-((R)-8-cyano-1,2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(3- (2-(((R)-((R)-8-cyano-1,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-4- fluorophenyl)acetic acid; 2-(2-methyl-5-(2-(((S)-((R and S)-2-oxo-1,2,3,4-tetrahydro-1,5- naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(5-(2-(((R)-((R)-8- cyano-1,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2-fluorophenyl)acetic acid; (R or S)-2-(3-(2-(((S)-((R)-5-cyano-1,2,3,4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(2-chloro-5-(2-(((R)-((R)-8-cyano-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2- (2-(difluoromethyl)-5-(2-(((S)-phenyl((R)-1,2,3,4-tetrahydro-1,5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-(2-(((S)-((S)-7-fluoro-2-oxo-1,2,3,4- tetrahydro-1,5-naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)acetic acid; 2-(3-((R or S)-1-(((S)-((R)-7-fluoro-1,2,3,4-tetrahydro-1,5-naphthyridin-3- yl)(phenyl)methyl)amino)propan-2-yl)-4-methylphenyl)acetic acid; 2-(2-chloro-5-(2-(((S)- phenyl((R)-1,2,3,4-tetrahydro-1,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(5-((S)-1-(((R)-((R)-8-cyano-3,4-dihydro-2H-benzo[b][1,4]oxazin-2- yl)(phenyl)methyl)amino)propan-2-yl)-2-methoxyphenyl)acetic acid; 3-(3-((S)-1-(((R)-((R)- 8-cyano-1,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)oxetane-3-carboxylic acid; (R and S)-2-(4-((R and S)-1-(((S)-((R)-5-cyano-1,2,3,4- tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(3-(2- (((R)-((R)-8-cyano-1,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-5- fluorophenyl)acetic acid; 2-(4-fluoro-3-((S or R)-1-(((S)-((R)-7-fluoro-1,2,3,4-tetrahydro-1,5- naphthyridin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-(2-(((S)-((R)- 5-cyano-1,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-2-fluorophenyl)acetic acid; (S or R)-2-(3-((R or S)-1-(((R)-((R)-8-cyano-1,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; (S or R)-2-(3-(2-(((R)-((R)-8- cyano-1,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)-3- methoxypropanoic acid; 2-(2,4-dimethyl-5-(2-(((S)-phenyl((R)-1,2,3,4-tetrahydro-1,5- naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2-fluoro-4-methyl-5-(2-(((S)- phenyl((R)-1,2,3,4-tetrahydro-1,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2-(3-((S or R)-1-(((S)-phenyl((R)-1,2,3,4-tetrahydro-1,5-naphthyridin-3- yl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(5-((R or S)-1-(((S)-((R)-7-fluoro- 1,2,3,4-tetrahydro-1,5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2- methylphenyl)acetic acid; 2-(4-methyl-3-(2-(((S)-((S)-2-oxo-1,2,3,4-tetrahydro-1,5- naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-methyl-3-(2-(((S)- phenyl((R)-1,2,3,4-tetrahydro-1,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; (S or R)-2-(4-((R or S)-1-(((R)-((R)-8-cyano-1,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(5-(2-(((S)-((R)-7-fluoro-2- oxo-1,2,3,4-tetrahydro-1,5-naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)acetic acid; 2-(4-chloro-3-(2-(((S)-phenyl((R)-l ,2,3,4-tetrahydro-l ,5- naphthyridin-3-yl)mcthyl)amino)cthyl)phcnyl)acctic acid; (R or S)-2-(3-(2-(((R)-((R)-8- cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)-3- methoxypropanoic acid; (S or R)-2-(4-methyl-3-(2-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-(2-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(2-fluorophenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2-fluoro-5-((R or S)-l-(((S)-((R)-7-fluoro- 1,2,3, 4-tetrahydro- 1 , 5-naphthyridin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(3-((S or R)-1-(((S)- phenyl((R)- 1,2, 3, 4-tetrahydro- l,5-naphthyridin-3-yl)methyl)amino)propan-2- yl)phenyl)propanoic acid; 2-(3-((R or S)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin- 2-yl)(2-fluorophenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-(2-(((S)-((R)-5- cyano-l,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2- methyl-5-((S or R)-l-(((S)-phenyl((R)- 1,2, 3, 4-tetrahydro- 1, 5-naphthyridin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-(2-(((S)-((R)-5-cyano-l,2,3,4- tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-2-fluorophenyl)acetic acid; 2-(5-(2- (((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2- methoxyphenyl)acetic acid; (S or R)-2-(3-(2-(((S)-((R)-5-cyano- 1,2,3, 4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((S)- 1 -(((S)-phenyl((R)- 1 ,2,3,4- tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R and S)-2- (3-((R and S)- l-(((S)-((R)-5-cyano- 1,2,3, 4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(3-(2-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(3-fluorophenyl)methyl)amino)ethyl)phenyl)acetic acid; 2- (3-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-4- methylphenyl)acetic acid; 2-(4-fluoro-3-((R or S)-l-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R or S)-2-(4-methyl-3-(2- (((S)-phenyl((R)- 1 ,2, 3, 4-tetrahydro- 1 ,5 -naphthyridin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(2-fluoro-3-((S or R)-l-(((S)-phenyl((R)-1.2.3.4-tetrahydro- l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-((R or S)-l-(((S)-((R)-5-cyano- 1,2,3, 4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)propan-2-yl)-3-methoxyphenyl)acetic acid; 2-(4-fluoro-3-((R or S)- l-(((S)-phenyl((R)- 1,2, 3, 4-tetrahydro- l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(4-(2-(((S)-((R)-5-cyano-l ,2,3,4-tetrahydroquinolin-3- yl)(phcnyl)mcthyl)amino)cthyl)phcnyl)propanoic acid; 2-(4-chloro-3-(2-(((R)-((R)-8-cyano- l,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2- (3-((R or S)-l-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(4-methoxy-3-(2-(((S)- phenyl((R)- 1 ,2,3,4-tetrahydro- 1 ,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2-(5-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)thiophen-3-yl)propanoic acid; 2-(4-fluoro-2-methyl-5-(2- (((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(5-((R and S)-l-(((R)-((R)-8-cyano-3,4-dihydro-2H-benzo[b][l,4]oxazin-2- yl)(phenyl)methyl)amino)propan-2-yl)-2-methoxyphenyl)acetic acid; 2-(2-chloro-5-((R or S)- l-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]oxazin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl) acetic acid; 2-(5-((R and S)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)-2,4-difluorophenyl)acetic acid; 2-(3-((S)-l-(((S)- phenyl((R)- 1 ,2,3,4-tetrahydro- 1 ,5-naphthyridin-3-yl)methyl)amino)propan-2- yl)phenyl) acetic acid; 2-(2-fluoro-5-((R or S)-l-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(2-iluoro-5-(2- (((S)-phenyl((R)- 1,2,3, 4-tetrahydro- 1 , 5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 3-(3-((S or R)-l-(((S)-phenyl((R)-l, 2,3,4- tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)oxetane-3-carboxylic acid; 2-(4-chloro-3-(2-(((R)-((R)-8-cyano-3,4-dihydro-2H-benzo[b][l,4]oxazin-2- yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-(2-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2-fluorophenyl)acetic acid; 5-(3-(2- (((S)-phenyl((R)- 1,2, 3, 4-tetrahydro- 1, 5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)thiazolidine-2, 4-dione; (R or S)-2-(3-((R or S)-l-(((R)-((R)-8- cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)propanoic acid; (R or S)-2-(3-fluoro-5-(2-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-((S or R)-l-(((S)-((R)-5- cyano- 1,2,3, 4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2- methoxyphenyl)acetic acid; 2-(4-methyl-3-((R or S)-l-(((S)-phenyl((R)-l,2,3,4-tetrahydro- l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-(2-(((R)-((R)-8-cyano- 1 ,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-4- mcthoxyphcnyl)acctic acid; 2-(3-((R and S)-l-(((R)-((R)-8-cyano-3,4-dihydro-2H- benzo[b][l,4]oxazin-2-yl)(phenyl)methyl)amino)propan-2-yl)-4-methoxyphenyl)acetic acid; 2-(5-(2-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2.4-difluorophenyl)acetic acid; 2-(2-methyl-5-(2-(((S)-phenyl((R)- 1,2, 3, 4-tetrahydro-l, 5- naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(5-(2-(((R)-((R)-8-cyano-l,2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2-methylthiophen-3-yl)acetic acid; 2-(2-methoxy-5-((R or S)-l-(((S)-phenyl((R)- 1,2,3, 4-tetrahydro-l, 5-naphthyridin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R or S)-2-(2,4-difluoro-5-(2-(((S)- phenyl((R)-l,2,3,4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-methyl-3-((R and S)-l-(((S)-phenyl((R)-l, 2, 3, 4-tetrahydro-l, 5-naphthyridin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(2-chloro-5-(2-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; (R and S)-2-(2,4-difluoro-5-(2-(((S)-phenyl((R)- 1,2, 3, 4-tetrahydro-l, 5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; (S)-2-(3-(2-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-5-fluorophenyl)propanoic acid; 2- (2, 4-dilluoro-5-(2-(((S)-phenyl((R)- 1,2, 3, 4-tetrahydro-l, 5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-fluoro-5-((S or R)-l-(((S)-phenyl((R)-l, 2,3,4- tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((R or S)-l-(((S)-((R)-7-fluoro- 1,2, 3, 4-tetrahydro-l, 5-naphthyridin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R o rS)-2-(2-fluoro-5-(2-(((S)- phenyl((R)-l,2,3,4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((S or R)-l-(((S)-((R)-7-fluoro-2-oxo-l, 2, 3, 4-tetrahydro-l, 5-naphthyridin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(5-(2-(((R)-((R)-8- cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2- methoxyphenyl)propanoic acid; 2-(5-(2-(((R)-((R)-8-cyano-3,4-dihydro-2H- benzo[b] [ 1 ,4]oxazin-2-yl)(phenyl)methyl)amino)ethyl)-2-methoxyphenyl)acetic acid; 2-(3- fluoro-5-((R or S)-l-(((S)-((R)-7 -fluoro- 1,2, 3, 4-tetrahydro-l, 5-naphthyridin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-methyl-2-(4-methyl-3-(2-(((S)- ((S)-2-oxo- 1,2, 3, 4-tetrahydro-l, 5-naphthyridin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-(2-(((S)-((S)-2-oxo-l,2,3,4-tetrahydro- 1 ,5-naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-(2- (((R)-((R)-8-cyano- 1,2,3, -tctrahydroquinoxalin-2-yl)(phcnyl)mcthyl)amino)cthyl)-2- fluorophenyl)acetic acid; 2-(2-chloro-5-((S or R)-l-(((R)-phenyl((R)-l,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-((R and S)-l-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(3- fluorophenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S)-2-(3-((2H-tetrazol-5- yl)methyl)phenyl)-N-((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3- yl)methyl)propan- 1 -amine; 2-(2-lluoro-4-methyl-5-(2-(((R)-phenyl((R)-l,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-((R and S)-1-(((S)-((R)-5-cyano- 1,2,3, 4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2- methoxyphenyl)acetic acid; 2-(5-((R or S)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)-2-fluorophenyl)acetic acid; 2-(4-methoxy-3-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-(2-(((S)-((R)-5-cyano-l,2,3,4- tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-3-fluorophenyl)acetic acid; 2-(3-((S or R)- l-(((S)-((R)-5-cyano- 1,2,3, 4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; (S or R)-2-(5-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)thiophen-3-yl)propanoic acid; 2-(2-fluoro-5-((S or R)-1-(((S)- phenyl((R)-l,2,3,4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)-2- methylpropanoic acid; 2-(5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)-2-(trifluoromethyl)phenyl)acetic acid; (R)-3-((R)-((3-((lH-tetrazol-5- yl)methyl)phenethyl)amino)(phenyl)methyl)-l,2,3,4-tetrahydroquinoxaline-5-carbonitrile; 2- (5-((S or R)- 1 -(((R)-((R)-8-cyano- 1 ,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)-2,4-difluorophenyl)acetic acid; (R or S)-2-(3-(2-(((R)- ((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-4- fluorophenyl)propanoic acid; 2-(3-(2-(((S)-((R or S)-7-(l-methyl-lH-pyrazol-4-yl)-l, 2,3,4- tetrahydro- 1 ,5-naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2- chloro-5-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl) acetic acid; 2-(5-(2-(((R)-((R)-8-cyano-l,2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)acetic acid; 2-(4-((R and S)-l-(((S)-((R)-5-cyano-l,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)-3-methoxyphenyl)acetic acid; (R or S)-2-(3-(2-(((R)-((R)-8-cyano-l ,2,3,4- tctrahydroquinoxalin-2-yl)(phcnyl)mcthyl)amino)cthyl)-5-fluorophcnyl)propanoic acid; (R and S)-2-(4-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)-2-fluorophenyl)propanoic acid; 2-(4-(2-(((S)-((R)-5-cyano-1.2.3.4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-3-methoxyphenyl)acetic acid; (R and S)-2-(2-chloro-5-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((R or S)-l-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(pyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(5-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)-2-fluorophenyl)propanoic acid; (S or R)-2-(3-(2-(((R)-((R)- 8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2- fluorophenyl)propanoic acid; 2-(2-methoxy-5-((S or R)-l-(((R)-phenyl((R)-l,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R and S)- 2-(3-(2-(((R)-((R)-8-cyano- 1,2,3 ,4-tetr ahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)- 5-fluorophenyl)propanoic acid; 2-(3-(2-(((S)-((R and S)-7-fluoro- 1,2,3, 4-tetrahydro- 1,5- naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)acetic acid; 2-(2,4-difluoro- 5-((S or R)- l-(((R)-phenyl((R)- 1 ,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R or S)-2-(3-(2-(((S)-phenyl((R)-l,2,3,4- tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; (R and S)-2-(3- (2-(((R)-((R)-8-cyano- 1 ,2,3,4-tetrahydroquinoxalin-2-yl)(3- fluorophenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(5-((R and S)-l-(((R)-((R)-8- cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)thiophen-3- yl)acetic acid; 2-(4-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2-(3-(2-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2-fluorophenyl)propanoic acid; (R and S)-2-(5-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)thiophen-3-yl)propanoic acid; 2-(4-(2-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(3-fluorophenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-((S or R)-l-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)-4-fluorophenyl)acetic acid; 2-(2-fluoro-5-((R and S)- l-(((S)-phenyl((R)- 1,2, 3, 4-tetrahydro- l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)-2-methylpropanoic acid; (R and S)-(3-chloro-4-(2-(((R)-((R)-8-cyano-l ,2,3,4- tctrahydroquinoxalin-2-yl)(phcnyl)mcthyl)amino)cthyl)phcnyl)propanoic acid; 2-(2-chloro-5- ((S or R)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(5-((S or R)-l-(((R)-((R)-8- cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)thiophen-3- yl)acetic acid; 2-(3-((R or S)-l-(((R)-(2-fluorophenyl)((R)-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)-2-methylpropanoic acid; 2-(2,4-dimethyl- 5-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-chloro-4-(2-(((R)-((R)-8-cyano-l,2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-(2-(((R)- ((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-3- methylphenyl)acetic acid; (S or R)-2-(4-(2-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin- 2-yl)(phenyl)methyl)amino)ethyl)-3-methoxyphenyl)propanoic acid; (R or S)-2-(5-(2-(((R)- ((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-2,4- dimethylphenyl)propanoic acid; (S or R)-2-(3-(2-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)propanoic acid; 2-(2-methyl-5-((R or S)-l-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R and S)-2-(3-(2-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-4-fluorophenyl)propanoic acid; 2-(3-chloro-4-((S or R)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R or S)-2-(5-(2-(((R)-((R)-8- cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2- methoxyphenyl)propanoic acid; (S or R)-2-(3-chloro-4-(2-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(5-((R or S)-1-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)-2.4-difluorophenyl)acetic acid; 2-(3-((S)- 1 -(((R)-((R)-8-cyano- 1 ,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetamide; 2-(4-(2-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-3-fluorophenyl)acetic acid; 2-(4-methyl-3-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2-(5-(2-(((R)-((R)-8-cyano-l,2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2-fluorophenyl)propanoic acid; 2-(4-(2-(((S)-((R)-5-cyano- 1 ,2,3, 4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-2- mcthoxyphcnyl)acctic acid; 2-(2-mcthoxy-5-(2-(((S)-phcnyl((R)-l,2,3,4-tctrahydro-l,5- naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(5-((R and S)-l-(((R)-((R)-8- cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)-2- fluorophenyl)acetic acid; (S or R)-2-(4-(2-(((S)-((R)-5-cyano- 1,2,3, 4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)ethyl)-2-methoxyphenyl)propanoic acid; (R and S)-2-(4-methoxy- 3-(2-(((R)-phenyl((R)- 1,2, 3, 4-tetr ahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-(2-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-4-methoxyphenyl)propanoic acid; 2- (4-(difluoromethyl)-3-(2-(((S)-phenyl((R)- 1,2, 3, 4-tetr ahydro-l,5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; (S or R)-2-(2,4-difluoro-5-((R or S)-1-(((R)- phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl)propanoic acid; 2-(4-fluoro-3-((S or R)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R or S)- 2-(3-(2-(((R)-((R)-7-fluoro- 1,2, 3, 4-tetr ahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)propanoic acid; 2-(5-((S or R)-1-(((R)-((R)- 8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)-2- methoxyphenyl)acetic acid; 2-(4-fluoro-3-(2-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)methyl)amino)ethyl)phenyl)-2-methylpropanoic acid; 2-(3-((lH-tetrazol-5- yl)methyl)phenyl)-N-((S)-phenyl((R)- 1,2,3, 4-tetrahydro-l, 5-naphthyridin-3-yl)methyl)ethan- 1-amine; 2-(2-fluoro-5-((S or R)-l-(((R)-((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-4-methylphenyl)acetic acid; (R or S)-2- (4-methoxy-3-(2-(((R)-phenyl((R)- 1,2, 3, 4-tetr ahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; (S or R)-2-(3-(2-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-4- methoxyphenyl)propanoic acid; (R)-3-((R)-((4-((lH-tetrazol-5- yl)methyl)phenethyl)amino)(phenyl)methyl)-l,2,3,4-tetrahydroquinoxaline-5-carbonitrile; (S or R)-2-(2-fluoro-5-(2-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)propanoic acid; 2-(5-((R or S)-1-(((R)-((R)- 8-cyano-3,4-dihydro-2H-benzo[b] [ 1 ,4]oxazin-2-yl)(phenyl)methyl)amino)propan-2- yl)thiophen-3-yl)acetic acid; 2-(3-chloro-4-((R and S)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-methyl- 2-(4-mcthyl-3-(2-(((R)-phcnyl((R)-l,2,3,4-tctrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(5-((S or R)-l-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)thiophen-2-yl)acetic acid; 2-(4- fluoro-3-(2-(((S)-phenyl((R)- 1 ,2,3,4-tetrahydro- 1 ,5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-((R or S)-l-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)thiophen-2-yl)acetic acid; (R or S)-2-(3-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(2- fluorophenyl)methyl)amino)ethyl)phenyl)propanoic acid; (R or S)-2-(2-methyl-5-(2-(((R)- phenyl((R)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-(2-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)acetic acid; 2-methyl-2-(3-(2-(((S)-phenyl((R)- 1,2,3, 4-tetrahydro- 1 , 5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(5-(2-(((S)-((R and S)-7-fluoro-2-oxo- 1 ,2,3,4-tetrahydro- 1 ,5-naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)acetic acid; 2-(2-fluoro-3-((S or R)-l-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R)-3-((S)-((2-(6-methylpyridin-3- yl)ethyl)amino)(phenyl)methyl)-l,2,3,4-tetrahydroquinoline-5-carbonitrile; 2-(5-(2-(((S)- ((R)-7-fluoro- 1,2, 3, 4-tetrahydro- l,5-naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)-2- methylphenyl)acetic acid; 2-(2,4-dimethyl-5-(2-(((R)-phenyl((R)- 1 ,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; (S or R)-2-(4-(2- (((S)-((R)-5-cyano- 1,2,3, 4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-3- methoxyphenyl)propanoic acid; (S or R)-2-(4-methyl-3-(2-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; (R or S)-2- (4-fluoro-3-(2-(((S)-phenyl((R)-l, 2, 3, 4-tetrahydro- l,5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; (S or R)-2-(3-(2-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(2-fluorophenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(5- ((S or R)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)furan-2-yl)acetic acid; (R and S)-2-(3-(2-(((R)-((R)-8- cyano- 1 ,2,3,4-tetrahydroquinoxalin-2-yl)(2- fluorophenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(2-fluoro-5-(2-(((S)-phenyl((R)-1.2.3.4-tetrahydro-! ,5-naphthyridin-3-yl)rnethyl)amino)ethyl)phenyl)acetic acid; 2-(3-fluoro- 5-(2-(((S)-phcnyl((R)-l,2,3,4-tctrahydro-l,5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; (S or R)-2-(5-(2-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)propanoic acid; 2-(5-((S or R)-l-(((R)-((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)propan-2-yl)-2,4-dimethylphenyl)acetic acid; 2-(2-chloro-4-((S or R)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; (S or R)-2-(3-((S or R)-l-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(2-chloro-5-((R or S)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-(2-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-3-methoxyphenyl)acetic acid; 2-(4- (2-(((R)-((R)-8-cyano- 1 ,2,3,4-tetrahydroquinoxalin-2-yl)(2- fluorophenyl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2-(4-methyl-3-(2-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-methyl-3-((S or R)-l-(((S)-phenyl((R)-1.2.3.4-tetrahydro- l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((S or R)-l-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)propan-2-yl)-4-methoxyphenyl)acetic acid; 2-(4-methyl-3-((S or R)-l-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl) acetic acid; (S or R)-2-(4-fluoro-3-(2-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-((R or S)-l-(((R)-((R)-8- cyano-l,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2- yl)phenyl) acetamide; 2-(3-((S)-l-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetamide; 2-methyl-2-(4-methyl-3-(2-(((R)- phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(2-fluoro-5-((S or R)-l-(((R)-((R)-7-fluoro-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl) acetic acid; 2-(2-fluoro-5-((R or S)-l-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)-2-methylpropanoic acid; (S or R)-2-(2- methoxy-5-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(5-((S or R)- l-(((R)-((R)-7-fluoro-l ,2,3,4- tctrahydropyrido[2,3-b]pyrazin-3-yl)(phcnyl)mcthyl)amino)propan-2-yl)-2- methoxyphenyl)acetic acid; (S or R)-2-(4-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)-3-methoxypropanoic acid; 2-(3-((S or R)-1-(((S)- ((R)-7-fluoro-l,2,3,4-tetrahydro-l,5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2-yl)- 4-methylphenyl)acetic acid; 2-(2-fluoro-5-((R or S)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-(2- (((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-3- fluorophenyl)propanoic acid; (R or S)-2-(4-(2-(((S)-((R)-5-cyano- 1,2,3, 4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-3-methoxyphenyl)propanoic acid; 2-(2-cyclopropyl-5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(5-(2-(((R)-((R)-8-cyano-l,2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)furan-2-yl)acetic acid; 2-(3-fluoro-5- ((S or R)- 1 -(((R)-phenyl((R)- 1 ,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-fluoro-5-((R and S)-l-(((R)-((R)-7- fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2- methylphenyl)acetic acid; 2-(4-chloro-3-(2-(((R)-phenyl((R)- 1 ,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; l-(3-((R and S)-l-(((S)-((R)-7-fluoro-1.2.3.4-tetrahydro- 1 ,5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)cyclopropane- 1 -carboxylic acid; 2-(5-(2-(((R)-((R)-8-cyano-l,2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2,4-difluorophenyl)-2- methylpropanoic acid; (R or S)-2-(3-((R or S)-l-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; (S or R)-2-(4-fluoro-3-(2-(((S)-phenyl((R)- 1,2,3, 4-tetrahydro- 1 , 5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-(2-(((S)-((R and S)-7-fluoro-2-oxo-1.2.3.4-tetrahydro- 1 ,5-naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)acetic acid; 2-(3-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)phenyl)acetamide; 2-(4-methoxy-3-(2-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)-2-methylpropanoic acid; (R or S)-2-(4-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)-3-methoxyphenyl)propanoic acid; (R or S)-2-(4-fluoro-3-(2-(((S)-phenyl((R)-l ,2,3,4-tetrahydro-l ,5-naphthyridin-3- yl)mcthyl)amino)cthyl)phcnyl)propanoic acid; (R and S)-2-(4-(2-(((S)-((R)-5-cyano-l,2,3,4- tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-3-methoxyphenyl)propanoic acid; 2-(5- (2-(((lS)-(7-fluoro-2-oxo- 1,2,3, 4-tetrahydro-l, 5-naphthyridin-3- yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)acetic acid; 2-(5-(2-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)thiophen-3-yl)-2- methylpropanoic acid; (S or R)-2-(3-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)-4-fluorophenyl)propanoic acid; 2-(2,4-difluoro-5-(2-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2-(3-chloro-4-(2-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-fluoro-2-methyl-5-(2-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-fluoro-3-((S or R)-l-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)-2-methylpropanoic acid; 2-(5-(2-(((R)-((R)-7-fluoro-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-2- methylphenyl)acetic acid; 2-(5-((R and S)-l-(((R)-((R)-8-cyano-3,4-dihydro-2H- benzo[b][l,4]oxazin-2-yl)(phenyl)methyl)amino)propan-2-yl)thiophen-3-yl)acetic acid; 2-(3- ((R or S)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)-4-fluorophenyl)acetic acid; 2-(4-chloro-3-(2-(((R)- phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)-2- methylpropanoic acid; 2-(2-chloro-5-((R or S)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)-2-methylpropanoic acid; 2-(5-((S or R)-l-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)thiophen-3-yl)acetic acid; 2-(4-chloro-3-((S or R)-1-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)- 2-methylpropanoic acid; 2-(4-chloro-3-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(2-methyl-5-(2-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2-fluoro-3-((S or R)-l-(((R)-((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(2-ethyl-5-(2-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-methyl-2-(5-((R or S)- 1 -(((R)-phenyl((R)- 1 ,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)mcthyl)amino)propan-2-yl)thiophcn-3-yl)propanoic acid; 2-(4-(2-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)acetic acid;(S or R)-2-(5-(2-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)-2,4-dimethylphenyl)propanoic acid; 2-(5-((S or R)-1-(((R)- ((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)-2- fluorophenyl)acetic acid; 2-(2,4-dimethyl-5-(2-(((S)-phenyl((R)-5,6,7,8-tetrahydropyrido[3,2- c]pyridazin-7-yl)methyl)amino)ethyl)phenyl)acetic acid; (R and S)-5-(3-(2-(((S)-phenyl((R)-1.2.3.4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)benzyl)thiazolidine-2, 4-dione;(R or S)-2-(2-fluoro-5-(2-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)propanoic acid; 2-(4-((R or S)-1-(((S)-((R)- 5-cyano-l,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R)-3-((R)-((3-(lH-tetrazol-5-yl)phenethyl)amino)(phenyl)methyl)-l,2,3,4- tetrahydroquinoxaline-5-carbonitrile; 2-(3-chloro-5-(2-(((R)-((R)-8-cyano-3,4-dihydro-2H- benzo[b][l,4]oxazin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)-2-methylpropanoic acid; (R or S)-2-(4-((S or R)-l-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(2-methoxy-5-((S or R)-l- (((S)-phenyl((R)- 1,2,3, 4-tetrahydro- 1 , 5-naphthyridin-3-yl)methyl)amino)propan-2- yl)phenyl)acetic acid; (S or R)-2-(3-fluoro-5-(2-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; (R or S)-2-(4-chloro-3-(2- (((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-fluoro-3-((S or R)-l-(((R)-((R)-7-fluoro-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl) acetic acid; 2-(2-(difluoromethoxy)-5-(2-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(5-((R or S)-l- (((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)-2- methoxyphenyl)acetic acid; 2-methyl-2-(3-(2-(((S)-((S)-2-oxo-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((R)-l-(((R)- ((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(3-fluorophenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; (R or S)-2-(2,4-difluoro-5-((S or R)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)propanoic acid; (R orS)-2-(2,4-difluoro-5-(2-(((R)-phenyl((R)-l ,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)mcthyl)amino)cthyl)phcnyl)propanoic acid; (R or S)-2-(3-(2-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-4- methoxyphenyl)propanoic acid; 2-(2-chloro-3-(2-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; (S or R)-2-(4- chloro-3-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; (S or R)-2-(3-(2-(((S)-phenyl((R)-l, 2,3,4- tetrahydro- 1 ,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-chloro-3- ((R or S)- 1 -(((R)-phenyl((R)- 1 ,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(5-((R and S)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)thiophen-3-yl)acetic acid; 2- (2-fluoro-4-((R and S)-l-(((S)-phenyl((R)- 1,2,3, 4-tetrahydro- 1 , 5-naphthyridin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((R and S)-l-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetamide; 2-(2-chloro-4-(2-(((S)-phenyl((R)- 1 ,2, 3, 4-tetrahydro- 1 ,5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; (S or R)-2-(2,4-difluoro-5-(2-(((S)-phenyl((R)-1.2.3.4-tetrahydro- l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((S or R)-l-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(2- fluorophenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R or S)-2-(4-(2-(((S)-((R)-5- cyano- 1,2,3, 4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)-2- methoxyphenyl)propanoic acid; (S or R)-2-(2-fluoro-5-(2-(((S)-phenyl((R)-l, 2,3,4- tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-((R and S)- l-(((R)-((R)-8-cyano-3,4-dihydro-2H-benzo[b][l,4]oxazin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-chloro-3-((S or R)-1-(((R)- ((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]oxazin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(2-fluoro-5-((R or S)-l-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-4- methylphenyl)acetic acid; (R or S)-2-(3-methyl-5-(2-(((R)-phenyl((R)-l,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(5-(2- (((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)-2- (trifluoromethoxy)phenyl)acetic acid; 2-(3-chloro-5-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)-2-methylpropanoic acid; 2- (5-((R or S)- 1 -(((R)-((R)-2,3-dihydro- lH-pyrido[2,3-b] [ 1 ,4]oxazin-3- yl)(phenyl)methyl)amino)propan-2-yl)-2,4-difluorophenyl)acetic acid; 2-(2-fluoro-5-(2-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-((S or R)-l-(((R)-((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)propan-2-yl)-5-methoxyphenyl)acetic acid; (R or S)-2-(2-chloro-5- (2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-((R and S)-l-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetamide; (R or S)-2- (5-(2-(((R)-((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)propanoic acid; 2-(5-((R or S)-1-(((R)-((R)- 2,3-dihydro-lH-pyrido[2,3-b][l,4]oxazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2- fluorophenyl)acetic acid; (S or R)-2-(3-((S or R)-l-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(2- chloro-4-((R or S)- 1 -(((R)-((R)-8-cyano- 1 ,2,3,4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-methoxy-5-((S or R)-1-(((R)- phenyl((R)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl) acetic acid; 2-(3-chloro-5-((R)-l-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(5-(2-(((R)-((R)-7- fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-2- methoxyphenyl)propanoic acid; 2-(5-((R or S)-l-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2,4- dimethylphenyl)acetic acid; 2-(2-fluoro-5-((R or S)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)-2-methylpropanoic acid; 3-(3-((R or S)-l-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5-naphthyridin-3- yl)methyl)amino)propan-2-yl)phenyl)oxetane-3-carboxylic acid; 2-(2,4-difluoro-5-((R or S)- l-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl)-2-methylpropanoic acid; 2-(5-((R and S)-l-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3- b][l,4]oxazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2,4-difluorophenyl)acetic acid; 2-(2- methyl-5-((R or S)-l-(((S)-phenyl((R)- 1,2,3, 4-tetrahydro-l, 5-naphthyridin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-(2-(((S)-phenyl((R)-l,2,3,4-tetrahydro-1 ,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-methyl-2-(3-methyl-5-(2- (((R)-phcnyl((R)- 1,2,3, 4-tctrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-methyl-5-((S or R)-l-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2- (2-fluoro-4-(2-(((S)-phenyl((R)- 1,2,3, 4-tetrahydro-l, 5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2-(3-((S or R)-l-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; (R and S)-2-(3-methoxy-5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; (R or S)-2-(2-fluoro-5-(2-(((S)-phenyl((R)-1.2.3.4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; (R orS)-2-(4-fluoro-5-(2-(((R)-((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)propanoic acid; 2-(3-((R or S)-1-(((R)-((R)- 2,3-dihydro-lH-pyrido[2,3-b][l,4]oxazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-4- fluorophenyl)acetic acid; 2-(3-((S)-l-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetonitrile; 2-(3-chloro-5-(2-(((R)-((R)-8- cyano-3,4-dihydro-2H-benzo[b][l,4]oxazin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2-fluoro-5-(2-(((S)-phenyl((R)- 1,2, 3, 4-tetrahydro-l, 5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)-2-methylpropanoic acid; 2-(2-methoxy-5-(2-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 3-(4-(2-(((S)-phenyl((R)- 1 ,2,3,4-tetrahydro- 1 ,5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; (S)-2-(3-(2H-tetrazol-5-yl)phenyl)-N-((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)propan-l-amine; 2-(2,4- difluoro-5-(2-(((S)-phenyl((R)- 1,2, 3, 4-tetrahydro-l, 5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)-2-methylpropanoic acid; 2-(3-( lH-tetrazol-5-yl)phenyl)-N- ((S)-phenyl((R)-l, 2, 3, 4-tetrahydro-l, 5-naphthyridin-3-yl)methyl)ethan-l-amine; 2-(3-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)-4- (trifluoromethyl)phenyl) acetic acid; 2-(2, 4-difluoro-3-methyl-5-(2-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2-methyl-5- (2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)thiophen-3-yl)acetic acid; 2-(4-methyl-3-((R or S)-l-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(5-((S)- 1-(((S or R)-((R)-7 -fluoro- 1 ,2, 3, 4-tetrahydro-l ,5-naphthyridin-3- yl)(phcnyl)mcthyl)amino)propan-2-yl)-2-mcthylphcnyl)acctic acid; 2-(3-fluoro-4-((R and S)-1-(((S)-phenyl((R)- 1,2,3, 4-tetrahydro-l, 5-naphthyridin-3-yl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(3-fluoro-5-((R or S)-l-(((S)-phenyl((R)-l, 2, 3, 4-tetrahydro-l, 5- naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-(2-(((S)-phenyl((R)-1.2.3.4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2- (2-fluoro-5-(2-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; (R or S)-2-(3-(2-(((R)-((R)-7-fluoro-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-5- methylphenyl)propanoic acid; 2-(5-((R or S)-l-(((R)-((R)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)thiophen-3-yl)acetic acid; 2-(2- fluoro-5-((R and S)-l-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)-2-methylpropanoic acid; 2-(4-fluoro-3-(2-(((R)- phenyl((R)- 1,2,3, 4-tetrahydropyridor2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)-2- methylpropanoic acid; 2-(4-fluoro-3-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; (S or R)-2-(2,4-difluoro-5-((S or R)-l- (((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl)propanoic acid; 2-(4-cyclopropyl-3-(2-(((R)-phenyl((R)-l,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(6-(2-(((S)- ((R)-5-cyano- 1,2,3, 4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)pyridin-3- yl)acetic acid; 2-(2-methyl-5-((S or R)-l-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(2-fluoro-4-(2-(((S)- phenyl((R)-l,2,3,4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((R)-l-(((R)-((R)-8-cyano-3,4-dihydro-2H-benzo[b][l,4]oxazin-2- yl)(phenyl)methyl)amino)propan-2-yl)-4-methoxyphenyl)acetic acid; 2-(4-chloro-3-((R and S)-l-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]oxazin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(4-((S or R)-1-(((R)- ((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)propanoic acid; (R or S)-2-(4-(2-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)-3-methoxypropanoic acid; 2-(3-chloro-4-(2-(((S)- phenyl((R)-l,2,3,4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid;(S or R)-2-(2,4-difluoro-5-(2-(((R)-phenyl((R)-l ,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)mcthyl)amino)cthyl)phcnyl)propanoic acid; 2-(3-chloro-4-((R or S)-l-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(2-methoxy-5-((R or S)-l-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(2-fluoro-3-(2-(((S)-phenyl((R)-l, 2,3,4- tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-ethyl-3-(2- (((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2-(2-fluoro-4-(2-(((S)-phenyl((R)-l, 2,3,4- tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; (S or R)-2-(2- methyl-5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-(2-(((R)-((R)-8-cy no-l, 2,3,4- tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)phenyl)acetamide; 2-(3-fluoro-5-(2- (((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)-2- methylpropanoic acid; 2-(3-fluoro-4-(2-(((S)-phenyl((R)- 1 ,2,3,4-tetrahydro- 1 ,5-naphthyridin- 3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2-chloro-5-(2-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)-2-methylpropanoic acid; (R or S)-2-(3-fluoro-5-(2-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((S)-l-(((S)-((S)-7-fluoro-2-oxo-1.2.3.4-tetrahydro- 1 ,5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-chloro-3-((S or R)-l-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((R and S)-l-(((S)-phenyl((R)-5, 6,7,8- tetrahydropyrido[3,2-c]pyridazin-7-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3- fluoro-5-((R and S)-l-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-methyl-3-(2-(((S)-phenyl((R)- 5,6,7,8-tetrahydropyrido[3,2-c]pyridazin-7-yl)methyl)amino)ethyl)phenyl)acetic acid; (S)-2- (3-(isoxazol-4-yl)phenyl)-N-((R)-phenyl((R)- 1,2,3, 4-tetr ahydropyrido[2, 3-b]pyrazin-3- yl)methyl)propan- 1 -amine; 2-(3-fluoro-5-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-((S or R)-l-(((S)-((R)-5-cyano-1.2.3.4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)-3-methoxyphenyl)acetic acid; (S or R)-2-(4-fluoro-5-(2-(((R)-((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)propanoic acid; 2-(4-((R or S)-1-(((S)-((R)-5-cyano- 1 ,2,3, 4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2- mcthoxyphcnyl)acctic acid; 2-(4-((S or R)-l-(((R)-((R)-8-cyano-l,2,3,4-tctrahydroquinoxalin- 2-yl)(phenyl)methyl)amino)propan-2-yl)thiophen-2-yl)acetic acid; (R and S)-2-(3-fluoro-4- (2-(((S)-phenyl((R)- 1 ,2,3,4-tetrahydro- 1 ,5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-chloro-5-(2-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; (S or S)-3- methoxy-2-(3-(2-(((R)-phenyl((R)- 1,2,3, 4-tetr ahydropyrido[2, 3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; (S)-2-(3-(isoxazol-4-yl)phenyl)-N-((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)propan-l-amine; 2-(5-((R or S)-l-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2- yl)thiophen-2-yl)acetic acid; 2-(5-((R)-l-(((R)-((R)-8-cyano-3,4-dihydro-2H- benzo[b][l,4]oxazin-2-yl)(phenyl)methyl)amino)propan-2-yl)-2-methoxyphenyl)acetic acid; (R and S)-2-(5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)thiophen-3-yl)propanoic acid; 2-(4-(difluoromethoxy)-3-(2-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; (R or S)-2-(2-methoxy-5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(2,4-difluoro-5-((R or S)-1-(((R)- phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(3-(2-(((S or R)-((S or R)-5-cy ano- 1,2,3, 4-tetrahydroquinolin-3- yl)(pyridin-3-yl)methyl)amino)ethyl)-4-methylphenyl)acetic acid; 2-(5-(2-(((R)-((R)-2,3- dihydro-lH-pyrido[2,3-b][l,4]oxazin-3-yl)(phenyl)methyl)amino)ethyl)-2,4- difluorophenyl)acetic acid; (S or R)-2-(4-fluoro-3-(2-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2- (3-((R and S)-l-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]oxazin-3- yl)(phenyl)methyl)amino)propan-2-yl)-2-fluorophenyl)acetic acid; 2-(3-fluoro-5-((S or R)-l- (((S)-((R)-7-fluoro- 1,2,3, 4-tetrahydro-l, 5-naphthyridin-3-yl)(phenyl)methyl)amino)propan- 2-yl)phenyl)acetic acid; 2-(2-chloro-4-((R or S)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(2- chloro-5-((R or S)-l-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-(2-(((S)-((S)-7-fluoro-2-oxo-l,2,3,4- tetrahydro-l,5-naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)-2-methylpropanoicacid; 2-(3-((S or R)-l-(((R)-phenyl((R)- 1 ,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)mcthyl)amino)propan-2-yl)phcnyl)acctamidc; 2-(2-fluoro-3-(2-(((R)-phcnyl((R)-l,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)-2-methylpropanoic acid; (R or S)-2-(5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)thiophen-3-yl)propanoic acid; 2-(3-((R or S)-l-(((R)-((R)-2,3-dihydro- lH-pyrido[2,3-b][l,4]oxazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-5-fluorophenyl)acetic acid; 2-(2-fluoro-3-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-methoxy-4-(2-(((S)-phenyl((R)-l, 2,3,4- tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2-fluoro-3-((R or S)-l-(((S)-phenyl((R)- 1,2,3, 4-tetrahydro- 1 , 5-naphthyridin-3-yl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(4-fluoro-3-((R or S)-l-(((S)-((R)-7-fluoro-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-chloro-4-((S or R)-l-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl)acetic acid; (S or R)-2-(2-fluoro-3-(2-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; (S or R)-2-(5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)thiophen-3-yl)propanoic acid; (S)-2-(3-bromophenyl)-N-((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)propan-l-amine; 2-(4-fluoro- 3-((S or R)-l-(((S)-phenyl((R)- 1,2, 3, 4-tetrahydro- l,5-naphthyridin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-((R and S)-l-(((S)-phenyl((R)-l,2,3,4- tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((R)-l- (((S)-phenyl((R)- 1,2, 3, 4-tetrahydro- 1, 5-naphthyridin-3-y l)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(4-fluoro-3-((S or R)-l-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(2-fluoro-5-((S)-l-(((S or R)-((R)-7-fluoro- 1,2, 3, 4-tetrahydro- l,5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; (R or S)-2-(5-(2-(((R)-((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-2-methoxyphenyl)propanoic acid; (S or R)-2-(3- methyl-5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; (R or S)-2-(4-fluoro-3-(2-(((R)-((R)-7-fluoro- l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(2-fluoro-5-((S or R)-l-(((S)-phenyl((R)- 1,2, 3, 4-tetrahydro- l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S orR)-2-(3-(2-(((R)-((R)-7-fluoro-l ,2,3,4- tctrahydropyrido[2,3-b]pyrazin-3-yl)(phcnyl)mcthyl)amino)cthyl)-5-mcthylphcnyl)propanoic acid; 3-(3-((R)-l-(((R)-((R)-8-cyano- 1,2,3, 4-tetrahydroquinoxalin-2- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)oxetane-3-carboxylic acid; (S or R)-2-(3- fluoro-5-(2-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(2-methyl-3-((S or R)-1-(((R)- phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(4-((R and S)-l-(((R)-(3-fluorophenyl)((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-methyl- 2-(4-methyl-3-(2-(((R)-phenyl((R)-5,6,7,8-tetrahydropyrazino[2,3-c]pyridazin-7- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-methyl-3-(2-(((R)-phenyl((R)-5, 6,7,8- tetrahydropyrazino[2,3-c]pyridazin-7-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-(2- (((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)thiophen- 2-yl)acetic acid; 2-(3-((S or R)-l-(((S)-((R)-7-fluoro-l,2,3,4-tetrahydro-l,5-naphthyridin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(2-fluoro-5-(2-(((R)- ((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((S or R)-l-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(pyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S or R)-2-(3-((R or S)-l-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5-naphthyridin-3- yl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(5-((R or S)-l-(((R)-((R)-8-cyano-1.2.3.4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)furan-2-yl)acetic acid;2-(3-((R or S)-l-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]thiazin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-(2-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-5-methylphenyl)acetic acid; 2-(3-methyl-5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(4-chloro-3-((R or S)-l-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)-2- methylpropanoic acid; 2-(4-(2-(((R)-(3-fluorophenyl)((R)- 1 ,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-((R or S)-l-(((R)-((R)-7-fluoro-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-5- methoxyphenyl)acetic acid; 2-(2-methyl-5-(2-(((S)-phenyl((R and S)-5,6,7,8-tetrahydropyrido[3,2-c]pyridazin-7-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2-methoxy- 4-(2-(((S)-phcnyl((R)-l,2,3,4-tctrahydro-l,5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-methyl-2-(2-methyl-5-(2-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(2- fluoro-5-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)-2-methylpropanoic acid; 2-(2,4-dilluoro-5-(2-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)-2- methylpropanoic acid; (R or S)-2-(2,4-dilluoro-5-((R or S)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(3- ((R)-l-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetamide; 2-methyl-2-(5-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)ethyl)thiophen-3-yl)propanoic acid; 2-(3-ethyl-5-(2-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(5-(2-(((R)-l-((R or S)-5-cyano-2-oxo- 1,2,3, 4-tetrahydroquinolin-3- yl)ethyl)amino)ethyl)-2,4-dimethylphenyl)acetic acid; 2-(5-((R or S)-l-(((R)-((R)-7-fluoro-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2- methoxyphenyl)acetic acid; 2-(3-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3-yl)methyl)amino)ethyl)-4-(trifluoromethoxy)phenyl)acetic acid; 2-(4-chloro-3-((R or S)-l-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]oxazin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(5-(2-(((S)-((S)-7-fluoro- 1,2,3, 4-tetrahydro-l, 5-naphthyridin-3- yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)acetic acid; 2-(5-(2-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)thiophen-2-yl)acetic acid; 2- (3-(2-(((R)-((R)-8-cyano-l,2,3,4-tetrahydroquinoxalin-2-yl)(phenyl)methyl)amino)ethyl)-2- methoxyphenyl)acetic acid; 2-(5-((S or R)-l-(((R)-((R)-8-cyano-3,4-dihydro-2H- benzo[b][l,4]oxazin-2-yl)(phenyl)methyl)amino)propan-2-yl)thiophen-3-yl)acetic acid; (R or S)-2-(2-fluoro-3-(2-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; (S or R)-2-(3-((R or S)-l-(((R)-((R)-7- fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)propanoic acid; 2-(2-fluoro-5-((R or S)-l-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-(2-(((R)-((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)acetic acid; 2-(4-fluoro-3-((R or S)-1 -(((R)- phcnyl((R)-l,2,3,4-tctrahydropyrido[2,3-b]pyrazin-3-yl)mcthyl)amino)propan-2-yl)phcnyl)- 2-methylpropanoic acid; (S or R)-2-(2-methyl-3-(2-(((R)-phenyl((R)-l,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((R or S)-l-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)propan-2-yl)-4-methoxyphenyl)acetic acid; (S or R)-2-(2-fluoro-3- (2-(((S)-phenyl((R)- 1 ,2,3,4-tetrahydro- 1 ,5-naphthyridin-3- yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-methyl-2-(2-methyl-3-(2-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3- methoxy-5-((R or S)-l-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-fluoro-3-((R or S)-l-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(5-((S or R)- 1 -(((R)-((R)-2,3-dihydro- lH-pyrido[2,3-b] [ 1 ,4]oxazin-3- yl)(phenyl)methyl)amino)propan-2-yl)-2,4-difluorophenyl)acetic acid; 2-(3-(2-(((R)- phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)-5- (trifluoromethyl)phenyl)acetic acid; 2-(5-(2-(((R)-((R)-8-cyano-3,4-dihydro-2H- benzo[b][l,4]oxazin-2-yl)(phenyl)methyl)amino)ethyl)furan-2-yl)acetic acid; (R or S)-2-(3- ((R or S)-l-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)propan- 2-yl)phenyl)propanoic acid; 2-(5-(2-(((R)-((R)-8-cyano-3,4-dihydro-2H-benzo[b][l,4]oxazin- 2-yl)(phenyl)methyl)amino)ethyl)furan-3-yl)acetic acid; 2-(3-((R or S)-l-(((S)-((R)-7-fluoro- 2-oxo- 1 ,2,3,4-tetrahydro- 1 ,5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(2-chloro-3-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2-methyl-3-(2-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2- fluoro-3-((R or S)-l-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((R)- l-(((S)-phenyl((S)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((R)- l-(((S)-((S)-7-iluoro-2-oxo- 1 ,2,3,4-tetrahydro- 1,5 -naphthyridin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(2-chloro-5-((S or R)-1-(((R)- ((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]oxazin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(3-(2-(((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)-5-(trifluoromethoxy)phenyl)acetic acid; 2-(2-chloro-5-((S or R)-l - (((R)-phcnyl((R)-l,2,3,4-tctrahydropyrido[2,3-b]pyrazin-3-yl)mcthyl)amino)propan-2- yl)phenyl)-2-methylpropanoic acid; 2-(3-(2-(((S)-((S or R)-7-(l-methyl-lH-pyrazol-4-yl)-1.2.3.4-tetrahydro- 1 ,5-naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; (S or R)-2-(3-((S or R)- l-(((S)-((S)-5-cy ano- 1,2,3, 4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(3-(2-(((R)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)acetamide; 2-(4- fluoro-3-((R or S)-l-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((S or R)-l-(((R)-((R)-2,3- dihydro-lH-pyrido[2,3-b][l,4]oxazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-5- fluorophenyl)acetic acid; 2-(3-chloro-5-((S or R)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3- cyclopropyl-5-(2-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(2-fluoro-5-((S or R)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(5-((S or R)-l-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]oxazin-3- yl)(phenyl)methyl)amino)propan-2-yl)-2-fluorophenyl)acetic acid; 2-(2-fluoro-5-((R and S)-1-(((S)-phenyl((R)- 1,2,3, 4-tetrahydro- 1 , 5-naphthyridin-3-yl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(3-fluoro-5-((R or S)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R or S)-2-(3-(2-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]thiazin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((R or S)-l-(((S)-((S)-7-fluoro-1.2.3. -tetrahydro- l,5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2-yl)-4- methylphenyl)acetic acid; 2-(5-((R or S)-l-(((S)-((S)-7-fluoro-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2-methylphenyl)acetic acid; 2-(5-((S or R)-l-(((S)-((S)-7-fluoro- 1,2, 3, 4-tetrahydro- l,5-naphthyridin-3- yl)(phenyl)methyl)amino)propan-2-yl)-2-methylphenyl)acetic acid; 2-(3-fluoro-5-((S or R)-l- (((S)-((S)-7-fluoro- 1,2, 3, 4-tetrahydro- 1, 5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl) acetic acid; 2-(3-fluoro-5-((S or R)-l-(((S)-((R)-7-fluoro-l,2,3,4-tetrahydro-l,5- naphthyridin-3-yl)(phen+G466yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-fluoro- 5-((R or S)-l-(((S)-((S)-7-fluoro-l,2,3,4-tetrahydro-l,5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R)-2-(3-(isoxazol-4-yl)phenyl)-N- ((R)-phcnyl((R)-l,2,3,4-tctrahydropyrido[2,3-b]pyrazin-3-yl)mcthyl)propcnamidc; (R)-2-(3- (isoxazol-4-yl)phenyl)-N-((R)-phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)propan- 1 -amine; 2-(3-((S or R)-l-(((R)-((R)-7-fluoro-l,2,3,4-tetrahydropyrido[2,3- b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)-2-methoxyphenyl)acetic acid; 2-(3-((R or S)-l-(((R)-((R)-7-fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)(phenyl)methyl)amino)propan-2-yl)-2-methoxyphenyl)acetic acid; 2-(3-((R or S)-1-(((S)- ((S)-7-fluoro- 1,2,3, 4-tetrahydro- 1 , 5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(2-fluoro-5-((S or R)-l-(((S)-((S)-7 -fluoro- 1,2, 3, 4-tetrahydro- 1,5- naphthyridin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((S or R)-l- (((S)-((S)-7-fluoro- 1 ,2, 3, 4-tetrahydro- 1 ,5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(2-fluoro-3-((R or S)-l-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((S or R)-l-(((S)-((S)-7-fluoro- 1,2, 3, 4-tetrahydro- 1, 5-naphthyridin-3- yl)(phenyl)methyl)amino)propan-2-yl)-4-methylphenyl)acetic acid; 2-(4-fluoro-3-((R or S)-l- (((S)-((S)-7-fluoro- 1,2, 3, 4-tetrahydro- l,5-naphthyridin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(4-fluoro-3-((S or R)-l-(((S)-((S)-7 -fluoro- 1,2, 3, 4-tetrahydro- 1,5- naphthyridin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(2,4-dimethyl-5- (2-(((S)-phenyl((S)-5,6,7,8-tetrahydropyrido[3,2-c]pyridazin-7- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-(2-(((S)-((S)-7 -fluoro- 1,2, 3, 4-tetrahydro- 1,5- naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)acetic acid; 2-(4-methyl-3- (2-(((S)-phenyl((S)-5,6,7,8-tetrahydropyrido[3,2-c]pyridazin-7- yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-(2-(((S)-((R)-7-fluoro-2-oxo-l,2,3,4- tetrahydro-l,5-naphthyridin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)-2-methylpropanoic acid; 2-(5-(2-(((S)-l-((S)-5-cyano-2-oxo- 1,2,3, 4-tetrahydroquinolin-3-yl)ethyl)amino)ethyl)- 2,4-dimethylphenyl)acetic acid; (R and S)-2-(3-(2-(((R)-((R)-7-fluoro-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)propanoic acid; 2-(3-(2-(((S)-l-((R or S)-5-cyano-2-oxo- 1,2,3, 4-tetrahydroquinolin-3- yl)ethyl)amino)ethyl)-4-methylphenyl)-2-methylpropanoic acid; 2-(5-(2-(((S)-l-((R or S)-5- cyano-2-oxo-l,2,3,4-tetrahydroquinolin-3-yl)ethyl)amino)ethyl)-2-methylphenyl)acetic acid; 2-(5-(2-(((S)-l-((R or S)-5-cyano-2-oxo-l,2,3,4-tetrahydroquinolin-3-yl)ethyl)amino)ethyl)-2.4-dimethylphenyl)acetic acid; 2-(3-(2-(((S)-l-((S or R)-5-cyano-2-oxo-l ,2,3,4- tctrahydroquinolin-3-yl)cthyl)amino)cthyl)-4-mcthylphcnyl)-2-mcthylpropanoic acid; 2-(5- (2-(((R)-l-((S or R)-5-cyano-2-oxo-l,2,3,4-tetrahydroquinolin-3-yl)ethyl)amino)ethyl)-2,4- dimethylphenyl)acetic acid; 2-(5-(2-(((S)-l-((S or R)-5-cyano-2-oxo-l, 2,3,4- tetrahydroquinolin-3-yl)ethyl)amino)ethyl)-2-methylphenyl)acetic acid; 2,2,2-trifluoroacetic acid— 2-(5-(2-(((R)- 1-((S or R)-5-cyano-2-oxo- 1 ,2,3,4-tetrahydroquinolin-3- yl)ethyl)amino)ethyl)-2-methylphenyl)acetic acid; 2-(3-(2-(((R)-l-((R or S)-5-cyano-2-oxo-1.2.3.4-tetrahydroquinolin-3-yl)ethyl)amino)ethyl)-4-methylphenyl)-2-methylpropanoic acid; 2-(5-(2-(((R)-l-((R or S)-5-cyano-2-oxo-l,2,3,4-tetrahydroquinolin-3-yl)ethyl)amino)ethyl)- 2-methylphenyl) acetic acid; 2-(3-(2-(((R)-((R)-6,7-dihydro-5H-pyridazino[3,4-b][l,4]oxazin- 7-yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)-2-methylpropanoic acid; 2-(3-(2-(((R)- 1 - ((S or R)-5-cyano-2-oxo- 1,2,3, 4-tetrahydroquinolin-3-yl)ethyl)amino)ethyl)-4- methylphenyl)-2-methylpropanoic acid; (R or S)-2-(2-methyl-3-(2-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3- methyl-5-((R or S)-l-(((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R or S)-2-(3-((S or R)-l-(((R)-((R)-7- fluoro- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)propanoic acid; 2-(2-methyl-3-((R or S)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S)-2-(3- (isoxazol-4-yl)phenyl)-N-((R)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)propanamide; (S)-2-(3-bromophenyl)-N-((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)propanamide; 2-(5-(2-(((R)-((S)-4-amino-3- chloro-6-oxo-5,6,7,8-tetrahydropyrazino[2,3-c]pyridazin-7-yl)(phenyl)methyl)amino)ethyl)- 2-methylphenyl) acetic acid; 2-(3-((R and S)-l-(((R)-((R)-6,7-dihydro-5H-pyridazino[3,4- b][l,4]oxazin-7-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (S)-phenyl((R)-1.2.3.4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methanamine; (R)-phenyl((S)-l,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methanamine; 2-(3-(2-(((R)-((R)-6,7-dihydro-5H- pyridazino[3,4-b][l,4]oxazin-7-yl)(phenyl)methyl)amino)ethyl)-4-methylphenyl)acetic acid; 2-(3-((S)-l-(((R)-phenyl((S)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((S)- l-(((R)-phenyl((S)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((R)-l-(((S)-phenyl((R)-l ,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phcnyl) acetic acid; 2-(3-((R)-l-(((S)-phcnyl((R)- 1,2,3, 4-tctrahydropyrido[2, 3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((R)-l-(((R)-phenyl((S)-l,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((R)- l-(((R)-phenyl((S)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(3-((S ) - 1 -(( (S)-phenyl((R)- 1 ,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((S)- l-(((S)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((S)- l-(((S)-phenyl((R)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl) acetic acid; (S)-phenyl((S)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3- yl)methanamine; 2-(5-(2-(((R)-((R)-6,7-dihydro-5H-pyridazino[3,4-b][l,4]oxazin-7- yl)(phenyl)methyl)amino)ethyl)-2-methylphenyl)acetic acid; 2-(3-((R)-l-(((S)-phenyl((S)- 1 ,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2- (3-((S)-l-(((S)-phenyl((S)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((S)-l-(((S)-phenyl((S)-l,2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((S)- l-(((S)-phenyl((S)- 1,2,3, 4-tetrahydropyrido[2, 3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl) acetic acid; 2-(3-chloro-4-((R or S)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methanamine; (S or R)-2-(3-((R or S)-l-(((S)-((S)-5-cyano-l,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)propanoic acid; (R or S)-2-(3-((R or S)-l-(((S)-((S)-5-cyano-l, 2,3,4- tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(3-((S or R)-l-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]oxazin-3- yl)(phenyl)methyl)amino)propan-2-yl)-4-lluorophenyl)acetic acid; 2-(5-((R or S)-1-(((R)- phenyl((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)thiophen- 3-yl)acetic acid; (S or R)-2-(3-(2-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3-b][l,4]thiazin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; (R and S)-2-(3-(2-(((R)-((R)-2,3- dihydro-lH-pyrido[2,3-b][l,4]thiazin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(3-((R or S)-l-(((S)-((S)-5-cy ano- 1,2,3, 4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(5-(2-(((R)-((R)-2,3-dihydro-lH-pyrido[2,3-b] [ 1 ,4]oxazin-3-yl)(phenyl)methyl)amino)ethyl)thiophen-2-yl)acetic acid; 2-(2- chloro-4-((S or R)-l-(((R)-phcnyl((R)- 1,2,3, 4-tctrahydropyrido[2,3-b]pyrazin-3- yl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R and S)-2-(3-(2-(((S)-((S)-5-cyano-1.2.3.4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; (R or S)- 2-(4-(2-(((S)-((S)-5-cyano- 1,2,3, 4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)ethyl)phenyl)propanoic acid; 2-(4-((R or S)-l-(((S)-((S)-5-cyano-1.2.3.4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; (R and S)-2-(4-((R or S)- l-(((S)-((S)-5-cy ano- 1,2,3, 4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(3-((R or S)-1-(((R)- phenyl((R)- 1,2,3, 4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl)acetamide; 2-(4-((S or R)- l-(((S)-((S)-5-cy ano- 1,2,3, 4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(3-((S or R)-l-(((R)-(2- fluorophenyl)((R)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl)-2-methylpropanoic acid; 2-(2,4-difluoro-5-((S or R)-l-(((R)-phenyl((R)-l, 2,3,4- tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2-yl)phenyl)-2-methylpropanoic acid; 2-(3-((S or R)-l-(((S)-((S)-5-cy ano- 1,2,3, 4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)acetic acid; 2-(4-(2-(((S)-((S )-5-cyano-l, 2,3,4- tetrahydroquinolin-3-yl)(phenyl)methyl)amino)ethyl)phenyl)acetic acid; (S or R)-2-(4-((S orR)-l-(((S)-((S)-5-cyano-l,2,3,4-tetrahydroquinolin-3-yl)(phenyl)methyl)amino)propan-2- yl)phenyl)propanoic acid; 2-(3-(2-(((R)- 1 -((R)-8-cy ano- 1 ,2,3,4-tetrahydroquinoxalin-2-yl)- 1 - phenylethyl)amino)ethyl)phenyl)acetic acid and 2-(3-(2-(((S)-l-((S)-8-cyano-l, 2,3,4- tetrahydroquinoxalin-2-yl)-l-phenylethyl)amino)ethyl)phenyl)acetic acid (1 / 1); (R or S)-2-(4- ((S or R)-l-(((S)-((S)-5-cyano-l,2,3,4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; (R or S)-2-(2-fluoro-3-(2-(((S)- phenyl((R)- 1 ,2,3,4-tetrahydro- 1 ,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)propanoic acid; (R or S)-2-(3-((S or R)-l-(((S)-((S)-5-cyano-l,2,3,4-tetrahydroquinolin-3- yl)(phenyl)methyl)amino)propan-2-yl)phenyl)propanoic acid; 2-(3-(l-((tert- butoxycarbonyl)amino)propan-2-yl)phenyl)acetic acid; 2-(2-fluoro-3-(2-(((S)-phenyl((R)-1.2.3.4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)ethyl)phenyl)acetic acid; 2-(3-((R andS)-l-(((S)-phenyl((S)-l,2,3,4-tetrahydropyrido[2,3-b]pyrazin-3-yl)methyl)amino)propan-2- yl)phenyl)acetic acid; 2-(3-((S)-l-(((S)-phenyl((R)-l,2,3,4-tetrahydro-l,5-naphthyridin-3-yl)methyl)amino)propan-2-yl)phenyl)acetic acid; and 2-(3-((S)-l-(((R)-phenyl((S)-l ,2,3,4- tctrahydropyrido[2,3-b]pyrazin-3-yl)mcthyl)amino)propan-2-yl)phcnyl)acctic acid.37. A pharmaceutical composition comprising the compound of any one of Embodiments 1 to 36 and a pharmaceutically acceptable excipient.38. A method of treating a disease or disorder associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1-36 or the pharmaceutical composition of embodiment 37.

[0173] In addition, one or more of the following embodiments are also provided:1. A method of treating a disease or disorder associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of Compound (1):or a pharmaceutically acceptable salt thereof; or2. A method for treating a disease or condition selected from the group consisting of an inflammatory disorder and an autoimmune disease, in a subject in need thereof, comprising administering a therapeutically effective amount of Compound 762:or a pharmaceutically acceptable salt thereof; or3. The method of embodiment 1 or embodiment 2, wherein the disease or condition is an autoimmune disease; or4. The method of embodiment 3, wherein the autoimmune disease is selected from the group consisting of: Crohn’s disease, ulcerative colitis, Graves’ disease, Hashimoto’s thyroiditis, multiple sclerosis, Guillain-Barre syndrome, rheumatoid arthritis, systemic lupus erythematosus, Behcet’s disease, Reynaud’s syndrome, acute disseminated encephalomyelitis Sjogren’s syndrome, type I diabetes mellitus, and vitiligo; or5. The method of embodiment 4, wherein the autoimmune disease is Sjogren’s syndrome; or6. The method of embodiment 1 or 2, wherein the disease or condition is an inflammatory disorder; or7. The method of embodiment 6, wherein the inflammatory disorder is selected from the group consisting of ulcerative colitis, Crohn’s disease, irritable bowel disease, chronic obstructive pulmonary disease (COPD); or gout, scleroderma, acute disseminated encephalomyelitis, psoriasis, asthma, ulcerative colitis, Alzheimer’s disease, and Parkinson’s disease8. The method of any one of embodiments 1 to 7, wherein the disease or disorder is characterized by overexpression of IL- 17 cytokines; or9. The method of any one of embodiment s 1 to 8, wherein the disease or disorder is characterized by overexpression of IgG; or10. The method of any one of embodiments 1 to 9, wherein the subject is a mammal; or11. The method of embodiment 10, wherein the subject is a human.

[0174] In addition, one or more of the following embodiments are also provided:1. A compound of Formula (I) :or a pharmaceutically acceptable salt thereof, wherein:A1is NRla, O, CRlbRlc, C(=O), S, SO, or SO2;A2is NR2a, O, CR2bR2c, C(=O), S, SO, or SO2;Rlais hydrogen, -CN, -Ci-C6alkyl, -CO(Ci-C6alkyl), -CO2(Ci-C6alkyl), -CONH2, - CONH(CI-C6alkyl), -CON(CI-C6alkyl)2, or -SO2(alkyl);Rlband Rlcare each independently hydrogen, halo, -OH, Ci-Ce alkyl, -O-tCi-Cr, alkyl), -NH2, -NH(CI-C6alkyl), -N(CI-C6alkyl)2, -CO(Ci-C6alkyl), -CO2(Ci-C6alkyl), -CONH2, - CONH(CI-C6alkyl), or -CON(CI-C6alkyl)2;R2ais hydrogen, -CN, -Ci-C6alkyl, -CO(Ci-C6alkyl), -CO2(Ci-C6alkyl), -CONH2, - CONH(CI-C6alkyl), -CON(CI-C6alkyl)2, or -SO2(alkyl);R2band R2care each independently hydrogen, halo, -OH, Ci-Ce alkyl, -O-(Ci-C6 alkyl), -NH2, -NH(CI-C6alkyl), -N(CI-C6alkyl)2. -CO(Ci-C6alkyl), -CO2(Ci-C6alkyl), -CONH2, - CONH(CI-C6alkyl), or -CON(CI-C6alkyl)2;R3aand R3bare each independently hydrogen, halo, -OH, -CN, Ci-Ce alkyl, -NH2, - NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)2, or-O-(Ci-Ce alkyl); or R3aand R3btaken together are =0; or R3aand R3btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring;R4aand R4bare each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C6-C10 aryl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, optionally substituted 3- to 10-membered heterocycloalkyl, -C0NH2, -CONH(Ci- G, alkyl), or -CON(CI-C6 alkyl)2; or R4aand R4btogether with the carbon atom to which they are attached form an optionally substituted 3- to 10- membered heterocycloalkyl ring or an optionally substituted C3-C10 cycloalkyl ring;R5is -L-R6, -C(O)-, -S(O2)-, -NH2, -NH(CI-C6alkyl), -N(CI-C6alkyl)2, or-O-(Ci-C6alkyl);R6is optionally substituted aryl,optionally substituted C3-C10 cycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocycloalkyl;R7is hydrogen, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce haloalkyl, optionally substituted Ce-Cio aryl, optionally substituted 3- to 10-memberedcycloalkyl, optionally substituted 3- to 10-membered heteroaryl, or optionally substituted 3- to 10-mcmbcrcd hctcrocycloalkyl;J is NH, N(CI-C6alkyl), O, CO, CH2, CH(OH), CHF, CF2, S, SO, or SO2;L is optionally substituted C1-C10 alkylene, optionally substituted C2-C10 alkenylene, or optionally substituted C2-C10 alkynylene;W is N or CR8;X is N or CR9;Y is N or CR10;Z is N or CR11;R8, R9, R10, and R11are each independently selected from the group consisting of hydrogen, halo, -Ci-C6alkyl, -Ci-C6haloalkyl, -CN, -CO2H, -CO2(Ci-C6alkyl), -CONH2, - CONH(CI-C6alkyl), -CON(CI-C6alkyl)?, -SO (alkyl), -SO(alkyl), -SO(NH)(alkyl), -SO2NH2, -SO2NH(CI-C6alkyl), -SO2N(CI-C6alkyl)2, C6-Cio aryl, C3-C10 cycloalkyl, 5- to 10- membered heteroaryl, 4- to 10-membered heterocycloalkyl,wherein said alkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents Q; each Q is independently selected from the group consisting of: halo, -CN, -OH, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce haloalkyl, optionally substituted Ci-Ce alkoxy, optionally substituted Ci-Ce haloalkoxy, -(CH2)mNH2, - (CH2)mSO2(optionally substituted Ci-Ce alkyl), -C(=0)NH2, -(CH2)mC(=O)NH(optionally substituted Ci-Ce alkyl), -(CH2)mC(=O)N(optionally substituted Ci-Ce alkyl)2, - (CH2)mC(=O)NH(optionally substituted Ce-Cio aryl), -(CH2)mC(=O)NH(optionally substituted 3- to 10- membered heteroaryl), -(CH2)mC(=O)NH(optionally substituted C3-C10 cycloalkyl), -(CH2)mSO NH(optionally substituted Ci-Ce alkyl), optionally substituted C7-C16 arylalkyl, - C(=O)(optionally substituted 3- to 10- membered heterocycloalkyl), (CH2)mCH(OH)(optionally substituted 3- to 10- membered heteroaryl), optionally substituted 5- to 10- membered heteroaryl-(Ci-C6 alkyl), optionally substituted C3-C10 cycloalkyl,optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 4- to 10- mcmbcrcd hctcrocycloalkyl-(Ci-C6 alkyl), optionally substituted C3-C10 cycloalkyl-(Ci-Ce alkyl), optionally substituted C6-C10 aryl, and optionally substituted 5- to 10- membered heteroaryl; and m is 0 or 1 ; or2. The compound of Embodiment 1, wherein A2is not NR2aor CR2bR2c, when A1is NRlaor when R3aand R3btaken together are not =0 or W is N; or3. The compound of Embodiment 2, whereinRlais hydrogen;Rlband Rlcarc each independently hydrogen;R2ais hydrogen;R2band R2care each independently hydrogen;R4bis hydrogen; andR5is -L-R6;W is N or C-CN;X is CH;Y is CR10;Z is CH;A1is NRla; andA2is NR2a, or O, or CH?; or4. The compound of Embodiment 3, wherein R3aand R3btaken together are =0; or5. The compound of Embodiment 4, having the structure of Formula (IIa-2), or Formula (IIb-2), or Formula (lie -2):or a pharmaceutically acceptable salt thereof; or6. The compound of Embodiment 3, wherein R3aand R3bare each independently hydrogen; or7. The compound of Embodiment 6, having the structure of Formula (Ila-2), or Formula (IIb-2), or Formula (lie -2) or Formula (IIIa-2)pharmaceutically acceptable salt thereof; or8. The compound of any one of Embodiments 1-7, wherein Rla, R8, R9and R11are each independently hydrogen; or9. The compound of Embodiment 8, wherein R7is hydrogen; or10. The compound of Embodiment 9, wherein J is NH; or11. The compound of Embodiment 9, wherein J is -O-; or12. The compound of any one of Embodiments 10-11, wherein L is -CH2CH2- or - CH2CH(CH3)-; or13. The compound of Embodiment 12, wherein R4ais optionally substituted 3- to 10-membered heteroaryl or R4ais optionally substituted phenyl; or14. The compound of Embodiment 13, wherein R10is pyrazolyl, optionally substituted with Ci-Ce alkyl, or R10is hydrogen, or R10is -Ci-Ce alkyl optionally substituted with -C(=O)NH2, or R10is halogen; or15. The compound of Embodiment 14, wherein R6is substituted phenyl or R6is substituted thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyridazinyl; or16. The compound of Embodiment 15, wherein R6is substituted with -COOH, cyano, or alkyl substituted with -COOH or cyano; or17. The compound of Embodiment 16, wherein R6is further substituted with alkyl, halo, hydroxy, oxo, - haloalkyl, or alkoxy; or18. The compound of Embodiment 17, wherein R4ais phenyl, R6is substituted phenyl or R6is substituted pyridinyl, and R6is substituted with -COOH, cyano, or alkyl substituted with -COOH or cyano; or19. The compound of Embodiment 18, wherein W is N and A2is O; or20. The compound of Embodiment 19, wherein R10is 1-methyl-l H-pyrazol-4-yl; or21. The compound of Embodiment 20, wherein R6is substituted with cyano, or alkyl substituted with cyano; or22. The compound of Embodiment 21, wherein the compound is selected from the group consisting ofpharmaceutically acceptable salt thereof; or23. The compound of Embodiment 21, wherein the compound is selected from the group consisting ofthereof; or24. The compound of Embodiment 18, wherein W is C-CN; or25. The compound of Embodiment 24, wherein A2is O or A2is NH or A2is CH2; or26. The compound of Embodiment 25, wherein R10is hydrogen; or27. The compound of Embodiment 25, wherein R10is halogen; or28. The compound of Embodiment 25, wherein R10is 1 -methyl- lH-pyrazol-4-yl; or29. The compound of any one of embodiments 24-28, wherein R6is phenyl or pyridinyl substituted with -(CH2)COOH, -(CH2)CN or -CN; or30. The compound of Embodiment 29, wherein A2is O and R6is phenyl substituted with -(CH2)COOH; or31 . The compound of Embodiment 29, wherein the compound is, or a pharmaceutically acceptable salt thereof; or33. The compound of Embodiment 1, wherein the compound ispharmaceutically acceptable salt thereof; or34. The compound of Embodiment 1, wherein the compound is35. The compound of Embodiment 1 , wherein the compound is, or a pharmaceutically acceptable salt thereof; or36. A compound, having the structure of any one of Compounds 101-764, or a pharmaceutically acceptable salt thereof; or37. A pharmaceutical composition comprising the compound of any one of Embodiments 1 to 36 and a pharmaceutically acceptable excipient; or38. A method of treating a disease or disorder associated with p300 activity in a subject, said method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1-36 or the pharmaceutical composition of Embodiment 37 ; or39. A method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of the compound of any one of Embodiments 1-36 or the pharmaceutical composition of Embodiment 37 to the subject; wherein the disease or condition is optionally selected from the group consisting of: the disease or condition is a cancer selected from the group consisting of a hematologic malignancy and a solid tumor; the disease or condition is a hematologic malignancy selected from the group consisting of lymphoma, multiple myeloma, or leukemia; the disease or condition is selected from the group consisting of small lymphocytic lymphoma, non-Hodgkin’s lymphoma, indolent non-Hodgkin’s lymphoma, refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+ / - villous lymphocytes), Nodal marginal zone lymphoma (+ / - monocytoid B-cells), Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissuetype, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-ccll lymphoma, mycosis fungoidcs, B-ccll lymphoma, diffuse large B-cell lymphoma, Mediastinal large B-cell lymphoma, Intravascular large B-cell lymphoma, Primary effusion lymphoma, small non-cleaved cell lymphoma, Burkitt’s lymphoma, multiple myeloma, plasmacytoma, acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, minimal residual disease, hairy cell leukemia, primary myelofibrosis, secondary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disease, and Waldestrom’s macroglobulinemia; the disease or condition is a solid tumor, wherein the solid tumor is from a cancer selected from the group consisting of pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, thyroid cancer, gall bladder cancer, lung cancer (e; org; or non-small cell lung cancer, small-cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (c; org; or, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi’s sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, and ACTH-producing tumors; the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, Goodpasture’s syndrome, glomerulonephritis, hemorrhage, pulmonary hemorrhage, atherosclerosis, rheumatoid arthritis, psoriatic arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis, Behget disease, autoimmune thyroiditis, Reynaud’s syndrome, acute disseminated encephalomyelitis, chronic idiopathic thrombocytopenic purpura, multiple sclerosis,Sjdgren’s syndrome, autoimmune hemolytic anemia, tissue graft rejection, hyperacute rejection of transplanted organs, allograft rejection, graft-vcrsus-host disease, diseases involving leukocyte diapedesis, disease states due to leukocyte dyscrasia and metastasis, granulocyte transfusion-associated syndromes, cytokine-induced toxicity, scleroderma, vasculitis, asthma, psoriasis, chronic inflammatory bowel disease, ulcerative colitis, Crohn’s disease, necrotizing enterocolitis, irritable bowel syndrome, dermatomyositis, Addison’s disease, Parkinson’s disease, Alzheimer’s disease, diabetes, type I diabetes mellitus, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome, multiple organ injury syndrome secondary to septicemia, trauma, hypovolemic shock, allergic conjunctivitis, vernal conjunctivitis, and thyroid-associated ophthalmopathy, eosinophilic granuloma, eczema, chronic bronchitis, acute respiratory distress syndrome, allergic rhinitis, coryza, hay fever, bronchial asthma, silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, emphysema, pneumonia, bacterial pneumonia, bronchiectasis, and pulmonary oxygen toxicity, reperfusion inju...

Claims

WHAT IS CLAIMED IS:

1. A method of treating a disease or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and any one of Compounds 101-692 or 694-764, or a pharmaceutically acceptable salt thereof.

2. A method of treating a disease or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and a compound having a structure selected from the group consisting of: , aa subject or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amount of aglucocorticoid and a compound having the structure of a pharmaceutically acceptable salt thereof. or condition associated with p300 activity in aor a a or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amount a glucocorticoid and a compound having the structure a pharmaceutically acceptable salt thereof.or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amount of a glucocorticoid and a compound having the structure of a pharmaceutically acceptable salt thereof.or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effectiveamount of a glucocorticoid and a compound having the structure of a pharmaceutically acceptable salt thereof. 1-6, wherein the glucocorticoid is selectedgroup beclomethasone, betamethasone, budesonide, cortisone, deflazacort, deoxycorticosterone acetate, dexamethasone, fludrocortisone acetate, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone 8. The method of any one of Claims 1-7, wherein the glucocorticoid is dexamethasone.

9. A method of treating a disease or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amount of any one of Compounds 101-692 or 694-764, or a pharmaceutically acceptable salt thereof and an additional active agent.

10. A method of treating a disease or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amount of a compound having a structure selected from the group consisting of: ,r a 11. A method of treating a disease or condition associated with p300 activity in a subject or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amount of a compound having the structure of , or a pharmaceutically acceptable salt thereof,12. A method of treating a disease or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amount a compound having the , or a pharmaceutically acceptable salt thereof,13. A method of treating a disease or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amountof a compound having the structure of , or a pharmaceutically acceptable salt thereof, and 14. A method of treating a disease or condition associated with p300 activity in a subject; or a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer in a subject; said method comprising administering to the subject a therapeutically effective amount of a compound having the a pharmaceutically acceptable salt thereof,15. The method of any one of claims 9-14, wherein the one or more additional active agents are selected from the group consisting of: Pomalidomide, Lenalidomide, Mezigdomide, and Thalidomide.

16. The method of claim 15, wherein the one or more additional active agents is Pomalidomide.

17. The method of any one of Claims 1 to 16, wherein the disease or condition is a cancer selected from the group consisting of a hematologic malignancy and a solid tumor.

18. The method of Claim 17, wherein the disease or condition is a hematologic malignancy selected from the group consisting of lymphoma, multiple myeloma, or leukemia.

19. The method of Claim 18, wherein the disease or condition is selected from the group consisting of small lymphocytic lymphoma, non-Hodgkin’s lymphoma, indolent non- Hodgkin’s lymphoma, refractory iNHL, mantle cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, Splenic marginal zone B-cell lymphoma (+ / - villous lymphocytes), Nodal marginal zone lymphoma (+ / - monocytoid B-cells), Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, cutaneous T-celllymphoma, extranodal T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, mycosis fungoides, B-cell lymphoma, diffuse large B-cell lymphoma, Mediastinal large B-cell lymphoma, Intravascular large B-cell lymphoma, Primary effusion lymphoma, small non-cleaved cell lymphoma, Burkitt’s lymphoma, multiple myeloma, plasmacytoma, acute lymphocytic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, minimal residual disease, hairy cell leukemia, primary myelofibrosis, secondary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, myeloproliferative disease, and Waldestrom’s macroglobulinemia.

20. The method of Claim 18, wherein the disease or condition is a solid tumor, wherein the solid tumor is from a cancer selected from the group consisting of pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, thyroid cancer, gall bladder cancer, lung cancer (e.g. non-small cell lung cancer, small-cell lung cancer), ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi’s sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, cancers of the adrenal cortex, and ACTH-producing tumors.

21. The method of any one of Claims 1 to 16, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, Goodpasture’s syndrome, glomerulonephritis, hemorrhage, pulmonary hemorrhage, atherosclerosis, rheumatoid arthritis, psoriatic arthritis, monoarticular arthritis, osteoarthritis, gouty arthritis, spondylitis, Behçet disease, autoimmune thyroiditis, Reynaud’s syndrome, acute disseminated encephalomyelitis, chronic idiopathic thrombocytopenic purpura, multiple sclerosis, Sjögren’s syndrome, autoimmune hemolytic anemia, tissue graft rejection, hyperacute rejection of transplanted organs, allograft rejection, graft-versus-host disease, diseases involving leukocyte diapedesis, disease states due to leukocyte dyscrasia andmetastasis, granulocyte transfusion-associated syndromes, cytokine-induced toxicity, scleroderma, vasculitis, asthma, psoriasis, chronic inflammatory bowel disease, ulcerative colitis, Crohn’s disease, necrotizing enterocolitis, irritable bowel syndrome, dermatomyositis, Addison’s disease, Parkinson’s disease, Alzheimer’s disease, diabetes, type I diabetes mellitus, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, and toxic shock syndrome, multiple organ injury syndrome secondary to septicemia, trauma, hypovolemic shock, allergic conjunctivitis, vernal conjunctivitis, and thyroid-associated ophthalmopathy, eosinophilic granuloma, eczema, chronic bronchitis, acute respiratory distress syndrome, allergic rhinitis, coryza, hay fever, bronchial asthma, silicosis, pulmonary sarcoidosis, pleurisy, alveolitis, emphysema, pneumonia, bacterial pneumonia, bronchiectasis, and pulmonary oxygen toxicity, reperfusion injury of the myocardium, brain, or extremities, thermal injury, cystic fibrosis, keloid formation or scar tissue formation, fever and myalgias due to infection, and brain or spinal cord injury due to minor trauma, diseases involving leukocyte diapedesis, acute hypersensitivity, delayed hypersensitivity, urticaria, food allergies, skin sunburn, inflammatory pelvic disease, urethritis, uveitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, alcoholic hepatitis, gastritis, enteritis, contact dermatitis, atopic dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitis, polycythemia vera, essential thrombocythemia, and polycystic kidney disease.

22. The method of any one of Claims 1 to 16, wherein the disease or condition is selected from the group consisting of systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease. systemic lupus erythematosus, myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjoegren’s syndrome, psoriasis, autoimmune hemolytic anemia, asthma, ulcerative colitis, Crohn’s disease, irritable bowel disease, and chronic obstructive pulmonary disease.

23. The method of any one of Claims 1 to 16, wherein the disease or condition is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, and systemic lupus erythematosus.

24. The method of any one of Claims 1, 7-9, or 15-23, wherein the compound is . or disorder associated with p300 activity in asubject, said method comprising administering to the subject a therapeutically effective amount of a compound having the structure: , or a26. A method for treating a disease or condition selected from the group consisting of an inflammatory disorder and an autoimmune disease, in a subject in need thereof, comprising administering a therapeutically effective amount of a compound having the structure: , or a27. The method of claim 25 or claim 26, wherein the disease or condition is an autoimmune disease.

28. The method of claim 27, wherein the autoimmune disease is selected from the group consisting of: Crohn’s disease, ulcerative colitis, Graves’ disease, Hashimoto’s thyroiditis, multiple sclerosis, Guillain-Barre syndrome, rheumatoid arthritis, systemic lupuserythematosus, Behçet’s disease, Reynaud’s syndrome, acute disseminated encephalomyelitis Sjögren’s syndrome, type I diabetes mellitus, and vitiligo.

29. The method of claim 28, wherein the autoimmune disease is Sjögren’s syndrome.

30. The method of claim 25 or 26, wherein the disease or condition is an inflammatory disorder.

31. The method of claim 30, wherein the inflammatory disorder is selected from the group consisting of ulcerative colitis, Crohn’s disease, irritable bowel disease, chronic obstructive pulmonary disease (COPD). gout, scleroderma, acute disseminated encephalomyelitis, psoriasis, asthma, ulcerative colitis, Alzheimer’s disease, and Parkinson’s disease 32. The method of any one of claims 25 to 31, wherein the disease or disorder is characterized by overexpression of IL-17 cytokines.

33. The method of any one of claims 25 to 32, wherein the disease or disorder is characterized by overexpression of IgG.

34. The method of any one of claims 1 to 33, wherein the subject is a mammal.

35. The method of claim 34, wherein the subject is a human.

Images